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The association of genomic DNA with histone proteins in the three-
dimensional structure known as chromatin is the central framework for “epigenetics,” 
which is defined as inherited phenotypes governed by differences that cannot be 
explained by changes in DNA sequence.  In recent years, studies have shown 
that regulated changes in the chemical and physical properties of chromatin often 
lead to dynamic changes in many cellular processes, including development and 
differentiation, by affecting the accessibility of the genomic information stored in 
the DnA.
The cell uses many different mechanisms to regulate chromatin in order to 
establish, maintain, and propagate patterns of gene expression that are necessary 
for proper development and differentiation.  Many of these mechanisms involve the 
histone component of chromatin, both through chemical and structural changes 
of the histone proteins themselves and via complex interactions with other non-
histone chromatin proteins.  Here, in my thesis work, I describe how a few of these 
chromatin regulatory mechanisms are used during mammalian differentiation, 
specifically focusing on those involving histone H3.
First, in Chapter 2, I describe how certain non-histone chromatin proteins 
that are key to development specifically interact with modified histones using 
biochemical, biophysical and structural approaches.  Next, in Chapter 3, I describe 
how chromatin undergoes specific, dramatic changes as cells lose their capacity for 
self-renewal and proceed toward a specific lineage using a mouse embryonic stem 
cell model of differentiation and early embryonic development.  These changes 
involve both the post-translational modification of histone H3 and the incorporation 
of different H3 variant proteins into the chromatin fiber.  Finally, I describe the 
observation that differentiating mouse embryonic stem cells proteolytically cleave 
histone H3 and identify a protease that accomplishes this cleavage.
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1Chapter 1: General Introduction
A fundamental question in biology is how a single genome is able to dictate 
the differentiation and development of many different cell types.  In vivo, the genome 
of a cell is packaged into a three-dimensional structure known as chromatin: 
DNA wraps around a core of histone proteins to form a chain of repeating units, 
or “beads on a string,” that is then further compacted into more complex fibers 
(Figure 1.1A).  As a result, the accessibility of the genome to transcription factors 
and other proteins is governed by the nature of this compaction (Van Holde, 1989). 
Chromatin that is less compact, and therefore appears lighter when stained with 
basic dyes, is termed euchromatin (Figure 1.1B); it is more accessible to the gene 
expression machinery of the cell, allowing those genes to be actively expressed 
(Van Holde, 1989).  Chromatin that is highly compacted, and therefore appears 
dark by the same stains, is categorized as heterochromatin (Figure 1.1B); tighter 
compaction makes the genetic loci in heterochromatin less accessible, causing 
those genes to be silent (Van Holde, 1989).  The association of genomic DNA with 
histone proteins thus provides the central framework for “epigenetics,” which is 
defined as inherited phenotypes governed by differences that cannot be explained 
by changes in DNA sequence.  It is therefore likely that both DNA and histone 
proteins participate in the mechanisms that regulate self-renewal and differentiation 
during cellular development.
Although for many years histone proteins were regarded as an inert scaffold 
for the genome, studies in our laboratory and others have shown that they are in 
fact dynamically regulated, both chemically and physically, in ways that lead to 
functional change.  The cell uses various mechanisms to achieve this regulation, 
including post-translational modification of histone proteins, the remodeling of 
chromatin by ATP-dependent complexes (including nucleosome sliding and 
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Figure 1.1: The organization of chromatin.
A. At the smallest level, the crystal structure of a nucleosome particle shows the histone octomer 
wrapped by the DNA helix (Luger et al., 1997); these particles are then linked together by the DNA 
to form the classic “beads on a string” organization; the string is then further condensed into a 
compact chromatin fiber in order to fit into the cell nucleus.  (Images adapted from (Marmorstein, 
2001).)
B. An electron micrograph of a mammalian cell nucleus (N); red arrows indicate the dark 
heterochromatic regions and the light euchromatic regions; n = nucleolous.  (Image adapted from 
(Lodish et al., 2008).)
C. The four core histone proteins are modified by many different covalent post-translational 
modifications.  Shown here are a few well documented examples, including histone methylation 
(green and red circles) on H3K4 and H3K27; acetylation (triangles) on H2AK5, H4K12, and H4K16; 
phosphorylation (yellow circles) at H2BK14, and ubiquitination (orange boxes) at H2AK119 and 
H2BK120.
3replacement), and the incorporation of variant histone isoforms into the nucleosome 
particle (Ahmad and Henikoff, 2002; Allfrey et al., 1964; Varga-Weisz et al., 1995). 
Since cells use these chromatin regulatory pathways to establish, maintain and 
propagate different patterns of gene expression during normal development and 
differentiation it then follows that errors made in their regulation of the “epigenome” 
could lead to inappropriate expression or silencing of genes and, in turn, alter 
cellular identity.  Moreover these alterations could lead to pathological situations, 
such as tumorigenesis, in certain physiological and developmental contexts.
In our laboratory and others in the chromatin field, we are interested in 
uncovering the ways in which the structural and biochemical properties of chromatin 
impact the biology of the cell.  In particular, we are interested in the many different 
ways the amino terminal tails of core histone proteins (H2A, H2B, H3 and H4) 
are chemically modified to create a dynamic functional readout (Figure 1.1C). 
These modifications include, but are not limited to, acetylation, methylation, 
phosphorylation and ubiquitination (Allis et al., 2006).  The combination of multiple 
types of modifications and multiple, yet specific, acceptor sites for them in each 
histone tail allows the cell to create many different biochemical patterns in its 
chromatin and, therefore, to relay and/or store many different bits of information 
without requiring any change to the DNA sequence. 
Here I describe my research in the Allis laboratory on the histone H3 protein, 
including studies on its biochemical profile, its interactions with other non-histone 
chromatin proteins, and its developmentally-regulated proteolysis.  For much 
of this work I used a mouse embryonic stem cell (ESC) model in order to study 
changes in chromatin, and histone H3 in particular, during the process of cellular 
differentiation.  Below I will briefly summarize the background theory and literature 
for each of these studies and the questions that they aim to address.
4Post-translational Modifications of Histone Proteins
In addition to their role in packaging the DNA into the nucleus, histones were 
also proposed to inhibit DNA function, i.e. RNA synthesis, from as early as 1951 
(Stedman and Stedman, 1951), although clear evidence for this effect was not 
presented for another decade (Allfrey et al., 1963; Allfrey and Mirsky, 1962; Huang 
and Bonner, 1962; Stedman and Stedman, 1951).  Vincent Allfrey and colleagues 
showed that histones inhibit RNA synthesis in nuclei isolated from calf thymus 
(Allfrey and Mirsky, 1962) and that they could increase the rate of RNA synthesis by 
removing histones from the nucleus (Allfrey et al., 1963; Allfrey and Mirsky, 1962). 
In subsequent work, they then presented evidence that histones were acetylated 
after translation and that this modification could affect their ability to inhibit RNA 
synthesis, despite the fact that such acetylated histones still retained a high affinity 
for DNA (Allfrey et al., 1964).  The Grunstein laboratory later demonstrated these 
effects in living cells, having pioneered the use of yeast genetics to study the 
functional effects of histone deletions and mutations (Durrin et al., 1991; Han 
and Grunstein, 1988; Han et al., 1988; Kayne et al., 1988; Mann and Grunstein, 
1992).  Importantly, Allfrey et al foresaw that the modification of histones might be 
part of a more subtle mechanism to regulate both the activation and repression of 
transcription at different genomic loci, rather than simply blocking all RNA synthesis 
(Allfrey et al., 1964).  
When James Brownell and colleagues identified the transcription factor 
GCN5 as an enzyme responsible for acetylating histones in 1996, they not only 
made the first identification of a histone-modifying enzyme but also provided 
the first direct link between a histone modification and cellular function, namely 
transcription (Brownell et al., 1996).  Strong support of this finding occurred nearly 
simultaneously when Taunton et al identified of a human enzyme with histone 
deacetlyase activity that is highly similar to the yeast transcriptional regulator 
5Rpd3p (Taunton et al., 1996).  Since then many histone-modifying enzymes have 
been identified, including Histone Acetyl Transferases (HATs) like GCN5, Histone 
DeACetylases (HDACs) like Rpd3p, Histone Methyl Transferases (HMTases), and 
kinases that phosphorylate specific histone residues, many of which have also 
been shown to play roles in transcription (de Ruijter et al., 2003; DeSouza et al., 
2000; Hsu et al., 2000; Rea et al., 2000; Roth et al., 2001).
Although histone acetylation had been correlated with gene transcription 
long before the identification of GCN5, the role of histone methylation was less 
clear until several responsible HMTases were identified and shown to associate 
with particular regions of chromatin and/or gene promoters (Kouzarides, 2002). 
For example, the first lysine methyltransferase identified, Suppressor of variegation 
39 (Suvar39), was already known to be enriched at heterochromatin when Rea et 
al demonstrated its specificity for H3K9 (Rea et al., 2000).  Moreover, position-
effect-variegation (PEV) is the phenomenon by which an actively expressed 
gene is silenced as the result of a chromosomal rearrangement that positions it 
next to heterochromatin.  Suppressors of this phenomenon restore normal gene 
expression when mutated, and therefore function to silence gene expression in wild-
type cells (Figure 1.2A).  Rea et al also mapped the catalytic activity of Suvar39 
to its evolutionarily conserved SET domain, which is found in many chromatin-
associated proteins.
Two groups of proteins that both possess HMTase activity and play important 
roles in development are the trithorax group (trxG) and polycomb group (PcG) 
proteins.  Their genes were discovered in Drosophila as activators and repressors 
of HOmeoboX (Hox) gene expression, respectively.  Hox gene regulation is critical 
to the development of metazoans because they encode transcription factors 
that establish body patterning along the anterior posterior axis (Pearson et al., 
2005).  Additional studies using Chromatin ImmunoPrecipitation (ChIP) and DNA 
6Figure 1.2: The “active” or “silent” state of chromatin is determined by the actions of non-
histone chromatin proteins.
A. A schematic of the position-effect-variegation (PEV) phenomenon: (a) the wild-type white 
gene (W+), which produces red-eyed flies when expressed, is normally located in a euchromatic 
region of chromatin and therefore not subjected to the silencing effects of heterochromatic Su(var) 
proteins since they do not spread beyond the hypothetical barrier element, B; (b) a chromosomal 
rearrangement (resulting from the repair of chromosomal breaks induced by irradiation) positions 
the white gene next to a heterochromatic region and moves the barrier element further along the 
chromosome, allowing the Su(var) proteins to spread beyond their normal limit in a stochastic 
fashion (i = initiation binding sites).  This results in the silencing of the white gene in some cells of 
the eye, giving a mottled (or variegated) appearance.  (Cartoon adapted from (Grewal and Elgin, 
2002).)
B. An illustration of the enzymatic machinery responsible for writing and reading histone methylation 
marks.  The trithorax group (trxG) proteins include histone methyltransferases (HMTases) such as 
human MLL that methylate histone H3 lysine 4, which is correlated with gene activation (thick arrow); 
PHD finger proteins such as hBPTF, the largest subunit of the human NUcleosome Remodeling 
Factor (NURF) complex, are then able to bind, or “read”, this mark and recruit additional complex 
members (brown ovals) in order initiate downstream remodeling events that lead to changes in gene 
expression.  The polycomb group (PcG) proteins, on the other hand, are required for gene silencing 
and include HMTases such as the Polycomb Repressive Complex 2 (PRC2) protein hEZH2, which 
methylates H3K27.  The chromodomain (CD)-containing PRC1 complex proteins (i.e. Drosophila 
Pc and mammalian CBX2, 4, 6, 7, and 8) can then engage this mark and recruit other PcG proteins 
(green ovals) that mediate transcriptional repression.  PcG proteins that contain MBT repeats rather 
than CDs, such as L3MBT and SFMBT, bind mono and di, but not tri, methylated lysines.
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Figure 1.2: The “active” or “silent” state of chromatin is determined by the actions of non-
histone chromatin proteins.
8sequencing have shown that trxG and PcG proteins target many other genes as 
well, including several families of key developmental regulators in addition to the 
Hox genes (Bracken et al., 2006; Lee et al., 2006; Milne et al., 2005; Orlando et al., 
1998).  Importantly, the trxG proteins include the HMTases such as dmTrx, dmAsh1 
and vertebrate MLL, all of which methylate histone H3 at lysine 4.  On the other hand, 
PcG proteins include the H3K27 HMTases dmE(z) and mammalian EZH2.  In other 
words, trxG and PcG proteins have a ying-yang relationship, in which trxG proteins 
methylate H3K4 and maintain gene activation, and PcG proteins methylate H3K27 
and maintain gene repression (Figure 1.2B).  The identification of the trxG and 
PcG complexes as those responsible for H3K4me3 and H3K27me3, respectively, 
contributed enormously to our understanding of the link between these particular 
covalent modifications and gene expression, particularly since their mutants were 
already known to affect that of Hox genes.  Other studies demonstrated that the 
trxG and PcG protein complexes are necessary to maintain rather than initiate 
gene expression (Schuettengruber et al., 2007).  Nevertheless, many questions 
still remain as to the exact mechanisms of trxG and PcG recruitment and the 
regulation of gene expression.
Histone Binding Proteins as Mediators of Downstream Function
The discovery of these histone-modifiying enzymes provided insight into the 
mechanisms that establish the various patterns of histone modifications.  However, 
many questions still remained as to how these marks were propagated and, 
importantly, translated into functional readouts.  Many laboratories, including ours, 
hypothesized that some chromatin-associated proteins specifically recognize 
individual histone modifications, and/or combinations of modifications, in order 
to recruit these chromatin proteins to certain regions of the genome (Fischle et 
al., 2003a).  Indeed, researchers have shown that histone acetylation increases 
the affinity of bromodomain proteins (Dhalluin et al., 1999; Hudson et al., 2000; 
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motifs such as the chromodomain and the PHD finger (Bannister et al., 2001; 
Lachner et al., 2001; Shi et al., 2006; Wysocka et al., 2006), and phosphorylation 
recruits proteins such as 14-3-3 (Macdonald et al., 2005).  These recognition 
proteins then interact with other proteins and protein complexes to propagate the 
histone modification itself and/or trigger additional activity.  Below I will describe 
the identification of three key methyl-binding motifs, since they pertain directly to 
my thesis work (Figure 1.2B).
One significant contribution to the understanding of how certain non-histone 
proteins, or “effectors,” interact with specific post-translational histone modifications 
to mediate downstream function was the identification of the plant homeodomain 
(PHD) finger as an H3K4me3 binding motif (Shi et al., 2006; Wysocka et al., 2006). 
At the time, no other H3K4me binding motifs had been identified.  This motif was 
identified simultaneously within the protein BPTF, the largest subunit of the human 
NUcleosome Remodeling Factor (NURF) complex (Wysocka et al., 2006) and the 
INhibitor of Growth, family member 2 (ING2) protein (Shi et al., 2006).  The NURF 
chromatin-remodeling complex was originally purified from Drosophila embryos 
(Tsukiyama and Wu, 1995) and later found to promote transcription from chromatin 
templates in vitro (Mizuguchi et al., 1997).  BPTF itself is essential for early 
mouse embryo development, and both BPTF mutant embryos and ESCs show 
severe defects in gene expression (Landry et al., 2008).  Although NURF was 
already known to be recruited to chromatin by gene-specific transcription factors 
(Badenhorst et al., 2005), Wysocka et al show that it is stabilized at these loci 
through its binding to H3K4me3 and that this stabilization is crucial for proper Hox 
gene regulation and, consequently, development in Xenopus embryos.  The ING2 
protein is a tumor suppressor protein and a native subunit of the mSin3a–HDAC1 
histone deacetylase complex, a complex with gene repressive activity (Shi et al., 
2006).  The discovery that the PHD finger of ING2 binds H3K4me3 and functions to 
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stabilize a repressive complex on chromatin revealed a novel role of the H3K4me3 
mark, which is normally associated with gene activation.  It also suggested that 
H3K4me3 may play a key role in tumor suppressor pathways.  Together, the work 
on the PHD fingers of BPTF and ING2 were critical in furthering our understanding 
as to how H3K4 methylation is mechanistically linked to gene expression.
An equal important finding was the identification of the chromodomain (CD) 
as the methyl-binding motif in the chromatin-associated protein Heterochromatin 
Protein 1 (HP1) (Bannister et al., 2001; Lachner et al., 2001).  Like the histone H3K9 
HMTase Suvar39 described above, HP1 was originally discovered as Su(var)205 
in Drosophila (Eissenberg et al., 1990).  Work by Eissenberg et al revealed that this 
gene encodes the heterochromatin-associated protein HP1 and that it enhances 
PEV in a dosage-dependent manner when expressed exogenously (Eissenberg et 
al., 1990; Eissenberg et al., 1992).  Given that Suvar39, Hp1, and Pc are all enriched 
at heterochromatin and also contain the evolutionarily conserved chromodomain, 
Lachner et al set out to test their affinity for H3K9 methylation.  Their work and 
that of others (Bannister et al., 2001) confirmed that the chromodomain region 
of HP1 binds preferentially to H3K9 methylation, and subsequent work further 
characterized the structure and affinity of this binding (Jacobs and Khorasanizadeh, 
2002; Jacobs et al., 2001).  The CD is part of the Royal Superfamily of protein 
folds, which also includes the Tudor, Chromo barrel, and MBT domains (Taverna 
et al., 2007).  Interestingly, both Royal Superfamily folds and PHD fingers use 
a common structural feature, a “cage” of aromatic residues, to bind methylated 
histones.  However, subtle differences between them are able to confer sequence 
and methylation state specificity.
For example, although the CD-containing Pc protein did not show strong 
affinity for H3K9 methyl in the aforementioned studies, Fischle et al demonstrate 
that the CD of Pc preferentially binds methylated H3K27 (Fischle et al., 2003b). 
Moreover, they show that the CDs of Drosophila proteins HP1 and Pc discriminate 
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between histone H3 lysine methylation at K9 (preferentially recognized by HP1) 
and K27 (preferentially recognized by Pc).  Although it had been suggested that the 
CD of Pc might bind either H3K9me or H3K27me (Cao et al., 2002; Czermin et al., 
2002; Kuzmichev et al., 2002; Muller et al., 2002), their study was the first to show 
that the CD of Pc preferentially binds H3K27me over H3K9me.  Moreover, they 
demonstrated the importance of the difference between the CDs of HP1 and Pc in 
terms of their ability to localize to distinct regions of chromatin in vivo.  This finding 
is particularly significant given that PcG proteins are known to play an important 
role in regulating development and differentiation (see above).  PcG proteins are 
grouped into two Polycomb Repressive Complexes (PRC), PRC1 and PRC2. 
Several chromatin-immunoprecipitation (ChIP) studies using antibodies against 
both H3K27me3 and PcG proteins suggest that PRC2 is indeed necessary for the 
recruitment of PRC1 (Boyer et al., 2006; Bracken et al., 2006; Lee et al., 2006). 
The H3K27me3 methylase EZH2 is a member of PRC2, and the CD-containing 
Pc/CBX proteins are members of PRC1 (Whitcomb et al., 2007).  The binding of 
H3K27me3 by the CD of Pc/CBX therefore fits with the model in which H3K27 
methylation by PRC2 enables the recruitment of PRC1 (see Figure 1.2B).  
Another Royal Superfamily member that binds methyated lysines and is 
found in a group of protein factors that function as transcriptional repressors is the 
Malignant Brain Tumor (MBT) repeat (Taverna et al., 2007).  One of these factors 
is the PcG protein human Lethal-3 Malignant Brain Tumor repeat-Like protein 1 
(L3MBTL1).  Consistent with its classification as a PcG protein, L3MBTL1 has 
been shown to repress transcription in human cells (Boccuni et al., 2003) and 
its Drosophila homologue bears high homology to another Drosophila protein 
encoded by the sex comb on midleg (Scm) PcG gene (Bornemann et al., 1996). 
Homozygous mutation of the Drosophila l(3)mbt gene causes malignant growth of 
the adult optic neuroblasts and ganglion mother cells in the larval brain, classifying 
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it as a tumor suppressor gene as well (Gateff et al., 1993; Wismar et al., 1995).  A 
common deleted region of the locus to which the human L(3)MBT gene maps is also 
associated with myeloid hematopoietic malignancies (Bench et al., 2000; Kurtin et 
al., 1996; MacGrogan et al., 2001; Wang et al., 2000).  Despite this accumulation of 
functional information about MBT repeat containing proteins, the role of the domain 
itself was not uncovered until more recently when it was identified as a potential 
methyl-binding motif (Kim et al., 2006; Trojer et al., 2007).  Different from most of the 
other methyl-binding motifs identified and discussed above, MBT repeats prefer to 
engage lower methylation states (i.e. mono and di), and are one of the few motifs 
identified to do so (Taverna et al., 2007).  Both the MBT repeats of L3MBTL1 and 
those of another Drosophila PcG protein, Scm-related gene containing Four MBT 
domains (SFMBT), prefer mono and dimethylated lysines and discriminate against 
trimethylated lysines (Klymenko et al., 2006; Li et al., 2007).  
In Chapter 2, I describe my contribution to the understanding of the molecular 
basis for methyl-lysine recognition, including the binding of H3K9 and H3K27 
methylation by the CDs of the five mammalian Pc proteins, H3K4me3 recognition 
by the PHD finger motif of BPTF, and lower lysine methyl state recognition by the 
MBT repeats of the L3MBTL1 protein.
Polycomb Proteins and X Inactivation
In addition to their role in repressing Hox genes, PcG proteins are also implicated 
in the silencing of the mammalian inactive X chromosome (Heard, 2004).  In 
mammals, female embryonic cells compensate for having two X chromosomes (as 
opposed to the single X in their male counterparts) by inactivating one of them.  The 
inactive X chromosome (Xi) was identified over 50 years ago as a heterochromatic 
structure that was only present in female cells (Barr and Bertram, 1949; Ohno et al., 
1960).  Mary Lyon then proposed that this structure must represent a genetically 
inactive female chromosome that is silenced early in development and inherited 
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through mitosis, thus causing the mosaic coat of female mammals such as the 
calico cat (Lyon, 1961).  Subsequent studies have shown that Xi silencing requires 
a long, non-coding RNA called Xist, which coats the chosen Xi as it transcribes and 
presumably antagonizes a series of events that lead to stable, heritable inactivation 
(see Xist RNA Fluorescence In Situ Hybridization (FISH) in Figure 1.3A, left).  The 
Xi is categorized as facultative heterochromatin, since its silent status is caused by 
and dependent upon its environment (namely, the existence of another X in that 
cell); this dependence on context also implies that the silencing is reversible under 
certain developmental circumstances.  Together the heritability and reversibility 
of its silent state make the Xi an excellent model for studying the formation of 
heterochromatin, particularly since it is regulated by cellular events that coincide 
with and/or result from differentiation (Figure 1.3B). 
Of interest to our laboratory and many other chromatin laboratories, the 
silent X chromosome bears a pattern of histone modifications that is characteristic 
of heterochromatin: hypoacetylation, hypo-H3K4me3, hyper-H3K9me2 and, 
in particular, hyper-H3K27me3 (see Figure 1.3A, right).  The mammalian PcG 
protein EZH2 is a component of PRC2 and is the HMTase responsible for H3K27 
methylation on the Xi (Plath et al., 2003); mammalian PcG proteins Ring1a and b 
are members of PRC1 and has been shown to ubiquinate the Xi on H2A at K119 
(de Napoles et al., 2004).  However, there are still many open questions about 
the roles of PcG proteins in X chromosome silencing.  For example, although 
the CD protein dmPc has been extensively studied in the fly, mammals have five 
different homologues to dmPc, CBX2, 4, 6, 7, and 8, suggesting that they each 
may behave quite differently.  In Chapter 2, I describe collaborative work on the 
five mammalian CBX proteins and their localization on the Xi during female mouse 
ESC differentiation.  This work introduced me to the mouse ESC model, which I 
then used for other studies.
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from Masui O & Heard E. Cold Spring Harb Symp Quant Biol. 2006
B
data produced by Edith Heard and used with permission
Figure 1.3: The mammalian inactive X chromosome is a model of heterochromatin formation 
and epigenetic silencing.  
A. Left panel: RNA Fluorescence In Situ Hybridization (FISH) with an XIST RNA probe (green) 
localizes to the inactive X chromosome in female mammalian cells (HEK-293); the DNA is stained 
with DAPI (blue). Right panel: immunofluorescent (IF) staining of the same cells with an antibody 
to the H3K27me3 modification (red); note that the green XIST loci mirror the red H3K27me3 loci, 
since both are markers of the inactive X chromosome.  (Images produced by Edith Heard, Curie 
Institute, and used with permission.)
B. A timeline of the many events that occur during the process of X-inactivation in differentiating 
ESCs.  (Image from (Heard et al., 2004).)
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Chromatin Remodelling During ESC Differentiation
In order to address the question of how the genome of a single cell directs the 
development of an entire multi-cellular organism, it is important to study the very 
early stages of the process.  The initial stages of mammalian development are 
difficult to study because the early embryo is composed of very few cells.  The 
development of the Embryonic Stem Cell (ESC) model was a huge step forward in 
our ability to study those first events in mammalian early embryonic development 
(Evans and Kaufman, 1981; Martin, 1981; Thomson et al., 1998).  After fertilization, 
the mouse egg undergoes a series of divisions and migrations that results in a 
hollow cavity of cells, called the blastocyst, after approximately four days (Alberts 
et al., 2002).  As depicted in Figure 1.4A, ESC lines are derived from a cluster of 
cells called the Inner Cell Mass (ICM) that are located on one side of this blastocyst. 
These cells are termed pluripotent because they can differentiate into all the cell 
types of the embryo proper.  After they are derived, we can test the pluripotency of 
ESCs by injecting them back into a normal mouse blastocyst and asking whether 
they contribute to the embryonic tissues.  ESC pluripotency is maintained in vitro 
by growing them on either a layer of irradiated (and thus non-dividing) mouse 
“feeder” cells or plates coated with gelatin.  Leukemic Inhibitory Factor (LIF) is 
also added to the cell media to maintain activation of the JAK-STAT and MAPK 
pathways, which promotes their proliferation and self-renewal and prevents them 
from differentiating (Smith, 2001).  Removing LIF and/or adding inducers such 
as retinoic acid leads to ESC differentiation and the loss of pluripotency, causing 
the cells to undergo dramatic changes in morphology (Figure 1.4B), cell cycle, 
and gene expression (Kim et al., 2008; Murry and Keller, 2008).  The ESC model 
is therefore a tractable system in which to study events that may occur in early 
embryogenesis when only a few cells are dividing.  
Since eukaryotic genomes are intimately associated with histone proteins to 
form chromatin, this physiologically-relevant structure must be remodeled as part of 
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Figure 1.4: Mouse Embryonic Stem Cells (ESCs) are a tractable model of early embryonic 
development.
A. A schematic of embryonic stem cell (ESC) derivation: the fertilized mouse egg goes through a 
series of cell divisions (1); after about 4 days, the cells have divided and arranged themselves into 
a hollow ball called the blastocyst (2); a cluster of cells located on one side of the blastocyst, called 
the Inner Cell Mass (ICM) is isolated (3) and removed to a plate coated with a layer of mouse feeder 
cells (4); after a period of recovery and growth, cells are split and re-plated onto new feeder cells 
(5) or plates coated with gelatin and allowed to grow up into new colonies(6).  (Image adapted from 
(Winslow and Duckwall, 2001).)
B. Phase-contrast images of live ESCs taken with the Olympus IX71 inverted microscope in the 
Bio-Imaging Center at Rockefeller University.  The self-renewal property of ESCs is maintained 
in the presence of Leukemic Inhibitory Factor (LIF); undifferentiated ESCs are highly proliferative 
and prefer to grow in tight, dense clusters (left).  After 10 days of differentiation with either LIF 
removal alone (right, top) or LIF removal + Retinoic Acid (RA, right, bottom) the cells have changed 
in morphology, becoming longer and more spindle-like in some cases and rounder and flatter in 
others; some cells in under differentiation conditions appear to make fewer cell-to-cell contacts and 
extend neuronal-like processes.
adapted from Terese Winslow, Caitlin Duckwall 2001 http://stemcells.nih.gov/info/scireport/appendixC.asp
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a large-scale mechanism to achieve rapid and drastic changes in gene expression 
(Arney and Fisher, 2004; Gan et al., 2007). For example, undifferentiated ESCs 
typically display increased physical plasticity and less compacted chromatin than 
their differentiated counterparts (Meshorer et al., 2006; Pajerowski et al., 2007). 
ESCs also undergo radical changes in gene expression as they differentiate, 
conveniently providing markers of “stemness” whose expression dramatically 
decreases (e.g. Oct 3/4) as differentiation progresses. Such changes suggest that 
cells undergo a significant reorganization of their genome during the differentiation 
process and that, moreover, this transition must be carefully regulated in order for 
the cell to differentiate properly and adopt a specific lineage.
Recent studies have shown that histone covalent modification patterns 
change significantly upon ESC differentiation (Giadrossi et al., 2007). For example, 
core histones (H2A, H2B, H3 and H4) are largely deacetylated upon differentiation 
and histone deacetylase activity may be required for ESC differentiation (Lee et 
al., 2004). Chromatin-immunoprecipitation (ChIP) experiments have also identified 
specific genes and/or genomic regions that change their “epigenetic signature” 
upon differentiation (Azuara et al., 2006; Bernstein et al., 2006).  Specifically, 
these researchers found that certain genes in undifferentiated ESCs were uniquely 
modified with both H3K4me3, a marker of gene activation, and H3K27me3, a 
marker of gene repression.  This finding was novel in that it not only suggested 
that ESCs have a unique chromatin biochemical profile, but also that the paradigm 
of active genes being marked by H3K4me3 and silent genes by H3K27me3 does 
not always hold.  However, this “bivalent domain” signature, as they termed it, 
resolves to the usual paradigm upon differentiation.  In Chapter 3, I describe my 
own Chromatin ImmunoPrecipitation (ChIP) studies in ESCs using an antibody 
raised against the H3K4me3 modification and show that this model fits with other 
descriptions of changes in chromatin during ESC differentiation.
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Remodelling Chromatin by Histone Isoform Replacement
Despite a wealth of emerging data describing changing patterns of epigenetic 
signatures during ESC differentiation, very little is known about the mechanisms 
used to achieve such change. Several possible mechanisms for removing the 
more stable histone modifications, e.g. lysine methylation, include enzymatic 
demethylation, histone replacement, and regulated histone proteolysis (see Figure 
1.5A) (Bannister and Kouzarides, 2004).  Although the identification of lysine 
demethylases was enigmatic for many years, the discovery that LSD1 removes 
mono and dimethyl groups from histone H3K4 (Shi et al., 2004) began a cascade 
of findings about this type of enzyme.  Since then, many demethylating enzymes 
have been identified, including those that can remove trimethyl groups and at least 
one that can remove methylation from arginine residues (Lan et al., 2008).
Similarly, for many years there was evidence that histone replacement 
occurred outside of S-phase, yet the mechanism was not know.  Although the bulk 
of histone deposition into nucleosomes occurs during S-phase as DNA is replicated, 
studies in rat neurons (Pina and Suau, 1987), mammalian tissues (Lennox and 
Cohen, 1988) and Tetrahymena (Yu and Gorovsky, 1997) show that variant isoforms 
of core histone proteins are incorporated into the chromatin fiber independent of 
replication.  Histone variant incorporation, specifically H3.3, was then first linked to 
actively transcribing loci in Drosophila (Ahmad and Henikoff, 2002).   Ahmad and 
Henikoff demonstrate that the alternate histone H3 variant, H3.3, is specifically 
and exclusively deposited at active loci outside of S-phase despite the fact that it 
differs in only four amino acids from the canonical Drosophila histone H3 (Figure 
1.5B).  Although typical replication-dependent histone deposition requires the 
N-terminal tail of H3, Ahmad and Henikoff further show that replication-independent 
deposition does not require the N-terminal tail.  Subsequent studies by Tagami et 
al then identified the enzymatic machinery responsible for these distinct deposition 
pathways when they purified two separate chaperone complexes with H3.1 (i.e. 
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Figure 1.5: Reversible and irreversible mechanisms for removing histone tail 
modifications.
A. Suggested mechanisms for the removal of methyl marks from chromatin: enzymatic 
demethylation, regulated histone replacement (including outside of S-phase), and histone tail 
“clipping” or proteolysis.  The red “check” marks indicate that the first two mechanisms have been 
well documented in the literature.  The red question mark indicates that histone clipping has not yet 
been established as a mechanism to regulate the removal of histone modifications.  The vertical 
arrow and black question mark suggests that histone clipping may lead to replacement of the entire 
histone protein.  (Image adapted from (Bannister and Kouzarides, 2004).)
B. A schematic of replication-dependent (left) versus replication-independent (right) histone 
deposition.  Ahmad and Henikoff show that the latter couples the incorporation of the histone H3 
variant isoform H3.3 with active transcription (right).  The red “X” indicates that H3.3 (variant) + 
H3 (canonical) heterodimers are not deposited into chromatin.  (Image taken from (Ahmad and 
Henikoff, 2002).)
C. Cathepsin L, like most cathepsins, is synthesized as a preproprotein: the signal peptide (blue) is 
removed in the endoplasmic reticulum, and the inhibitory region (red) must be removed in order for 
the mature protein (grey) to be activated.  The Cathepsin L protein sequence contains alternative 
translation start sites that would exclude the signal peptide and, for at least one site, most of the 
inhibitory region.
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canonical H3) and H3.3 from mammalian cells (Tagami et al., 2004).  In Chapter 3, 
I describe collaborative work in which we provide evidence that suggests regulated 
histone H3 replacement occurs during ESC differentiation.
Remodelling Chromatin by Regulated Proteolysis
There is also precedence for the third aforementioned mechanism of histone 
modification removal, controlled histone proteolysis, in both Tetrahymena 
thermophila and mammalian cells infected with the foot-and-mouth disease virus 
(Allis et al., 1980; Falk et al., 1990).  Both these studies describe H3-specific 
histone proteolysis.  Recent work in the Kouzarides laboratory also suggests that 
histone H3 cleavage occurs in s.cerevisiae (Santos-Rosa et al., 2009).  However, 
specific, regulated, endogenous proteolysis of histone proteins had not been well 
documented in mammalian cells.  In Chapter 4, I describe my characterization 
of H3 proteolysis in differentiating ESCs and identification of Cathepsin L as a 
protease that creates this cleavage.
Cathepsins are a subclass of cysteine proteases in the papain family; the 
majority have only endopeptidase activity, although there are some exceptions 
(Barrett et al., 2003).  Cathepsins are normally synthesized as preproenzymes 
(Figure 1.5C), including a signal peptide that directs them to the endoplasmic 
reticulum and an inhibitory region that must be cleaved for their activation (Barrett et 
al., 2003).  The removal of this inhibitory region is thought to occur via autocatalytic 
processing at acidic pH or by the peptidase activity of other proteases, such as the 
aspartic protease Cathepsin D (Barrett et al., 2003).  Cathepsins L and B are the 
most abundant lysosomal cysteine proteases, and the double knockout of both 
genes is lethal during the second to forth week in the mouse (Felbor et al., 2002). 
Interestingly, the single knockout of either gene is not lethal but rather produces 
divergent phenotypes, suggesting that these two proteases have both overlapping 
and unique roles (Turk et al., 2000).
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Although cathepsins were previously thought to reside exclusively in the 
lysosome, recent evidence suggests that cathepsins, in particular Cathepsin L, 
may localize to the nucleus under certain conditions (Goulet et al., 2004; Hiwasa 
and Sakiyama, 1996).  Despite the obvious differences in environment between 
the lysosome and the nucleus, Goulet et al show that Cathepsin L has limited 
proteolytic activity when localized to the nucleus and plays a role in regulating 
transcription factor binding and cell cycle progression (Goulet et al., 2004).  Their 
data suggesting that the nuclear form of Cathepsin L is translated from an alternative 
start site downstream of the signal peptide.  Moreover, Goulet et al propose that the 
non-optimal nuclear pH may be an important feature in the regulation of Cathepsin 
L activity in the nucleus.  Other biochemical studies have also shown that pro-
Cathelsin L is localized to the nucleus in ras-transformed mouse fibroblasts (Hiwasa 
and Sakiyama, 1996).  In addition, evidence of a naturally occurring nuclear serpin 
inhibitor (Myeloid and Erythroid Nuclear Termination stage-specific protein, MENT) 
with the ability to inhibit Cathepsin L activity (Bulynko et al., 2006; Irving et al., 2002) 
further supports the notion that Cathepsin L and other cysteine proteases do indeed 
traffic to the nucleus to play important roles in regulated nuclear proteolysis.
 Such regulated proteolysis of histone proteins could have broad 
impact on chromatin structure and function.  For example, removing the histone 
H3 tail also removes the post-translational modifications on that sequence and any 
downstream effectors recruited by those marks.  Furthermore, as I will describe 
in Chapters 2 and 4, the removal of the N-terminal tail also impacts the binding 
affinity of proteins, such as Pc, that bind modifications C-terminal to the cleavage 
site.  Taken together, it is clear that the changes that occur within chromatin during 
differentiation and development are both dynamic and mutually dependent.
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Chapter 2: Biophysical studies of methyl-histone binding 
proteins
Summary
One major goal of our laboratory is to understand the downstream biological effects 
of covalent histone modifications.  In this chapter, I describe three distinct, yet 
mechanistically related, projects in which I investigated the biophysical interactions 
between methylated histone proteins and several non-histone proteins.  In 
collaboration with the Heard Laboratory at the Curie Institute, post-doctoral fellow 
Emily Bernstein and I investigated the binding interactions of all five mammalian 
Polycomb proteins with methylated histones and the role of this interaction in 
vivo (Bernstein et al., 2006).  After a colleague in the Allis laboratory discovered 
that a Plant HomeoDomain (PHD)-finger of the NUcleosome Remodeling Factor 
(NURF) chromatin-remodeling complex binds to histone H3K4me3 (Wysocka et 
al., 2006), I collaborated with the Patel Laboratory at Memorial Sloan Kettering 
Cancer Center to investigate the molecular basis of this interaction (Li et al., 2006). 
In another collaboration with the Patel Laboratory, I investigated the differences 
in molecular interaction between the trimethyl-lysine binding PHD finger and the 
mono- and dimethyl-lysine binding Malignant Brain Tumor (MBT) repeats of the 
protein L3MBTL1 (Li et al., 2007).
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Results
Mouse Pc Proteins Bind Differentially to Methylated Lysine H3 In Vitro
I first started studying the mammalian Polycomb (Pc) proteins as part of a collaborative 
project with Emily Bernstein, a post-doctoral fellow in our lab.  In particular, we 
focused on the five mammalian homologues of the namesake Drosophila Pc protein 
that contains the defining chromodomain (CD).  The chromodomain (CHRomatin 
Organization MOdifier domain) was originally identified as a conserved sequence 
motif in proteins that are modifiers of variegation in Drosophila, including Pc and 
Heterochromatin Protein 1 (HP1), both of which induce silencing by condensing 
chromatin structure (see Chapter 1 and Figure 1.2A).  The mammalian homologues 
to both these proteins are named CBX after this domain, otherwise known as a 
ChromoBoX (HP1=CBX1, 3, 5, Pc=CBX2, 4, 6, 7, 8).
The CDs of both dmHP1 and dmPc have been shown to bind methylated 
histone H3 (Bannister et al., 2001; Fischle et al., 2003; Jacobs and Khorasanizadeh, 
2002; Jacobs et al., 2001; Lachner et al., 2001; Min et al., 2003).  Specifically, the 
CD of Drosophila Pc has been shown to have a higher affinity for H3 peptides 
trimethylated at lysine 27 while dmHP1 strongly prefers those trimethylated at K9 
(Fischle et al., 2003).  Although the mechanism of chromatin compaction through 
the recruitment of repressive binding proteins such as HP1 and Pc is still unclear, 
this differential binding suggests a paradigm in which HP1 is recruited to genomic 
loci enriched in H3K9me3 and Pc to those loci decorated by K27me3 (Figure 2.1A). 
Since the CDs of the mouse Pc proteins (CBX2, 4, 6, 7, 8) share a high degree of 
sequence conservation with that of dmPc itself (Figure 2.1B), we posited that they 
would show strong affinity for the H3K27me3 mark as well.
After we cloned and optimized the expression of the chromodomains of 
these five proteins, I used two in vitro binding assays to assess the binding ability of 
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Figure 2.1: Mammalian Polycomb proteins expand the Drosophila HP1/Pc binding 
paradigm.
A. An illustration of the dmHP1/Pc binding paradigm:  dmHP1 preferably binds to H3K9me3 while 
dmPc has a higher affinity for H3K27me3.  Their interactions with these histone methyl marks are 
thought to stabilize these repressor proteins at specific genomic loci as they mediate chromatin 
compaction and gene silencing, although the exact mechanisms are still unclear.
B. A ClustalW alignment of the five mouse Pc-like chromodomains (CDs; aa 1-62) and the Drosophila 
Pc CD (aa 16-78). Asterisks represent the caging aromatic residues that mediate the histone methyl-
lysine interaction. Note the high degree of conservation among these family members.
C. Peptide pull-down assays.  Left: CBX2, 4, 6, 7 and 8 were examined for binding to unmodified 
and trimethylated peptides representing H3K9, H3K27 and H4K20.  Right: CBX7 CD, CBX7 caging 
aromatic point mutant F11A, and human HP1β recombinant proteins were tested for the ability to 
bind unmodified and me1, 2 and 3 peptides of H3K9 and K27.  As a control, GST alone was also 
tested for binding to unmodified and trimethylated peptides representing H3K9 and H3K27.
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these Pc proteins and/or their CDs alone to modified histone tails (e.g. H3 K27m3). 
First, I performed peptide “pull down” assays in which histone peptides are labeled 
with biotin, conjugated to avidin-coated beads through the strong interaction of 
biotin with avidin, and incubated either with cell extracts or, as in the experiment 
shown in Figure 2.1C, a mixture of recombinant protein plus 20 fold excess of 
BSA.  The beads are then washed rigorously and the protein eluted from the beads. 
The eluates are then run on SDS-PAGE gels and stained.  As shown in Figure 
2.1C, left, CBX2-CD and CBX7-CD both bind strongly to H3K9me3 as well as to 
H3K27me3; CBX4-CD prefers H3K9me3; CBX8-CD shows a slight preference for 
H3K27me3 over H3K9me3 or unmodified peptide, and CBX6-CD does not show 
strong affinity for any of these peptides.  I also tested the full-length CBX7 protein 
in this assay, and it behaves identically to the CD alone (data not shown).  We 
also tested a mutant CBX7-CD protein (F11A), in which one of the three residues 
that form the aromatic cage of the CD was changed to an alanine (Figure 2.1C, 
right).  Earlier mutagenesis and structural studies have shown that the conserved 
hydrophobic, aromatic pocket, or cage, of both the HP1 and Pc chromodomains is 
responsible for the recognition of the methylammonium group of methylated lysine 
K9 and K27, respectively (Jacobs and Khorasanizadeh, 2002; Jacobs et al., 2001; 
Min et al., 2003).  In keeping with what was previously reported, mutating this 
residue to alanine abolished the binding affinity of CBX7-CD for both H3K9me3 
and H3K27me3.  I also purified and tested mouse CBX5-CD protein (mHP1α) as 
a control for preferential H3K9me3 binding, and my results support those using 
human HP1α (Fischle et al., 2005).  Since these proteins all contain GST tags on 
their N termini, I also purified recombinant GST protein and tested it for binding; as 
shown in Figure 2.1C (right), GST tag alone did not show any affinity for the key 
peptides used in our assay.
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I then quantified the binding affinities of these chromodomains using 
fluorescence anisotropy (Park and Raines, 2004).  In this assay, recombinant 
protein was incubated with short histone peptides, either unmodified (control) 
or modified (experimental), fluorescently labeled with a Ferrocenyl substituted 
AziridinylMethanol (FAM) conjugate.  Upon binding with the protein, the movement 
of the fluorescent peptide is slowed, and the degree of this retardation (its 
fluorescence anisotropy) is calculated from the polarization measurement of each 
binding reaction.  These numbers are then plotted against the concentration of 
protein in each reaction well to determine a binding constant (Kd).  Figure 2.2A 
shows representative binding curves of CBX7-CD and CBX4-CD with H3 K9me and 
H3 K27me peptide (mono-, di- and tri-methylated peptides and an unmodified H3 
peptide were tested for each) as well as full length CBX7 protein, which produced 
nearly identical binding curves to those of CBX7-CD.   I also tested CBX5-CD, the 
mouse homologue of HP1α, as a control and my results supported those shown 
above in the peptide pulldown assay: CBX5-CD bound much more strongly to 
methylation at H3K9 than at H3K27 (Figure 2.2B).  The binding constants of each 
CBX-CD to these peptides are then summarized in Figure 2.2C, for comparison. 
These results support and quantify those of the peptide pulldown assay above: the 
control, HP1α, shows a 10-fold preference for H3K9me3 over H3K27me3 (2µM 
vs 204µM), CBX7 binds strongly to H3 K9me3 (12µM) and H3 K27me3 (22µM), 
and CBX4-CD prefers H3 K9me3 over K27me3 much like HP1 (49µM vs 150µM). 
Moreover, CBX7-CD binds either H3K9me3 or H3K27me3 with greater affinity than 
any other Pc-CD, although still not as strongly as HP1.
Mouse Pc Proteins Bind Differentially to the H3K27me3 Enriched Xi In Vivo
Together, the data shown in Figure 2.2 challenges the HP1/Pc paradigm established 
with the Drosophila proteins (Figure 2.1A): although the CD of dmPc strongly 
prefers H3 K27me3, the CDs of both mouse CBX2 and CBX7 have affinity for both 
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Figure 2.2: Quantification of the mammalian Pc-CDs binding affinity for methylated H3 
peptides.
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Figure 2.2: Quantification of the mammalian Pc-CDs binding affinity for methylated H3 
peptides.
A. Representative fluorescence polarization binding curves of CBX4-CD (top), CBX7-CD (middle), 
and CBX7-Full-Length to histone tail peptides, including the me1, me2 and me3 states on residues 
K9 (left) and K27 of H3 (right).
B. Representative fluorescence polarization binding curves of Cbx5-CD (mouse HP1α) to H3K9 
(left) and H3K27 (right) histone tail peptides in the me1, me2 and me3 states.
C. Dissociation constants (KD in µM) for Cbx 2, 4, 6, 7 and 8, as well as Cbx5 (mHP1α), with both H3K9 
(aa 1-15) and H3K27 (aa 19-35) peptides.  Values represent mean ± SD for at least 3 independent 
experiments in all cases (except for Cbx5 with certain peptides); ND=not determined.
H3 K27me3 and H3 K9me3, and CBX4-CD prefers H3 K9me3.  The differential 
binding preferences of these CDs suggests that 1) the full-length CBX proteins 
differ from one another in their histone binding affinities and 2) such differences in 
binding may translate to distinct biological readouts.  This finding led us to seek an 
appropriate in vivo model in which to study these Pc-like proteins.  Many organisms 
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use these marks to regulate and/or “remember” gene silencing (see Figure 2.3A 
for depiction), and we chose to study these proteins in the context of their potential 
role in mammalian X-inactivation.  
Mammalian X-inactivation is a classic example of heterochromatin silencing 
and epigenetic memory.  Organisms use different mechanisms to ensure equal 
dosage of the genes on their sex chromosomes: male Drosophila upregulate the 
transcription of their X-chromosome, C. elegans hermaphrodites downregulate 
each of their two X-chromosomes by half, and female mammals silence one of 
their two X-chromosomes by converting it to heterochromatin.  It is known that 
the initiation of X-inactivation and establishment of the inactive X chromosome 
(Xi) requires the non-coding RNA Xist (Penny et al., 1996).  However, Xist is only 
required at a crucial, early window of time; in experiments where Xist was removed 
after this point, there was no effect on the silent state of the Xi (Csankovszki et al., 
1999).  Therefore, many scientists hypothesize that the maintenance and clonal 
inheritance of the Xi must require the recruitment of specific proteins, perhaps 
including Pc proteins, whose function is to convert the selected X chromosome into 
its stable heterochromatic state.  It is known that trimethylated K27 is a hallmark of 
the silenced X chromosome in female mammalian cells, and researchers in both 
the chromatin and X-inactivation fields questioned whether Pc proteins bind this 
mark as well.  If so, the question remains as to how such binding plays a role in the 
silencing of the chosen X chromosome.
In order to study X inactivation, many labs use a female mouse embryonic 
stem cell (ESC) differentiation model.  We collaborated with the Heard Laboratory 
at the Curie Institute to study the binding of mouse Pc proteins to the H3K27me3-
enriched inactive X in this in vivo model.  The Heard Laboratory observes the 
formation of Xis in 3 day retinoic acid (RA) differentiated mouse ESCs and observes 
an enrichment of H3K27m3 on those Xis by immunofluorescence (IF) combined 
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Figure 2.3: In vivo association of mammalian Pc proteins with the inactive X chromosome.
A. Model organisms from all eukaryotic kingdoms use mechanisms involving non-coding RNAs and 
histone modifications to regulate gene expression.  In the animal kingdom, both flies and mammals 
use such mechanisms to regulate gene dosage compensation on the sex chromosomes.  In flies, 
the roX RNAs are integral to the two-fold upregulation of transcription on the male X chromosome 
and it is marked by “active” histone modifications, such as H3K4me and H4K16ac.  In female 
mammals, Xist RNA is required to silence one of two X chromosomes, which is also marked by 
“silencing” marks (H3K9me, H3K27me, and H4K20me).  “Active” chromatin is represented in green 
shading and “silent” chromatin is shown in red. (Image taken from (Bernstein and Allis, 2005).)
B. Immunofluoresce (IF) images of CBX-EGFP fusion proteins in 3 day +RA differentiated female 
ESCs (green).  All CBX-EGFP proteins, except CBX4, localize to the Xi.  The Xi is visualized by 
K27me3 staining (red) and DNA is stained with DAPI (blue).  (Images produced by Edith Heard and 
used with permission.)
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with RNA-FISH for Xist (as originally described in (Plath et al., 2003).  In order to 
test whether or not the five mammalian Pc proteins also co-localize to the Xi, Heard 
and colleagues transfected GFP-fusion constructs into differentiating ES cells and 
then used IF to stain the Xi for H3 K27me3 (unfortunately, the available α-CBX abs 
do not work in IF).  As shown in Figure 2.3B, several of these CBX-GFP fusion 
proteins co-localize with K27me3 staining, suggesting that they are recruited to the 
Xi.  Albeit correlatively, this data supports the Xi binding data in Figure 2.2: CBX7 
is both the strongest H3 K27m3 peptide binder in vitro and that which co-localizes 
with H3 K27me3 on the Xi most robustly.
CBX7 Associates with Chromatin Upon Differentiation in ESCs
Nevertheless, while the in vitro binding and GFP-fusion protein localization 
experiments described above provide information as to whether or not specific 
associations are possible, they do not directly demonstrate if or when these 
associations actually occur in vivo during ESC differentiation.  Although our initial 
interest in the CBX/Pc proteins grew from a collaborative project that aimed to 
analyze their potential role in X-inactivation, the lack of IF-compatible antibodies 
to these proteins makes it impossible to assess the kinetics of their endogenous 
association with the Xi.  For this reason, we decided to survey the association of 
CBX proteins with chromatin at a global level.  To address this question, I isolated 
chromatin from ES cells at various time points of differentiation (see Figure 2.4A 
for schematic of procedure) and surveyed for changes in the presence of CBX 
proteins (using antibodies that have been shown to work for immunoblotting).  As 
shown in Figure 2.4B, CBX7 showed a dramatic difference in chromatin association 
between undifferentiated and differentiated ES cells.  Although the protein is present 
throughout the time course, it is clearly only associated with the chromatin (P3) of 
the differentiated cell samples, starting from day 6 (in Figure 2.4B, compare CBX7 
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Figure 2.4: Differential global chromatin-association of mammalian Pc protein CBX7.
A. A schematic of chromatin fractionation by centrifugation.
B. Female ESCs were tested for CBX7 chromatin-association through day 7 of differentiation 
(un=undifferentiated). CBX7 and K27me3 are expressed throughout the differentiation process 
(top, “Whole Cell Extracts”), yet CBX7 only associates with chromatin (“Chromatin Extracts (P3)”) 
on days 6 and 7 and is absent from chromatin prior to day 6.  In contrast, both HP1β and K27me3 
are associated with chromatin throughout the differentiation time course.  The PVDF membranes 
were stained with Ponceau to demonstrate that samples were loaded in roughly equal amounts.
C. Undifferentiated (un) and 6 days +RA differentiating ESCs were fractionated according to the 
scheme in A.  CBX7 protein is present in the S2 fraction of both undifferentiated and 6 days 
differentiating cells, but is only present in the P3 fraction of the 6 days differentiateing cells.  Another 
repressive chromatin protein, HP1, does not change its global chromatin associated in the same 
samples.  The PVDF membrane was stained with Ponceau to demonstrate that samples were 
loaded in roughly equal amounts.
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panel of “Whole-cell extracts” versus that of “Chromatin-extracts”).  On the other 
hand, when the same blot was stripped and probed with an antibody against HP1β, 
which also binds silent chromatin marks, there was no difference in chromatin 
association (Figure 2.4B, “Chromatin Extracts”), suggesting that this effect is not 
general for heterochromatin binding proteins.  Moreover, H3K27me3 is maintained 
through the time course (Figure 2.4B, both “Whole Cell Extracts” and “Chromatin 
Extracts” panels) suggesting that this binding is mediated through additional 
mechanisms that remain unclear.  In Figure 2.4C, all chromatin isolation fractions 
(see schematic Figure 2.4A) from undifferentiated and 6 days RA differentiated 
cells are compared, and data supports that in Figure 2.4B.
CBX Proteins Bind RNA In Vitro and Show RNA-dependent Chromatin 
Association In Vivo
We then wanted to test whether the CDs of CBX proteins might interact with RNA 
in addition to H3K27 methylation in order to be recruited and/or stabilized in their 
association with chromatin.  My colleague Emily Bernstein first performed a series 
of in vitro RNA gel-shift assays (REMSAs) to assess whether the CDs of CBX 
proteins could bind to RNA molecules.  Her findings suggested that all CBX-CDs 
except CBX2-CD bound ssRNA (Figure 2.5A), and that the CD of a mammalian 
Pc protein (CBX7) interacted with ssRNA much more strongly than with the CD of 
mammalian HP1α protein (CBX5) (Figure 2.5B).
 We then asked if this interaction occurred in vivo.  Our collaborators in the 
Heard laboratory used IF to show that localization of CBX7-EGFP protein to the 
Xi diminished upon treating the cells with RNase (Figure 2.5C).  Similarly, when I 
treated chromatin isolated from differentiated ESCs with RNase, I also saw loss of 
CBX7 association by immunoblot (Figure 2.5D); however, I did not see loss of the 
chromatin-associated WDR5 or HP1β proteins upon RNase treatment.  Although 
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Figure 2.5: The CDs of some mammalian Pc/CBXs interact with RNA.
A. Recombinant CDs were tested for RNA binding by gel shift using a 500 nucleotide single-stranded 
(ss) RNA.  CBX4, 6, 7, and 8 CDs interact with RNA, while CBX1 (mHP1β) and CBX2 do not.
B. The CBX5 (mouse HP1α) CD was compared to that of CBX7 for RNA binding; only the latter 
produces a shift.  (Images in A and B produced by Emily Bernstein and used with permission.)
C. RNase-treatment of 3 day differentiated ES cells strongly diminished the accumulation of CBX7-
EGFP signal on the Xi when examined by IF.  The Xi is visualized by K27me3 staining (red) and 
the signal of the CBX7-EGFP fusion protein was enhanced using α-GFP antibody (green).  DNA is 
stained with DAPI (blue).  (Images produced by Edith Heard and used with permission.)
D. CBX7 is depleted from 6 day differentiated ES cell chromatin by RNase treatment (left), while 
WDR5 (left) and HP1β (right) are not affected.  The PVDF membrane was stained with Ponceau to 
demonstrate that samples were loaded in roughly equal amounts.
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we did not see any sequence specificity in this interaction, it is interesting to 
hypothesize that the non-coding RNA Xist might play a direct role in this interaction 
in vivo.
A PHD Finger of the NURF Complex Binds H3K4me3 Via an Aromatic Cage
In collaboration with another post-doctoral fellow in our laboratory, Joanna Wysocka, 
I also studied the binding affinity of another methylated histone binding module, 
a PHD finger of the NURF complex component BPTF.  After several studies (Ng 
et al., 2003; Santos-Rosa et al., 2002; Schneider et al., 2004) demonstrated that 
trimethylation of H3 at lysine 4 (H3K4me3) strongly correlates with transcriptional 
activation, many researchers in our field became interested in identifying H3K4me3 
effector proteins in order to learn more about the mechanisms through which this 
modification affects transcription.  Wysocka et al identified the PHD motif of BPTF as 
an H3K4me3 binding module after observing that the NURF chromatin-remodeling 
complex preferentially associated with H3K4me3 peptide over peptides that were 
either unmodified, mono- or dimethylated at H3K4 when all four peptides were 
incubated with nuclear extracts from mammalian cells (Wysocka et al., 2006). 
Since NURF is known to promote transcription (Georgel et al., 1997), this finding 
suggests that H3K4me3 may play a role in activating transcription through the 
stabilization of chromatin remodeling complexes (see Chapter 1 and Figure 1.2B). 
Moreover, the association was shown to be specific for H3K4me3 over other known 
trimethylated lysines in histone H3, specifically the repressive marks H3K9me3 
and H3K27me3.  In addition, only one of the two PHD fingers in human BPTF and 
one of the three in the homologous Drosophila protein NURF 301 (PHD2) was 
shown to bind H3K4me3 (Wysocka et al., 2006).
We then wanted to investigate the molecular basis for this interaction.  We 
collaborated with the Patel laboratory at Memorial Sloan Kettering Cancer Center 
to solve the crystal structure of the BPTF H3K4me3-binding PHD-finger in both 
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Figure 2.6: The molecular basis of the interaction between H3K4me3 and a PHD finger of the 
human NURF complex subunit BPTF.
A. Ribbon representation of the crystal structure of the BPTF PHD finger + H3K4me3 peptide 
complex with the electron density highlighted for the bound H3K4me3 peptide (aa 1–15).  
B. Electrostatic surface representation (red = negatively charged and blue = positively charged 
surface) of the crystal structure of the BPTF PHD finger + H3K4me3 peptide complex; the peptide 
is shown in a space filling representation.  This view shows how K4me3 is positioned in a “cage” 
and arginine (R) 2 in an adjacent “channel”, separated by tryptophan (W) 32 of BPTF.  
C. Representation of the intermolecular backbone interactions between the A1-T6 segment of the 
H3K4me3 peptide and the PHD finger of BPTF.  Note the interactions between the very N-terminus 
of the H3 peptide and BPTF.  (Images in A-C produced by Haitao Li and used with permission.)
the free and peptide-bound (H3 1-15 K4me3) states (Li et al., 2006).  The crystal 
structure in complex with the H3K4me3 peptide (Figure 2.6) revealed two interesting 
features of this PHD finger: first, that the H3K4 trimethyl group is positioned within 
an aromatic cage composed of amino acids Y10, Y17, Y23 and W32 (which is 
reminiscent of the aromatic cage in the Pc/CBX chromodomain) and second, that 
H3 residue R2 and the H3K4 trimethyl group are positioned in adjacent surface 
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channels separated by residue W32 (see Figure 2.6A and B).  These features not 
only demonstrate the molecular basis of the interaction between the PHD finger and 
the K4 trimethyl group, but also point to a possible explanation for the specificity of 
this interaction with H3K4me3 versus other methylated lysines, such as H3K9me3 
or H3K27me3.  The positioning of W32 to create two binding channels that fit 
H3R2 and H3K4me3 requires that they be separated by one amino acid, as they 
are in the H3 sequence surrounding K4 (i.e. R2-T3-K4) but not in the sequences 
surrounding H3K9 or H3K27 (i.e. R8-K9 or R26-K27).  The structure also reveals 
that the amino terminus of the H3 1-15 peptide interacts with the PHD finger to 
anchor it, suggesting the possibility that steric hindrance caused by the longer 
stretch of residues amino to H3K9me3 and H3K27me3 (eight and 26 amino acids, 
versus 3 for H3K4) may also contribute to their lack of interaction with this PHD 
finger (Figure 2.6C).
To test the influence of specific residues lining the aromatic cage and R2 
channel, I measured the binding constants of the wild-type PHD finger of BPTF 
versus several mutants using fluorescence anisotropy.  The Patel laboratory 
generated and purified point mutant proteins to each of the four aromatic residues 
in the cage (Y10, Y17, Y23, W32) and to three key residues in the R2 channel 
(G25, D27, Q30).  As shown in Figure 2.7, wild-type BPTF interacted strongly to 
1-15 H3K4me3 peptide with a Kd of 1.6±0.1µM while point mutations to both the 
aromatic cage (Fibure 2.7A) and R2 channel (Figure 2.7B) significantly decreased 
the binding affinity of these proteins (see Figure 2.7C for table of all Kds).  Of the 
cage mutants, Y17T affected binding the least (~6 fold decrease versus ~20-40 
fold for the other three) and, interestingly, this residue is the least conserved of the 
four in comparison with PHD finger homologues (Figure 2.7D).  Similarly, G25 and 
Q30 mutants affected binding somewhat less than mutations to D27, and these 
residues also vary between different PHD finger homologues.
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Figure 2.7: Mutational analysis of H3K4me3-binding by the BPTF PHD finger.
A. Fluorescence polarization binding curves for FAM-labeled H3K4me3 peptide (aa 1-15) with 
BPTF PHD finger wild-type (WT) protein and proteins with K4me3-binding cage mutations.
B. Binding curve for peptide + WT protein and proteins with R2-binding pocket mutations.
C. Dissociation constants (KD in µM) for the binding in A and B.  Values represent mean ± SD for at 
least 3 independent experiments in all cases.
D. Alignment of the protein sequence of 12 different PHD fingers: 1wep=PHF8 [Mus musculus]; 
1wen=ING4 [Mus musculus]; 1wem=DIDO1 (DATF-1) [Mus musculus]; 1x4i=ING3 [Homo sapiens]; 
1wes=ING1-like [Mus musculus]; 1wew=AT5g60420 [Arabidopsis thaliana]; 1we9=Alfin-1-like 
[Arabidopsis thaliana]; 1mm2=MI2B/CHD4 2nd PHD domain [Homo sapiens]; 1f62=WSTF [Homo 
sapiens]; 1fp0=KAP-1 corepressor [Homo sapiens]; 1xwh=AIRE1 [Homo sapiens]; 1wev=PHF22 
[Mus musculus].  There are two subsets (1 and 2) of PHD fingers in terms of CxC and CxxC spacing 
of the first zinc finger.  * = residues that form the K4me3-binding cage.  Note that most members in 
group 2 lack the aromatic cage residues of BPTF.  Blue arrows point to those residues that are less 
well-conserved and cause less impact on binding affinity when mutated.  (Alignment produced by 
Haitao Li and used with permission.)
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A Co-Crystal Structure of L3MBTL1 and Dimethylated Lysine Peptide Provides 
Insight Into Aromatic Cage Binding Interactions
The above studies focused on two different protein motifs, the CD and one class of 
PHD fingers, that both bind trimethylated lysines via a cage of aromatic residues. 
Much less is known about protein motifs that bind mono- or dimethylated lysines. 
One of the few proteins that is know to interact preferentially with mono- and 
dimethylated lysines is the human Lethal (3) Malignant Brain Tumor-Like protein 
1 (L3MBTL1) (Li et al., 2007).  Its function suggested an interesting connection to 
chromatin in that it is a transcriptional repressor and is required for the progression 
of mitosis, perhaps through a role in chromosome compaction (Boccuni et al., 
2003).
 Our collaborators in the Patel Laboratory crystallized the structure of the 
three MBT repeats of this protein and showed that each repeat contains an aromatic 
cage motif, much like that of the CD and PHD finger (Wang et al., 2003).  Further 
crystallization and quantitative binding studies confirmed that pocket 2 of L3MBTL1 
binds mono- and dimethylated lysine residues strongly and preferentially, although, 
interestingly, without strong sequence specificity (Li et al., 2007).  Among those 
peptides tested, L3MBTL1 pocket 2 bound mono- and dimethylated H1K26, H3K4, 
H3K9, H3K27, H3K36, and H4K20.  We then compared the co-crystal structures 
of L3MBTL1 and BPTF and the H3K4me peptides (H3K4me1 and me2 peptides 
for L3MBT and H3K4me3 for BPTF) in order to learn more about the molecular 
differences that might potentially allow the former to prefer mono- and dimethylated 
lysines and the latter trimethylated H3K4.  Our structural collaborators in the Patel 
laboratory concluded that aromatic cage of L3MBTL1 pocket 2 is deep and narrow, 
and therefore restricted to interact with the smaller mono- and dimethyl groups, 
while that of BPTF-PHD is more of a shallow cleft and can accommodate the larger 
trimethyl group.
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Figure 2.8: The Y17E mutant of a PHD finger of BPTF has increased affinity for H3K4me2 
compared to the wild-type protein.
A. Fluorescence polarization binding curves for fluorescein-labeled unmodified, H3K4me1, 2 and 3 
peptides (aa 1-15) with the WT BPTF PHD finger protein (left) and the Y17E mutant (right).
B. Dissociation constants (KD in µM) for the unmodified, H3K4me1, 2 and 3 peptides (aa 1-15) with 
the WT BPTF PHD finger and the Y17E, Y17Q and Y17D mutants.  Values represent mean ± SD 
for at least 2 independent experiments in all cases.
C. Electrostatic surface representation (red = negatively charged and blue = positively charged 
surface) of the crystal structure of the BPTF PHD finger + H3K4me2 peptide (aa 1-9) complex.  This 
view shows the surface groove recognition mode of binding and complex formation.
D. A closer view of the dimethyl-lysine sidechain of the H3K4me2 peptide (aa 1-9) inserted into the 
engineered Y17E BPTF PHD finger mutant.  The aromatic residues of the K4me-binding cage are 
shown in the dotted van der Waals representation.  The carboxylate of the mutated residue E17 
forms a direct hydrogen bond with the dimethylammonium group of K4me2 when positioned in the 
correct orientation.  (Images in C and D produced by Haitao Li and used with permission.)
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 To test this theory, we mutated the PHD finger of BPTF to see if we could 
engineer a pocket more similar to that of L3MBTL1 and subsequently change its 
binding preference from tri- to dimethylated lysine.  One of the four residues making 
up the aromatic cage of the BPTF-PHD finger, Y17, was mutated to glutamic acid, 
glutamine, and aspartic acid to assay the effects of changes in size and charge at 
this position.  I then compared the binding affinity of these mutant proteins to wild-
type BPTF-PHD finger using fluorescence anisotropy.  As shown in Figure 2.8A, 
mutating Y17 to E successfully reversed the preference of the mutated PHD finger 
from trimethylated lysine to dimethylated lysine.  This mutation also improved 
the binding affinity of this PHD finger for monomethylated lysine (Figure 2.8B). 
Mutations of Y17 to D or Q reduced the overall binding of BPTF-PHD for all three 
methylation states (Figure 2.8B).  The Patel laboratory then crystallized the Y17E 
mutant in complex with dimethylated lysine peptide to show that this difference in 
binding was not due to an artificial change in protein folding (Figure 2.8C).  They 
showed that the alignment of the 1-9 H3K4me2 peptide was almost identical to 
that shown in our earlier work (see above) with an H3K4me3 peptide, with only 
a single critical recognition difference in the contacts between K4me2 and the 
glutamic acid residue at position 17 (Figure 2.8D).
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Chapter 2 Discussion
The idea that proteins bind to histone modifications and lead to biological outputs 
is strongly supported (Bannister et al., 2001; Fischle et al., 2005; Wysocka et 
al., 2005; Wysocka et al., 2006).  In collaboration with my colleagues in the Allis 
Laboratory and with the Heard and Patel Laboratories, I performed studies that 
support the idea that the aromatic cage motif that is a recurrent and crucial structural 
feature of many methylated-histone binding proteins.  Our studies show that even 
subtle differences in sequence between similar domains, whether natural (e.g. 
CBX4-CD vs CBX7-CD) or engineered (e.g. BPTF-PHD wild-type versus Y17E), 
can impact significantly the binding affinity of these “effector” proteins for their 
histone substrates, which could therefore affect the functional readout of histone 
methylation.
Fischle et al demonstrated in vitro that the chromodomain (CD) of chromatin-
associating protein dmHP1 binds strongly to H3K9me3 peptide versus a non-
modified control, and that of dmPc preferentially binds H3K27me3 peptide (Figure 
2.1A) (Fischle et al., 2003).  However, as described above, although the CDs of 
mammalian Pc-like proteins (CBX2, 4, 6, 7, 8) are highly similar to that of Drosophila 
Pc (Figure 2.1B) and bind H3K27me3 peptides, some also bind H3K9me and one 
even prefers K9me (see Figures 2.1C and 2.2).  We also see this differential 
binding in vivo in the context of the mammalian inactive X chromosome (Figure 
2.3).  Importantly, the differential binding preferences of these proteins suggests 
that such binding may translate to distinct biological readouts.  Nevertheless, it is 
still unclear how such a highly conserved domain binds these marks differentially.
 One possible approach to solving this question is to perform structural studies 
on the CD of each mammalian CBX in complex, such as those described above in 
collaboration with the Patel laboratory.  As we learned from the structural studies 
of BPTF and L3MBTL1, certain residues are often critical in both the recognition 
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of backbone sequence and the accommodation of the methyl group (Figures 
2.6, 2.7 and 2.8).  Crystal structures and/or NMR studies of the five mammalian 
CBX CDs could reveal which residues differ in their contacts with the H3 peptide 
backbone sequence and/or the methyl group at K9 or K27, which would then allow 
for mutagenesis studies to confirm such observations and/or to test hypotheses 
as to which residues might be mutated so that, for example, the CBX4 CD now 
prefersH3K27me3 rather than H3K9me3.
There are also many questions remaining about the function of the CBX CDs 
in the context of the full proteins in vivo.  As described above, although both CBX7 
and H3K27me3 are present throughout the differentiation of ESCs, the mammalian 
Pc protein CBX7 only associates with chromatin upon ESC differentiation (Figure 
2.4).  On the other hand, HP1, which also binds silent chromatin marks, showed no 
difference in global chromatin association in undifferentiated versus differentiating 
ESCs.  Together, these results strongly suggest that there is a mechanism, or 
several concerted mechanisms, that specifically and developmentally regulate 
the chromatin-association of CBX7.  Moreover, they suggest that this association 
cannot be mediated by H3K27me3-binding alone, which is supported by the 
findings of others as well (Schoeftner et al., 2006; Vincenz and Kerppola, 2008).  
Several mechanisms could lead to this regulated chromatin-association: 
the post-translational modification of other histones and/or with marks besides 
H3K27me3, differential post-translational modification of the CBX7 protein itself, 
or the formation of different biochemical complexes and/or the association with 
transient complex members at different stages of differentiation.  One hypothesis as 
to why CBX7 is present in the nucleus but remains unassociated with chromatin in 
the early days of differentiation is that the protein itself is differentially glycosylated 
and phorphorylated post-translation.  Using algorithms I found on several website, 
I discovered that CBX7 has several O-linked glycosylation and phosphorylation 
sites.  These modifications are often thought to regulate protein function in a “ying/
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yang” dualism, in which the glycosylation of the protein at a serine or threonine 
site has one effect (i.e. prevents the protein from binding chromatin) and the 
phosphorylation of that same site has the opposite effect (i.e. allows the protein 
to bind chromatin).  It would be interesting to test whether CBX7 is differentially 
glycosylated during differentiation.  Possible experiments include simple blots 
assays with biotin labeled lectins and streptavidin HRP, as well as using wheat 
germ agglutin conjugated agarose beads to enrich for glyscolylated proteins in 
nuclear and chromatin extracts from different time points of differentiation.  In 
both types of experiments the available CBX7 antibody could be used to confirm 
whether a lectin tagged/purified band corresponds to CBX7 protein.
Although mammalian PcG protein targets have been studied extensively 
in recent years (Boyer et al., 2006; Bracken et al., 2006; Bracken et al., 2007; 
Lee et al., 2006), some very basic, yet critical, questions still remain unanswered. 
First, what is the minimal mechanism(s) that is sufficient for the recruitment of 
mammalian Polycomb Repressive Complex 1 (PRC1) group proteins (which include 
CBX) to chromatin?  The fly genome contains conserved Pc binding elements 
(or Polycomb Repressive Elements, PREs), yet their counterparts have yet to be 
defined in mammalian cells, if they exist at all (Otte and Kwaks, 2003). The work 
described above suggests the CD may play an important role in recruitment by 
binding H3K27me3.  Our data also suggests that an interaction between the CBX-
CDs and RNA may be involved in their recruitment to chromatin.  Moreover, the 
ability of particular CDs to bind both methylated histone tails and RNA suggests 
that a cooperative binding mechanism may mediate their enrichment in chromatin. 
Functional and structural studies will be required to determine the nature of this 
potential synergy; Assistant Professor Emily Bernstein is currently conducting 
such studies in her laboratory at Mount Sinai School of Medicine.  Nevertheless, 
the exact mechanism through which the CD enables PRC1 recruitment and/or 
stabilization on chromatin is still not known.
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Second, what is the mechanism of silencing through the recruitment 
of repressive binding proteins such as Pc?  There is evidence for PcG protein 
dimerization, including in vitro data for the self-interaction of dmPc (Min et al., 
2003) and the Xenopus homologue M33 (Reijnen et al., 1995), and both in vitro and 
in vivo data showing that Mel-18 dimerization is regulated by its phosphorylation 
(Fujisaki et al., 2003).  Such interactions may function to cause heterochromatin 
compaction and therefore silencing.  However, studies in ESCs showing that H3K27 
methylation via PcG proteins is dominant over H3K4 methylation at bivalent domain 
loci (Azuara et al., 2006) suggests that complete heterochromatin compaction is 
not necessary for silencing.  The work described above, as well as that of others 
(Zhao et al., 2008), suggests that PcG protein interactions with non-coding RNAs 
may play a role, particularly in the case of Xist and the mammalian inactive X 
chromosome.  Importantly, PcG proteins also include Ring1A and B, which have 
ubiquitinating activity (de Napoles et al., 2004).  It may be that mammalian Pc 
proteins (CBXs) employ different modes of silencing by varying their interactions 
with other proteins; data from the Reinberg lab shows that this type of complex-
swapping regulation occurs during differentiation amongst the proteins of the 
PRC2 complex (Kuzmichev et al., 2005).  Moreover, very recent work suggests 
that PcG proteins (specifically Polycomb Repressive Compex 1 (PRC1) proteins, 
which include Pc itself) can remain bound to chromatin during DNA replication 
(Francis et al., 2009).  This implies that PcG proteins are not only critical to the 
regulation of gene silencing, but also to the inheritance of this silent status through 
cell division.
The studies described above build upon the work of many other groups 
and support the idea that interactions between covalent modifications on histone 
proteins and non-histone chromatin proteins can have significant biological 
consequences.  Moreover, they emphasize the fact that conservation between 
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primary protein sequences does not provide complete information about the 
functional conservation of domains such as the methyl-binding CD.  Structural and 
mutagenesis studies, such as those described for the methyl-binding PHD finger 
and MBT repeats, can pinpoint features that are critical to specific protein-protein 
interactions and potentially help to create testable models and hypotheses about 
how these domains mediate biological function.
The studies described in this Chapter focus on the specific features of 
various non-histone chromatin proteins that mediate their binding to particular 
histone modifications.  However, most of these experiments were done in vitro 
with histone peptides that are a simplified representation of the canonical histone 
H3.  In the next few chapters, I will describe how the H3 substrate actually changes 
significantly during the process of mouse ESC differentiation.  Moreover, in Chapter 
4 I will describe how one of these changes, in particular, impacts the affinity of the 
CBX7-CD for H3K27me3.
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Chapter 3: Analysis of global histone H3 profiles across ESC 
differentiation
Summary
As described in Chapter 2, I began using a female ESC model in order to study the 
recruitment of mammalian Polycomb proteins to chromatin during differentiation. 
In this chapter, I will describe two studies in which I analyzed the global profile of 
histone H3 in these ESCs during differentiation.  In the first study, post-doctoral 
fellow Sandra Hake and I used biochemical methods to separate and measure the 
three histone H3 isoforms in mouse ESCs at different stages of differentiation.  In 
the second, I performed chromatin immunoprecipitation (ChIP) with an antibody 
to the well-characterized histone modification H3K4 trimethylation (H3K4me3) 
and then collaborated with both fellow student Aaron Goldberg to sequence the 
associated DNA and Assistant Professor Deyou Zheng at Albert Einstein College 
of Medicine to analyze those sequences.  In both studies, our aim was to see how 
H3 isoforms and modifications known to correlate with gene activation change 
during the process of ESC differentiation.  The results of these studies support 
both the findings of previous reports (Azuara et al., 2006; Bernstein et al., 2006; 
Lennox and Cohen, 1988; Pina and Suau, 1987) and, importantly, the validity of 
this ESC differentiation model.
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Results
Incorporation of H3 Isoforms Into Chromatin During ESC Differentiation
Histone proteins are among the most conserved proteins in the proteome.  Histone 
H3 is particularly well conserved, although its diversity is increased by the expression 
of more than one isoform in multicellular organisms.  Mammalian cells have been 
shown to express three “core” histone isoforms: H3.1, H3.2 and H3.3 (Figure 
3.1A).  H3.1 and H3.2 are incorporated into chromatin in a replication-dependent 
manner (RD); H3.3, on the other hand, can be incorporated into chromatin at any 
point in the cell cycle, including both S-phase and outside of replication (replication-
independent, RI; see Figure 1.5B).  Although these isoforms differ by at most five 
amino acids (i.e. mammalian H3.1 compared to H3.3), they have been shown 
to correlate with functionally distinct regions of the genome.  In Drosophila, RI 
H3.3 was shown to be enriched over the RD H3 isoform in regions of chromatin 
undergoing active transcription (Ahmad and Henikoff, 2002).  Importantly, the 
incorporation of RI H3.3 into chromatin outside of S-phase was abolished when 
the four differing amino acids between the two isoforms were mutated to those of 
the RD H3.  In addition, other studies have shown that these isoforms associate 
with distinct protein complexes (Tagami et al., 2004) that serve as chaperones for 
the deposition of these H3 isoforms into chromatin.
My colleague Sandra Hake and I were interested in analyzing the relative 
amounts of histone H3 isoforms in the chromatin of mammalian cells.  Since there 
are currently no antibodies available that can distinguish between the three H3 
isoforms, she chose to use two different biochemical methods to separate and 
measure the relative amounts of these proteins in mammalian cells.  First, she 
used reverse-phase high-pressure liquid chromatography (RP-HPLC) to separate 
total histone extracts (Figure 3.1B).  Although many previous studies had shown 
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Figure 3.1: Mammalian cell lines differ in their H3 protein composition.
A. Sequence alignment of the three histone H3 variants: H3.1, H3.2 and H3.3.  H3.1 and H3.2 
deposition occurs during S-phase and is therefore dependent on replication, while H3.3 deposition 
occurs both during and outside of S-phase and is therefore independent of replication.  Differences 
in amino acid sequence are shown in colored font (black = “canonical” H3.1 sequence, colors = 
differences found in H3.2 and H3.3); identical amino acids are shown as dashes (-).
B. Top: a typical Reverse Phase-High Pressure Liquid Chromatography (RP-HPLC) profile of 
HEK293 histones. Peaks that correspond to individual histones are labeled.  Histone H3 elutes as 
two peaks (boxed): peak1 and peak2.  Bottom: RP-HPLC profiles of histone H3, peak1 and peak2, 
from six representative mammalian cell lines.
C. Ratios of RP-HPLC peak areas (peak1/peak2) from H3 samples isolated from nine different 
mammalian cell lines, including data for undifferentiated mouse ESCs (LF2) and ESCs treated with 
Retinoic Acid (RA) for 3, 6, and 10 days (red box).
that H3 elutes in two separate peaks (i.e. “peak 1” and “peak 2”), Sandra noted that 
the ratio of the areas of these H3 peaks differed between different mammalian cell 
lines.  Mass spectrometry analysis of these peaks by Benjamin Garcia of the Hunt 
Laboratory (UVa) confirmed that peak 1 consisted of H3.2+H3.3 and peak 2 of 
H3.1.  Sandra therefore hypothesized that the change in peak area ratio reflected 
a change in H3 isoform deposition into chromatin.
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We then wondered how this ratio might change in ESCs as they differentiated. 
Using the same retinoic acid (RA) differentiation method described in Chapter 2, 
I differentiated female mouse ESCs (LF2 line) with RA for 3, 6 and 10 days.  I 
then extracted the histones from these cells, separated them by RP-HPLC, and 
calculated the peak area ratios between H3 peaks 1 and 2.  As shown in Figure 
3.1C, the ratio of peak1/peak2 increases as ESCs differentiate (see data boxed in 
red).  We also noted that, interestingly, both ESCs and the neuroblastoma cell line 
N2a had much higher peak1/peak2 ratios than other cell types tested.
Since the differences in these ratios could be due to an increase in H3.2 
or H3.3 or a decrease in H3.1, we then wanted to develop a way to separate all 
three isoforms.  We turned to a 2D gel electrophoresis system, in which the first 
dimension was separation by Triton-Acid-Urea (TAU) gel electrophoresis and the 
second was separation by standard SDS-PAGE gel electrophoresis.  As shown in 
Figure 3.2A, this method allowed us to separate all three histone H3 isoforms. We 
confirmed that the boxed bands (Figure 3.2A) were indeed H3.1, H3.2 and H3.3 
by mass spectrometry (performed by Benjamin Garcia in the Hunt Laboratory). 
We then used this 2D gel system to separate total histones extracted from each 
cell type (Figure 3.2B) and used Image Gauge software to calculate the relative 
amount of each H3 isoform for each cell type (Figure 3.2C).  
This quantification revealed several interesting differences, both between 
the stem-like cells (LF2 and N2a) and other cell lines and within the different stages 
of ESC differentiation.  First, stem-like cells appear to incorporate a relatively low 
amount of H3.1 into their chromatin versus H3.2 or H3.3 as compared to other cell 
types.  Cells such as Raji and HeLa have a much higher relative amount of H3.1 
than H3.2 or H3.3, whereas the opposite is true of LF2 or N2a cells.  This supports 
the data in Figure 3.1 showing that the stem-like cells have greater peak1/peak2 
ratios.  Second, H3.3 appears to increase in its relative amount upon differentiation 
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Figure 3.2: Mouse ESCs have an increased amount of the variant H3.3 as compared with 
more differentiated cell lines.
A. An example of total acid-extracted histones separated by 2-dimension (2D) gel electrophoresis: 
the first dimension separation is by Triton Acid Urea (TAU) gel electrophoresis and the second 
by SDS/PAGE.  The gel is then stained with Coomassie blue.  Mammalian histone H3 variants 
separate into three different spots (box): H3.1, H3.2, and H3.3, from left to right.
B. The region containing H3.1, H3.2, and H3.3 (boxed in A) of 2D TAU gel analysis (as in A) of total 
acid-extracted histones from representative mammalian cell lines (see Figure 3.1C).
C. Quantification of H3.1, H3.2, and H3.3 proteins in 2D TAU gels (shown in B).  Total H3.1, H3.2, 
and H3.3 protein was set as 100% and the distribution of H3.1 protein (light gray bars), H3.2 (dark 
gray bars), and H3.3 (black bars) is shown as % of total H3.  Data for undifferentiated mouse ESCs 
(LF2) and ESCs treated with Retinoic Acid (RA) for 3, 6, and 10 days are boxed in red.
D. DNA histogram of asynchronously growing undifferentiated ESCs stained with propidium iodide 
and analyzed by flow cytometry.  Data was analyzed using FloJo FACS software.
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of ESCs, although the latest point of differentiation (10 days post RA induction) 
shows a relative increase in H3.2 as well.  This second finding is interesting in that 
it both agrees with and raises interesting questions about some hypotheses of 
differential H3 isoform deposition.
Since H3.3 is deposited into chromatin in a replication-independent manner, 
it has been hypothesized that its relative amount should increase upon differentiation 
into non-dividing cells such as neuronal cells (Lennox and Cohen, 1988; Pina and 
Suau, 1987).  Indeed, rat tissue types such as heart and brain that are enriched in 
post-mitotic cells were found to have higher levels of H3.3 protein, when analyzed 
by RP-HPLC (Garcia et al., 2008).  Our findings support this hypothesis in that 
both ESCs differentiated toward a neuronal lineage with RA and the stem-like 
neuroblastoma cell line N2a have increased relative amounts of H3.3.  At the same 
time, given that stem-like cells cycle and proliferate very rapidly compared to other 
cell lines and spend more time in S-phase (as shown by FACS profile in Figure 
3.2D, ~64% of undifferentiated ESCs are in S-phase as compared to ~10-30% in 
most other asynchronously grown cell lines), it is interesting that these cells have 
so much H3.3 incorporated into chromatin.  This suggests that there must be an 
active remodeling and/or deposition mechanism to maintain this elevated ratio of 
RI H3 to RD H3, or that these cells express relatively high levels of H3.3 protein, 
which could be incorporated during as well as outside of S-phase.
Changes in H3K4me3 Localization During ESC Differentiation
In addition to the incorporation of different isoforms of the histone H3 protein, 
variation is also introduced into the chromatin template by enzymes that add 
(and remove) post-translational covalent modifications to specific residues of 
H3.  One well-characterized modification is H3K4me3, which has been shown 
to correlate with the transcription start site of genes (Barski et al., 2007).  This 
correlation occurs predominantly at gene loci that are being actively transcribed, 
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although studies have also shown that H3K4me3 also localizes at lower levels 
to the transcription start site of genes that are not being expressed (Guenther et 
al., 2007).  One interesting example of this is found in ESCs, in which Bernstein 
and colleagues have shown that H3K4me3 co-occupies many of the same loci as 
H3K27me3, a modification that has been correlated with transcriptional silencing 
(Bernstein et al., 2006).  They also demonstrate that this duality of modifications 
is mostly “resolved” upon differentiation, so that only one modification (H3K4me3 
or H3K27me3) localizes to a particular locus, and that this resolution restores 
the correlation between H3K4me3 and active transcription.  These studies and 
others (Azuara et al., 2006) suggest the possibility that H3K4me3 correlates both 
with genes that are being actively transcribed as well as those that are simply 
“poised” for transcription, i.e. transcription can quickly proceed upon removal of 
the dominant silencing mark H3K27me3.
 This interesting finding prompted me to investigate the localization of 
H3K4me3 in differentiating ESCs using the method I typically employ (see Chapter 
6: Materials and Methods).  Chromatin immunoprecipitation (ChIP) is a method 
used to map the loci at which a particular histone modification is enriched or 
the target loci of a given non-histone chromatin protein.  The schematic shown 
in Figure 3.3 depicts the steps of a typical ChIP experiment.  Using a well-
characterized and highly specific antibody to H3K4me3, I performed ChIP on the 
cross-linked chromatin of both undifferentiated ESCs and ESCs differentiated for 
3 days with RA.  I then assayed for the presence of specific DNA sequences by 
Q-PCR with Sybergreen to test the success and specificity of the ChIP.  I first 
tested basic positive and negative controls (Figure 3.4A).  Since the actin gene is 
highly expressed in both undifferentiated and differentiated ESCs, and therefore 
presumably marked by H3K4me3, I assayed for the presence of actin DNA in these 
ChIP samples.  H3K4me3 was indeed associated with actin, with an enrichment of 
54
adapted from John Arne Dahl and Philippe Collas, Nature Protocols 2008
ATGCCGGATG
GGCGGTTAAC
CTGATGCGAG
TAGCGATGCA
Solexa sequencing
Figure 3.3: Chromatin ImmunoPrecipitation (ChIP) is a method for determining the genomic 
targets of chromatin proteins.
A schematic of the Chromatin ImmunoPrecipitation (ChIP) method for isolating gemonic sequences 
associated with a given chromatin protein.  The DNA is first fixed to nearby proteins by cross-linking 
with formaldehyde, and then sheared into ~500-1000 base pair segments through sonication to form 
a lysate.  Cells that have not sheared well and other non-soluble debris is cleared by centrifugation 
and the resulting supernatant is divided into “input” and “ChIP” samples.  Magnetic beads coated in 
the chosen antibody are then incubated with the ChIP samples to allow the binding of the antibody 
with its specific epitope(s).  The beads are then washed of any non-specific interactions.  The 
remaining chromatin fragments are then eluted from the beads and treated (along with the input 
sample) to reverse the cross-linking between DNA and protein.  The DNA is then isolated from input 
and ChIP samples and ready for quantitative PCR and/or sequencing.
7.8% and 11.1% over input DNA for undifferentiated and 3 days +RA differentiated 
cells, respectively.  The 3 days +RA differentiated cells showed higher enrichment 
of H3K4me3 at the actin gene in this particular experiment, but only ~1.4 fold. 
Conversely, Q-PCR for a DNA sequence in an intergenic region of the mouse 
genome did not show any significant enrichment over input (< 0.5%).
 I was then interested in testing genes associated with either pluripotency 
(markers of undifferentiated ESCs) or a particular lineage (markers of differentiation). 
As shown in Figure 3.4B, representative markers of both pluripotency and lineage 
behaved as expected: Oct3/4, a marker of pluripotency, showed greater enrichment 
55
Figure 3.4: H3K4me3 is differentially enriched at stem cell marker Oct3/4 and differentiation 
marker Sox17 in undifferentiated and 3 days +RA differentiating ESCs, respectively.
A. H3K4me3 ChIP data for both negative (an intergenic region) and positive (β-actin) control 
ChIP targets as assayed by RT-PCR.  Input and H3K4me3 antibody ChIP eluates from both 
undifferentiated ESC (black) and 3 days +RA differentiating ESC (grey) samples were assayed for 
the presence of intergenic region and β-actin DNA by RT-PCR with SYBRgreen.  Signal for each 
DNA primer pair (intergenic region or β-actin) with each sample (undifferentiated ESCs or 3 days 
+RA differentiated ESCs) was normalized to the corresponding input signal and plotted as shown.
B. H3K4me3 ChIP data for both a stem cell marker (Oct3/4) and a marker of differentiation (Sox17) 
as assayed by RT-PCR with SYBRgreen.
C. Gene expression (mRNA) data for both a stem cell marker (Oct3/4) and a marker of differentiation 
(Sox17) as assayed by RT-PCR with SYBRgreen.
D. H3K4me3 ChIP data for both a stem cell marker (Oct3/4) and a marker of differentiation (Sox17) 
as assayed by Solexa sequencing.  BED file data generated by The Rockefeller University Genomic 
Resource Center was uploaded to the UCSC Genome Browser, which then mapped the sequenced 
DNA to the mouse genome.  Each box represents a representative gene locus (Oct3/4 or Sox17). 
Sequence tags that map to a given region are represented as red and blue vertical dashes.  The 
location of the selected gene is labeled at the top of each box; its exon-intron organization is 
labeled at the bottom.
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Figure 3.4: H3K4me3 is differentially enriched at stem cell marker Oct3/4 and differentiation 
marker Sox17 in undifferentiated and 3 days +RA differentiating ESCs, respectively.
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for H3K4me3 in undifferentiated cells (12.9%) than in 3 days +RA differentiated cells 
(4.1%, ~3.1 fold change); Sox17, a marker of endodermal differentiation, showed 
greater enrichment for H3K4me3 in 3 days +RA differentiated cells (9.6%) than in 
undifferentiated cells (2.7%, ~3.6 fold change.  Importantly, expression of both the 
Oct3/4 and Sox17 genes, as measured by Q-PCR of mRNA levels, correlated with 
the enrichment of H3K4me3 at these loci (Figure 3.4C): Oct3/4 showed greater 
expression in undifferentiated ESCs as compared to 3 days +RA differentiated 
ESCs, while Sox17 showed greater expression in the differentiated cells.
 After establishing that ChIP with H3K4me3 antibody produced the expected 
results for the above control genes in undifferentiated and 3 days +RA differentiated 
ESCs, I wanted to perform a more comprehensive, less biased analysis of the 
genes that associated with H3K4me3 these samples.  I therefore collaborated with 
a fellow graduate student in our laboratory, Aaron Goldberg, who has optimized a 
method for ChIP followed by sequencing with Solexa sequencing technology (ChIP-
seq).  After performing the above ChIP, the samples were prepared for sequencing 
by adding specific adaptors to the precipitated DNA and amplifying the sequences 
by PCR.  We then submitted these samples to The Rockefeller University Genomic 
Resource Center for sequencing.  In order to assess whether the sequencing 
results agreed with those generated by RT-PCR, I mapped the Solexa sequences 
to the mouse genome using the University of California at Southern California 
(UCSC) Genome Browser.  As shown in Figure 3.4D, the Solexa sequencing 
data correlated well with the traditional ChIP data in Figure 3.4B.  At the locus of 
stem cell marker Pou5f1 (Oct3/4, left), many more sequencing tags map there in 
the undifferentiated ESC sample (top line) than to the 3 days +RA differentiating 
sample (bottom line).  In contrast, many more sequencing tags map to the 3 days 
+RA differentiating sample (bottom line) than to the undifferentiated ESC sample 
(top line) at the locus of differentiation marker Sox17 (right).
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 We then collaborated with Assistant Professor Deyou Zheng at Albert 
Einstein College of Medicine to perform a global analysis of the data.  Dr. Zheng 
generated lists of genes that were differentially enriched in H3K4me3, i.e. genes 
that are significantly marked by H3K4me3 in undifferentiated and those that are 
enriched in the 3 days +RA sample.  The lists included > 300 genes marked by 
H3K4me3 in the undifferentiated sample and >500 genes that show enrichment 
in the 3 days +RA sample (see Appendix for complete list).  To check the validity 
of this analysis, I used the UCSC Genome Browser to map the raw sequence 
data and check representative genes.  Included in the list of genes marked by 
H3K4me3 in undifferentiated ESCs was the stem cell marker Nanog. As shown in 
the snapshot of the Nanog locus in the UCSC Genome Browser (Figure 3.5A, panel 
a), our undifferentiated sample (top line) indeed contained many more sequencing 
tags mapping to the Nanog locus than did the 3 days +RA differentiating sample 
(bottom line).  This result correlated, as expected, with the increased expression 
of Nanog in undifferentiated ESCs versus 3 days +RA differentiating ESCs as 
measured by RT-PCR (Figure 3.5A, panel b).  Similarly, the differentiation marker 
GATA6 was included in the list of genes marked by H3K4me3 in 3 days +RA 
differentiating ESCs and, likewise, the raw data (Figure 3.5B, panel a) confirms 
that the differentiated sample (bottom line) contained many more sequencing tags 
that map to the GATA6 locus than did the undifferentiated sample (top line).  This 
result also correlates well with RT-PCR expression data for the GATA6 gene in 
undifferentiated and 3 days +RA differentiating samples (Figure 3.5B, panel b). 
Notably, the representative genes analyzed by ChIP-RT-PCR and ChIP-seq in 
Figure 3.4 above (Oct3/4 and Sox17) do not appear on the lists generated by 
global bioinformatic analysis.  This inconsistency is most likely because of the high 
stringency used in this initial global analysis, which can produce false negatives.
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Figure 3.5: H3K4me3 is differentially enriched at functionally different genes in undifferentiated 
and 3 days +RA differentiating ESCs.
A. H3K4me3 ChIP data for a stem cell marker (Nanog) as assayed by Solexa sequencing 
(a).  Corresponding gene expression (mRNA) data for this marker as assayed by RT-PCR with 
SYBRgreen (b).
B. H3K4me3 ChIP data for a marker of differentiation (GATA6) as assayed by Solexa sequencing 
(a).  Corresponding gene expression (mRNA) data for this marker as assayed by RT-PCR with 
SYBRgreen (b).
C. Global analysis of all ChIP-sequence data using Database for Annotation, Visualization and 
Integrated Discovery (DAVID) functional annotation tools: DNA sequences for each sample 
(undifferentiated ESCs and 3 days +RA differentiating ESCs) were clustered according to their 
association with various pathways, assayed for significance (P-value), and ranked accordingly.
D. Global analysis of all ChIP-sequence data using DAVID functional annotation tools: DNA 
sequences for each sample (undifferentiated ESCs and 3 days +RA differentiating ESCs) were 
clustered according to their association with various keywords, assayed for significance (P-value), 
and ranked accordingly.
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Figure 3.5 cont’d: H3K4me3 is differentially enriched at functionally different genes in 
undifferentiated and 3 days +RA differentiating ESCs.
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 Having verified the validity of the ChIP-seq data, I then used the lists to 
ask whether H3K4me3 preferentially marks genes involved in specific pathways 
or functions in undifferentiated and/or differentiating ESCs.  Using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) tools available 
online at http://david.abcc.ncifcrf.gov/, I was able to cluster each gene list into 
functionally relevant categories for comparison (Figure 3.5C and D).  First, I 
analyzed the gene lists by their association with Kyoto Encyclopedia of Genes 
and Genomes (KEGG) Pathways (Figure 3.5C).  Interestingly, 25 genes of the 3 
days +RA list grouped significantly (P-value = 1.7E-6) in the “Neuroactive ligand-
receptor interaction” pathway (Figure 3.5C, bottom).  This association agrees with 
other data that suggests these cells are progressing toward a neuronal lineage. 
Genes from this list also clustered into pathways related to cell motility, which 
is consistent with the changes these cells undergo during differentiation.  The 
genes of the undifferentiated ESCs (Figure 3.5C, top) formed fewer clusters with 
less significance (P-values in the range of E-2), perhaps because there are fewer 
genes in the undifferentiated list.  The undifferentiated genes clustered in pathways 
associated with metabolism, but none that indicate development or differentiation 
as with the 3 days +RA genes.
 Next, I analyzed the gene lists by their association with Swiss-Prot (SP) 
and Protein Information Resource (PIR) database keywords (Figure 3.5D).  Again, 
the genes of the undifferentiated ESCs (Figure 3.5D, top) formed fewer clusters 
with less significance than those of the 3 days +RA gene list, and these clusters 
are all generally related to cell growth and proliferation.  Genes in the 3 days +RA 
differentiated sample list, however, formed several highly significant groupings 
(Figure 3.5D, bottom), and the most significant amongst them are related to 
differentiation and development.  The most significant clustering of genes from 
this list are those categorized as Homeobox, a finding that also results from the 
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clustering of these genes according to protein domain (data not shown).  Since 
Homeobox, or Hox, genes are well-characterized as regulators of development 
and have been shown to be modified by H3K4me3 previously (Milne et al., 2002), 
this finding further validates both this ESC model of differentiation and our ChIP-
seq method.
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Chapter 3 Discussion
Both H3.3 incorporation and H3K4me3 are linked to transcriptional activation 
(Ahmad and Henikoff, 2002; Ng et al., 2003; Santos-Rosa et al., 2002; Schneider et 
al., 2004; Sutcliffe et al., 2009).  Since the transcriptional profile changes dramatically 
during the differentiation of ESCs, many groups have logically asked whether these 
two aspects of chromatin change as well and, if so, whether these changes are 
correlative or causal.  In collaboration with other Allis laboratory members and 
Assistant Professor Deyou Zheng at Albert Einstein College of Medicine, I showed 
that both the covalent modification profiles and the specific isoforms of histone H3 
change during mouse ESC differentiation and that these changes correlate with 
differences in the transcriptional profile of these cells.  Our findings both agree with 
and add to other studies of mouse ESC differentiation (Mikkelsen et al., 2007), and 
therefore help to validate this method of ESC differentiation (Smith, 1991) as a 
model in which to study changes in histone biology during early development.
 The association of histone H3 variant H3.3 with transcriptionally active loci 
was originally established in Drosophila, a genetically tractable system (Ahmad 
and Henikoff, 2002).  Studying the potential differences between the three 
mammalian H3 variants has been more challenging, both because of the greater 
number of copies of H3 genes in the mammalian genome and because of the 
lack of specific H3 variant antibodies.  Some studies have used epitope tagging 
to differentially label each H3 variant and investigate their potential differences 
in chromatin incorporation and function in mammalian cells (Chow et al., 2005; 
Daury et al., 2006; Jin and Felsenfeld, 2006; Torres-Padilla et al., 2006); however, 
this approach does not adequately address the possibility that differences in H3 
variant expression, as dictated by their endogenous promotors, may influence 
their differences in chromatin incorporation and function.  Although it has been 
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shown in Tetrahymena that expression of H3.3 outside of S-phase is sufficient for 
its replication-independent incorporation (Yu and Gorovsky, 1997) and that epitope 
tagged H3.3 immunoprecipitates a unique chaperone (HIRA) in its complex from that 
of epitope tagged H3.1 (Tagami et al., 2004), it is still unclear how these chaperone 
proteins mediate the differential incorporation of the H3 variants.  Moreover, the 
histone H3.3 gene structure is significantly different from that of the canonical 
replication dependent H3 genes: whereas H3.1 and H3.2 genes are intronless and 
are transcribed into non-polyadenylated mRNAs with short 3’ and 5’ untranslated 
regions (UTRs), H3.3 genes have introns and are transcribed into polyadenylated 
mRNA with lengthy UTRs and an atypical codon usage pattern (Wells et al., 1987). 
It may therefore be critical to study the expression, incorporation and function of 
epitope-tagged H3.3 protein under conditions in which it is expressed from its 
endogenous promoter.  Such studies are currently being conducted by my fellow 
graduate student Aaron Goldberg.
 As described above, we chose to use a proteomic approach to study 
the composition of histone H3 in chromatin in various mammalian cell lines. 
Chromatography and gel electrophoresis enabled us to separate the three H3 
variants and then confirm their identity by mass spectrometry.  Although this 
method does not provide information about the differential association of each H3 
variant with specific genomic loci, it did allow us to gain some valuable information 
about the differences in H3 variant incorporation between various mammalian cell 
lines and stages of ESC differentiation.  ESCs and neuroblastoma (N2a) cells 
were observed to have a higher relative amount of H3.3 than other cell lines. 
Moreover, the relative amount of H3.3 generally increased as ESCs differentiated. 
Interestingly, each of these observations is consistent with a particular theory of 
H3.3 function or deposition, yet together they are potentially contradictory.  The first 
observation, that the pluripotent (ESCs) or multipotent (N2a) cells have relatively 
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more H3.3 variant protein than the differentiated cell lines tested, fits a model in 
which H3.3 is associated with genes that are “poised” for activation: stem-like cells 
are presumed to have many such loci so that they are ready to progress toward 
any given lineage upon induction.  However, it is also true that these cells are 
rapidly proliferating and therefore spend a higher percentage of time in S-phase, 
when the canonical H3 variants (H3.1 and H3.2) should equally be available for 
deposition.  To this end, our second observation, that the relative amount of H3.3 
generally increases as ESCs differentiate and slow their proliferation, fits with a 
model in which amitotic cells accumulate H3.3 (relative to H3.1 and H3.2) since it 
can be deposited it into chromatin outside of S-phase.  However, as noted above, 
other even more differentiated cell lines (e.g. Raji or U2OS) have relatively less 
replication-independent H3.3 than do the ESCs.  Although there are many trivial 
explanations for these apparent contradictions (e.g. differences between primary 
and transformed cell lines), it is also possible that H3.3 has functions in addition to 
its association with transcription.  Moreover, it may be that H3.3 has a unique and 
specialized function(s) in ESC differentiation and/or early mammalian development 
that has yet to be identified.  This question is also being addressed by my colleague 
Aaron Goldberg.
 Trimethylation of H3K4 is another important marker of active transcription, 
and one that has potentially important implications in development since it is 
catalyzed by trithorax proteins, which are required for the proper expression of 
key developmental regulators such as Hox genes (Ringrose and Paro, 2004). 
Several groups have examined the H3K4me3 profile, and that of the PcG 
mediated H3K27me3 modification, in ESC models to see whether it contributes 
to the maintenance and/or loss of pluripotency (Azuara et al., 2006; Bernstein et 
al., 2006; Mikkelsen et al., 2007).  As expected, and in agreement with my own 
results described above, these studies find that H3K4me3 marks the transcription 
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start site of genes required for pluripotency in undifferentiated ESCs and of genes 
that regulate specific lineages in differentiating ESCs.  However, Bernstein et al 
and Azuara et al additionally found that H3K4me3 was also present on genes 
that expressed at very low levels.  These genes were dually marked by both 
H3K4me3 and H3K27me3, suggesting that the repressive H3K27me3 modification 
is dominant over the activating H3K4me3 mark.  Bernstein et al termed these loci 
“bivalent domains”, in which large regions of H3K27me3 marked chromatin contain 
smaller regions of H3K4me3.  Azuara et al further demonstrate the dominance of 
H3K27me3 over H3K4me3 by showing that the transcription at these “bivalent” 
genes increases in ESCs lacking H3K27me3 (Eed null ESCs, which cannot 
methylate H3K27 since the lack of Eed disrupts the HMTase activity-containing 
PRC2 complex).  Bernstein et al hypothesize that this bivalent status enables 
ESCs to keep key developmental regulators in a “poised” state so that they are 
ready for activation upon differentiation.
 Importantly, these studies not only reveal that ESCs have a unique 
modification profile but also that H3K4me3 may have a unique role in pluripotent 
cells.  Nevertheless, since they were done using ChIP (see Figure 3.3) and were 
therefore constrained by the antibodies chosen and/or available, they may have 
missed other modifications or patterns of modifications (on histone H3 or another 
histone) that are potentially unique and important to ESC chromatin.  Although 
here I used the fact that H3K4me3 is a well-established mark to validate my 
method of ESC differentiation, in the future it would be interesting to use a non-
biased approach to assess the global modification patterns on all histones (and 
histone variants) in ESCs as they differentiate towards different lineages.  Such 
an investigation could potentially reveal other “bivalent” marks, perhaps on or 
between other histone tails.  Two complementary approaches could be used to 
explore this possibility.  First, one could use a proteomic strategy such as that 
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used by Taverna et al (Taverna et al., 2007) to show long-distance combinatorial 
methylation and acetylation modifications on the H3 tail in Tetrahymena.  In this 
approach, chromatographic methods would be used to separate differently modified 
histone tails after appropriate digestion with an enzyme that leaves the histone tail 
intact (e.g. GluC to digest H3, as described in Chapter 4).  Mass spectrometry 
can then be employed to determine the precise combination of modifications on 
the proteins that elute from the stationary phase at a given time.  By comparing 
the modification profiles of undifferentiated ESCs to that of differentiated ESCs 
(and repeating with multiple ESC lines and methods of differentiation) it would be 
possible to identify modification patterns that correlate with the maintenance and/
or loss of pluripotency.  Second, one could use a ChIP approach with antibodies 
selected based on either theoretical hypotheses or the data generated using the 
proteomic approach.  The second strategy would then allow one to compare the 
genomic targets of any novel “stem cell” marks to those mapped by Bernstein et al 
using H3K4me3 and H3K27me3 ChIP.  It may also be important to use functional 
annotation tools, such as the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) tools described above, to compare the gene targets of these 
modifications since they may regulate common pathways even if they are not 
enriched at identical genomic loci.
 Epigenetic regulation is necessary for both the self-renewal and proper 
differentiation of ESCs; this regulation is accomplished by altering structural and 
biochemical aspects of chromatin.  Here I show that my adaptation of a method of 
ESC differentiation (Smith, 1991) produces changes in histone H3.  These results 
both support and expand upon the findings of others (Lennox and Cohen, 1988; 
Mikkelsen et al., 2007; Pina and Suau, 1987), and help to validate this method as 
a model of ESC differentiation.  In the next chapter, I will describe another change 
that occurs to H3 during ECS differentiation.
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Chapter 4: Study of histone H3 proteolysis in ESCs
Summary
When screening samples from a time course of RA-induced differentiating ESCs for 
changes in histone modifications, as described in Chapters 2 and 3, I observed that 
histone H3 was proteolytically cleaved at its N-terminus during differentiation.  In 
this chapter, I will describe how I mapped the sites of H3 cleavage (in collaboration 
with the Hunt laboratory at The University of Virginia) and identified Cathepsin L 
as at least one protease responsible for proteolytically processing the N-terminal 
H3 tail.  Although cathepsin, and Cathepsin L in particular, are typically thought 
to reside in the lysosome, our study supports those of others (Goulet et al., 2004; 
Hiwasa and Sakiyama, 1996) by showing cathepsin activity in the nucleus.  Such 
regulated, limited proteolysis is a mechanism by which the cell can irreversibly 
remove modifications present on the H3 tail as well as trigger downstream 
functional effects via chromatin remodeling and/or affecting the affinity of non-
histone chromatin proteins (e.g. Polycomb/CBX, discussed in Chapter 2).  In 
addition, I present some data that suggests H3 cleavage may be regulated by 
covalent modifications present on the histone tail itself.  These studies underscore 
the intriguing possibility that histone proteolysis, brought about by Cathepsin L and 
potentially other family members, plays a role in development and differentiation 
that was not previously recognized (Duncan et al., 2008). 
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Results
A Faster Migrating H3 Species Is Detected in Differentiating Mouse ESCs
To survey changes in histone proteins and their modifications during mouse ESC 
differentiation, I used immunoblotting to probe whole-cell extracts (WCEs) with 
various histone antibodies.  When probing with specific histone H3 antibodies (e.g. 
the H3 general C-terminal, H3K27me2, and H3K27me1 antibodies), I observed 
reproducibly a faster migrating band in samples taken at time points corresponding 
to days two and three post-induction with retinoic acid (RA).  Notably, this band(s) 
was observed using an H3 general antibody generated against the C-terminus 
of histone H3 (Figure 4.1A and 4.1B, left), but not with an H3 general antibody 
generated against the first six N-terminal amino acids (Figure 4.1B, right).  The 
faster migrating H3 species was also observed when probing immunoblots with 
an H3-K27me2 antibody (Figure 4.1A); in contrast, it was not recognized when 
replicate immunoblots were probed with the H3-K4me3 antibody (Figure 4.1A). 
Taken together, the results of these experiments suggested that an extreme amino-
terminal fragment of H3 was missing in the faster-migrating H3 sub-band.
I then asked if the H3 sub-band was chromatin associated.  Micrococcal-
digested chromatin was prepared by standard methods (Wysocka et al., 2001) 
from both undifferentiated ESCs and ESCs undergoing differentiation with RA, and 
soluble mononucleosomes were probed with the H3 general antibody.  As shown 
in Figure 4.1C, the faster migrating H3 band was seen in the undigested chromatin 
pellet as well as in the solubilized mononucleosomes derived from differentiating 
cells, but not the chromatin isolated from undifferentiated ESCs (Figure 4.1C).
I next asked if the appearance of the faster migrating H3 species was 
dependent on the methods employed to trigger ESC differentiation.  To address 
this question, ESCs were differentiated using three different methods: monolayer 
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Figure 4.1: A distinct histone H3 species is detected in chromatin during ESC 
differentiation.  
A. Undifferentiated (und) ESCs were differentiated with RA in a monolayer, harvested for WCEs at 
the time points indicated, and analyzed by immunoblotting with the antibodies indicated to the right 
of each panel; H3gen will refer to the H3 general C-terminal antibody, unless otherwise indicated. 
Molecular weights (in kD) are indicated to the left.
B. Recombinant(r) histone H3, rH2A, H3 1-20 peptide and RP-HPLC purified endogenous H3 from 
differentiated ESCs (eH3 diff) were analyzed by immunoblotting; although the H3gen (C-terminal) 
antibody recognized the faster migrating H3 sub-band, an H3 N-terminal antibody does not.
C. Chromatin isolated from either undifferentiated ESCs (top panel) or those differentiated with 
RA for 3 days was subsequently digested with micrococcal nuclease for the indicated times; the 
solubilized chromatin pellet input (P), Mnase digested chromatin, and solubilized post-Mnase pellet 
(P’) was then analyzed by immunoblotting with the H3-gen antibody.
D. ESCs were differentiated using three basic methods: monolayer differentiation with RA (left), 
monolayer differentiation with LIF withdrawal (middle), and embryoid body (EB) formation by cell 
aggregation (right); WCEs were analyzed as in A for both a marker of pluripotency (Oct 3/4, top 
panels) and the histone H3 sub-band.
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differentiation with RA, monolayer differentiation by withdrawal of leukemic inhibitory 
factor (LIF), and embryoid body formation (EB formation) by cell aggregation.  As 
shown in Figure 4.1D (upper panels), the time course for expression of pluripotency 
marker Oct3/4 differs for each of the induction methods employed, suggesting 
differences in the timing and progression of differentiation.  Timing of the appearance 
of the faster migrating H3 band was also dependent on the method used to induce 
ESC differentiation (Figure 4.1D, lower panels), suggesting that this event is 
also dependent on the progress of differentiation.  The faster migrating H3 was 
observed at days two and three post RA induction during monolayer differentiation 
(Figure 4.1A, upper panel, and Figure 4.1D, lower left panel), but delayed until 
day five following withdrawal of LIF (Figure 4.1D, lower middle panel), the latter 
correlating with the similarly delayed decrease of Oct3/4.  During EB formation, 
the faster migrating H3 species appeared early and then peaked between days 
eight and twelve (Figure 4.1D, lower right panel), suggesting a slower and more 
complex differentiation progression.  I chose to use monolayer differentiation with 
RA for subsequent experiments in order to minimize differences in the timing and 
heterogeneity of differentiation.
Histone H3 Proteolysis Does Not Correlate With Markers of Apoptosis
To address the question of whether this proteolysis is the result of apoptosing 
cells rather than differentiating cells, I probed both +RA differentiating cells and 
cells induced to die with markers of apoptosis and DNA damage.  As shown in 
Figure 4.2A, ESCs treated with RA did not show strong evidence of caspase 3 
activation.   However, since ESCs treated with the apoptosis inducers etoposide 
(VP16) and staurosporine did not show caspase 3 activation either, I also treated 
HL60 cells with etoposide to verify that this drug could indeed induce apoptosis. 
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Figure 4.2: Histone H3 cleavage does not correlate with markers of apoptosis or DNA 
damage.
A. Human promyelocytic leukemia (HL60) cells and ESCs were treated with either etoposide 
(VP16), staurosporine (stp), or retinoic acid (RA) for the indicated time.  Although HL60 cells 
showed caspase 3 activation upon VP16 treatment, ESCs did not show significant caspase 3 
activation under any of the conditions tested.
B. ESCs treated with VP16 do show upregulation of the DNA damage marker γ-H2A.X, but do not 
show H3 cleavage.  ESCs treated with RA do show H3 cleavage, as described above, but do not 
show upregulation of γ-H2A.X.
C. To test whether uncontrolled proteolysis occurred upon cell lysis, unmodified rH3-HIS was added 
to SDS-Laemmli sample buffer prior to adding it to cell pellets and solubilization to generate WCEs. 
The unmodified rH3-HIS showed no evidence of cleavage when added to the lysing cells (right); 
however, endogenous H3 cleavage was detected in the lysates of 2 and 3 day differentiated ESC, 
as expected, which was shown by immunoblotting with an H3K27me2 antibody (left).
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The etoposide did cause apoptosis of the HL60 cells, as shown by the appearance 
of caspase 3 activation (indicated by its cleavage to the smaller products migrating 
at ~16kD).  Interesting, ESCs treated with etoposide, but not RA, did show signs of 
DNA damage, as indicated by the induction of γH2A.X signal (Figure 4.2B).  These 
results are consistent with reports in the literature showing that ESCs are more 
resistant to apoptosis than other cell types, and that they have greater activation of 
mechanisms to repair DNA damage.
Recombinant Histone H3 Is Not Cleaved “Ex Vivo”
To test whether proteolysis occurred upon cell lysis, I added unmodified rH3-HIS 
to SDS-Laemmli sample buffer prior to adding it to cell pellets and then proceeded 
as usual.  As shown in Figure 4.2C, the unmodified rH3-HIS showed no evidence 
of cleavage when added to the lysing cells (right); however, the lysates did show 
evidence of endogenous H3 cleavage, as shown by immunoblotting with an α-H3-
K27me2 antibody (Figure 4.2C, left).
Histone H3, Marked by Both “Active” and “Silent” Modifications, Is 
Proteolytically Cleaved in The N-terminal Tail During ESC Differentiation
To determine the nature of the faster migrating H3 sub-species, I extracted histones 
from differentiating ESC nuclei three days post RA induction and separated the 
four core histone proteins by reverse phase high pressure liquid chromatography 
(RP-HPLC, C8 column, as in Figure 3.1B).  Fractions containing the H3 sub-band 
were pooled and further resolved by RP-HPLC (C18 column, Figure 4.3A), and 
the resulting fractions were screened by immunoblot as shown in Figure 4.3B 
(left panel).  I then subjected C18-RP-HPLC fractions containing the H3 sub-band 
to two separate sequencing methods.  First, I pooled equal amounts of fractions 
52-54, separated the protein by SDS-PAGE, and transferred it to immunoblot; the 
74
Figure 4.3: Histone H3 is N-terminally cleaved during ESC differentiation.
A. Total histones were acid-extracted from 3 days +RA differentiating nuclei and purified using RP-
HPLC with a C8 column (not shown); fractions containing the histone H3 sub-band were pooled 
and re-fractionated by RP-HPLC with a C18 column (chromatogram).
B. Fractions eluted from the C18 column (as shown in A) were then screened by immunoblotting 
with the H3-gen antibody (left). Equal amounts of fractions 52-55 were pooled, separated by 
SDS-PAGE, transferred to PVDF membrane and stained with Ponceau Red (middle). Both bands 
of the sub-band doublet (asteriks) were excised from the membrane and subjected to Edman 
degradation, which provided evidence that the faster migrating H3 had been N-terminally cleaved 
between residues A21 and T22 and between K27 and S28 (right). Residues not clearly identified in 
the generated sequence are denoted “X.”
C. Sample in fraction 54 from the RP-HPLC enrichment (screened in B) was digested with GluC, 
which generates intact N-terminal peptides that terminate with E50. Peptides generated were 
then analyzed on a linear ion trap–Fourier transform mass spectrometer. Six highly modified, 
truncated fragments of the GluC-generated 1-50 peptide were observed (right panel; detected 
post-translational modifications are summarized in Figure 4.4). Summed ion currents for all 
charge states and modified forms of the above sequences were employed to estimate the relative 
abundances of the six peptides beginning with the indicated residues as follows: T22 and A24 > 
than K23 and K27 > A25 and S28 (see right hand list). The peptide beginning with R26 was not 
detected.  Note that the two sequences detected by Edman degradation were also detected by 
MS (see asterisks). All six of the truncated 1-50 peptides contain Ala at position 31 (underlined) 
and are thus derived from the H3 isoform H3.2. Three highly modified forms of the complementary 
N-terminal fragments, A1-A21, A1-K23, and A1-R26 (left hand list) are also present in the same 
HPLC fraction. 
D. The sequence of the mammalian histone H3 tail and the cleavage sites mapped in A-C; the bold 
solid line indicates the “primary” cleavage site mapped by both Edman degradation and MS (H3.
cs1); additional significant cleavage sites are marked with regular solid lines; less abundant sites 
are marked by dashed lines. Lysines found by MS to be highly acetylated (ac) or methylated (me) 
are marked by a triangle or circle.
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Figure 4.3: Histone H3 is N-terminally cleaved during ESC differentiation
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material in each of in the two sub-bands labeled by asteriks were then sent to 
Richard Cook at Baylor University and subjected to Edman degradation (Figure 
4.3B, right).  Although multiple amino acids were released during each cycle for 
both samples, the observed data strongly suggested that the top and bottom sub-
bands contained sequences derived from cleavage following residues A21 and 
K27, respectively, in the N-terminal tail of H3.
Second, to define in greater detail the peptide sequences and post-
translational modifications present in the faster migrating H3 species, additional 
sample from fraction 54 (Figure 4.3B) was sent to the Hunt Laboratory at The 
University of Virginia where they digested it with GluC to produce N-terminal 
H3-fragments ending in E50; the resulting peptides were then analyzed by MS. 
Spectra recorded detected six, highly-modified, truncated, N-terminal, histone H3-
peptides beginning at residues T22, K23, A24, A25, K27 and S28 (Figure 4.3C, 
right panel).  Relative abundances of the six peptides suggest that the preferred 
cleavage sites are C-terminal to A21 and K23.  These results suggest that the 
primary H3 cleavage site is between amino acids 21 and 22 of the amino terminus 
(Figure 4.3D, H3.cs1) and that the final cleavage site is between amino acids 27 
and 28.  Notably, the list of cleavage sites detected by MS contains the two sites 
detected by Edman degradation (asterisks).
In addition, new mass spectrometric methods using a combination of 
electron transfer dissociation/proton transfer charge reduction and accurate 
mass measurements were employed by the Hunt laboratory to characterize the 
modification patterns on the proteolyically cleaved H3 (Coon et al., 2005; Taverna 
et al., 2007).  Interestingly, the data revealed that the cleaved H3 sub-species has 
a distinct covalent modification profile, suggesting that the H3 sub-band may be 
preferentially marked, before or after proteolytic processing, with a specific epigenetic 
signature (Figure 4.3D).  Specifically, marks of both “active” (e.g. H3K23Ac and 
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H3K36me) and “silent” transcription (e.g. H3K27me) were reproducibly detected 
on a single GluC-digested peptide derived from the proteolytically-processed H3 
fragment.  Moreover, all six of the truncated peptides contained Ala at position 
31, revealing that the cleaved H3 peptide is H3 isoform H3.2, not H3.3.  Although 
non-cleaved H3.3 peptide was detected in the same RP-HPLC fraction as the 
cleaved H3 species, cleaved H3.3 was not detected.  Since H3.2 and H3.1 elute 
in two separate peaks (Figure 4.3B), we cannot definitively conclude that H3.2 
is preferentially cleaved over H3.1, however significantly less H3 cleavage was 
detected in peak 2 (H3.1) than in peak 1 (H3.2+H3.3) by immunoblotting.  Although 
it is unclear how this particular pattern of modifications and H3 isoform affect 
the mechanism of proteolysis, these data suggest the intriguing possibility that 
that regulation via post-translational modification of the substrate and/or isoform 
preference may regulate the proteolytic processing (see Figure 4.12).
Also detected by MS in fraction 54 (Figure 4.3B) were highly modified 
forms for three of the most abundant, complementary, N-terminal fragments 
generated by proteolytic cleavage of H3 (Figure 4.3C, left panel).  The detection 
of these intact, complementary cleavage products indicates that the cleavage sites 
mapped above are the result of endopeptidase activity alone.  Post-translational 
modifications detected on these three N-terminal peptides again include marks 
of both “active” (e.g. H3K14Ac) and “silent” transcription (e.g. H3K9me) as seen 
on the C-terminal fragments (Figure 4.4).  These findings support the conclusion 
that a small fraction of total histone H3.2 undergoes highly specific endoproteolytic 
cleavage during ESC differentiation that may be regulated by unique patterns of 
covalent modifications.
The detection of the N-terminal cleavage product was unexpected, given that 
the ESC histones were acid-extracted and purified over two columns.  However, 
the abundance observed by the Hunt Laboratory for the N-terminal fragments were 
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Figure 4.4: Summary of the post-translational modifications detected on proteolytically 
cleaved H3 obtained from differentiating ESCs. 
Material from fraction 54 (Figure 4.3B) was digested with GluC to produce N-terminal, H3 fragments 
ending in E50.  The resulting mixture was then analyzed by nano-flow HPLC interfaced with both a 
linear ion trap-Fourier transform mass spectrometer and a linear ion trap instrument equipped for 
electron transfer dissociation.  Spectra recorded with the former instrument detected six, highly-
modified, truncated, N-terminal, histone H3-peptides beginning at residues T22, K23, A24, A25, K27 
and S28 and ending at E50  (Figure 4.3C, right panels).  Post-translational modifications detected 
by recording electron transfer dissociation (ETD) mass spectra on different isoforms of these six 
peptides are shown above in the right panel.  Sixty-seven different forms of the above six peptides 
were characterized.  Ten contain marks associated with active transcription (H3K23Ac, H3K36me, 
H3K36me2 or H3K36me3), ten contain marks associated with gene silencing (H3K27me, H3K27me2 
or H3K27me3), and 43 contain combinations of above active and repressive marks.  Summed ion 
currents for all charge states and modified forms of the above sequences were employed to estimate 
the relative abundances of the six peptides beginning with the indicated residues as follows: T22 
and A24 > than K23 and K27 > A25 and S28 (see right hand list). The peptide beginning with R26 
was not detected.  Three of the most abundant, complementary, N-terminal fragments generated by 
proteolytic cleavage of H3 (A1-A21, A1-K23, and A1-R26) were also detected in HPLC fraction 54 
(Figure 4.3C, left panels).  Post-translational modifications detected on different isoforms of these 
three peptides are shown above in the left panel.  Monomethyl-, dimethyl-, and trimethyl-marks are 
depicted by one, two, and three solid circles, respectively.  Acetyl marks are depicted by triangles. 
An asterisk indicates that the modified isoform was detected by accurate mass measurement only. 
All ETD spectra were interpreted manually.
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Figure 4.4: Summary of the post-translational modifications detected on proteolytically 
cleaved H3 obtained from differentiating ESCs. 
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down by 10 fold compared to that observed for the complementary C-terminal 
fragments.  Moreover, we processed histones from undifferentiated cells in parallel 
and did not detect any evidence of cleaved histone H3.  I also found that the 
cleavage sites presented were mapped in three separate samples, arguing against 
the random, artifactual degredation.
The Lysosomal Cysteine Protease Cathepsin L is Present in Fractions That 
Are Enriched with H3 Protease Activity
To identify and characterize the putative H3 protease(s), I first established an in vitro 
H3 cleavage assay.  Undifferentiated or differentiating ESCs were harvested and 
their proteins extracted; these lysates were then incubated with C-terminally 6xHIS 
tagged, full-length recombinant histone H3 (rH3-HIS), and the reaction products 
were analyzed by immunoblotting with the Qiagen Penta HIS-HRP antibody (Figure 
4.5A).  Although this assay has the potential to detect any N-terminal H3 cleavage, 
chromatin extracts isolated from differentiating ESCs at the time point when in vivo 
cleavage was observed (~3 days +RA) consistently possessed strong in vitro H3 
cleavage activity that reproduced the size difference of the endogenously cleaved 
H3 (Figure 4.5B). 
To better ensure that the cleaved H3 product observed in our in vitro cleavage 
assay was physiologically relevant, I generated an antibody that recognized the 
primary site of H3 cleavage, H3.cs1 (Figure 4.3D), using a 2x branched peptide 
(Figure 4.6A).  ELISA results indicated that this antibody (“H3.cs1”) was specific 
for the primary site of in vivo generated H3 cleavage product (A21/T22) and was 
not sensitive to the acetylation status of H3K23 (Figure 4.6B).  Importantly, the 
H3.cs1 antibody fails to react with full length H3 and its signal is highly enriched 
at the same time point at which I detect an H3 sub-band using the H3-general or 
H3 K27me2 antibodies during our standard RA-induced ESC differentiation time 
course (Figure 4.6C).
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Figure 4.5: The cysteine protease Cathepsin L is detected in fractions enriched for histone 
H3 cleavage activity.
A. Schematic of in vitro H3 cleavage assay (see text for details).
B. An example of the H3 cleavage assay comparing soluble cytosolic + nuclear protein extract (S) 
and solubilized chromatin extract (C) from undifferentiated and 3 days + RA differentiating ESCs. 
C. Nuclear extracts were prepared as described (Dignam et al., 1983) from 3 days +RA differentiated 
cells; after the initial extraction of nuclear proteins with 420 mM KCl (420), the chromatin pellet (P) 
was further extracted by sequential 60mM increases in KCl concentration. The remaining chromatin 
pellet was then solubilized by sonication in buffer A. The cytosolic (cyt), high salt, and chromatin 
extracts were then assayed for H3 cleavage activity using the H3 cleavage assay described in A.
D. Schematic of extract fractionation for protease enrichment.
E. H3 cleavage assay of hydroxyapatite fractions generated by scheme shown in D; assay reactions 
were analyzed by immunoblotting with both HIS-HRP and H3.cs1 antibodies.
F. Hydroxyapatite fractions assayed in D were analyzed for the presence of Cathepsin L by 
immunoblotting with Cathepsin L antibody; # designates proprotein (~37kD), • indicates intermediate 
processed form (~30kD), and * indicates mature processed form (~25kD).
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I then used both the HIS-HRP antibody and the H3.cs1 antibody in the above 
H3 cleavage assay to follow the biochemical enrichment of H3 protease activity in 
nuclear extract derived from differentiating ESCs.  In the process of generating and 
testing extracts for protease activity, I noted that the majority of protease activity 
remained in the chromatin pellet even after multiple high salt extractions (Figure 
4.5C).  For this reason, I sought a method with which I could solubilize, extract and 
fractionate chromatin directly.  I turned to hydroxyapatite resin fractionation since 
it has been used in the literature for this exact purpose and, in fact, often used 
to purify histone proteins themselves (Bloom and Anderson, 1978; Simon and 
Felsenfeld, 1979).  I fractionated nuclear extract as described by the schematic in 
Figure 4.5D and detected two peaks of putative H3 cleavage activity by both the 
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Figure 4.6: Characterization of H3.cs1 antibody.
A. A 2x branched peptide sequence used to generate antibody (see Chapter 6: Materials and 
Methods for details).
B. Rabbit serum was tested for biological specificity by immunoblotting on WCEs from 
undifferentiated, 3 days +RA, and 5 days +RA.
C. Rabbit serum was tested for amino acid sequence and modification specificity (H3K23ac) by 
ELISA.
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HIS-HRP antibody and the H3.cs1 antibody (Figure 4.5E).  I then sent two activity-
containing fractions (#22 and 23, Figure 4.5E) and an adjacent non-activity-
containing fraction (#20) to the Hunt Laboratory for MS analysis.  Four peptides 
were detected for the cysteine protease Cathepsin L in both activity-containing 
fractions 22 and 23, yet none of these peptides were detected in the neighboring 
non-activity containing fraction 20 (Figure 4.7).  To validate this identification 
further, I used a commercially available antibody to screen for the presence of 
Cathepsin L in the hydroxyapatite fractions (mCathL, Figure 4.5F).   Importantly, 
reactivity with mCathL correlates well with the detection of H3 cleavage activity in 
the fractions aligned above (compare Figure 4.5E to 4.5F).  
>gi|6753558|ref|NP_034114.1| cathepsin L preproprotein 
Mus musculus]
MNLLLLLAVLCLGTALATPKFDQTFSAEWHQWKSTHRRLYGTNEEEWRRAIWE
KNMRMIQLHNGEYSNGQHGFSMEMNAFGDMTNEEFRQVVNGYRHQKHKK
GRLFQEPLMLKIPKSVDWREKGCVTPVKNQGQCGSCWAFSASGCLEGQMFLK
TGKLISLSEQNLVDCSHAQGNQGCNGGLMDFAFQYIKENGGLDSEESYPYEAK
DGSCKYRAEFAVANDTGFVDIPQQEKALMKAVATVGPISVAMDASHPSLQFYS
SGIYYEPNCSSKNLDHGVLLVGYGYEGTDSNKNKYWLVKNSWGSEWGMEGYI
KIAKDRDNHCGLATAASYPVVN
Four Peptides Detected
ENGGLDSEESYPYEAK
NSWGSEWGMEGYIK
DRDNHCGLATAASYPVVN
DNHCGLATAASYPVVN
data produced by Tara-Muratore-Schroeder and used with permission
Figure 4.7: Mass spectrometry analysis of hydroxyapatite fractions identifies the cysteine 
protease Cathepsin L specifically in those fractions exhibiting H3 cleavage activity.
To identify the putative H3 protease, proteins in two of the active fractions (#22 and #23) and one 
of the adjacent non-active fractions (#20) were digested with trypsin.  The resulting peptides were 
analyzed by nano-flow HPLC interfaced with a linear ion trap-Fourier transform mass spectrometer 
and several thousand collision activated dissociation (CAD) mass spectra were acquired.  By 
searching theses spectra against a database of murine proteins with the SEQUEST algorithm, we 
identified more than 1,000 peptides from 80-100 proteins in each fraction.  Four low level tryptic 
peptides (0.5%) detected in each of the two active fractions but not in the inactive fraction, matched 
to the mature form of the lysosomal cysteine protease, Cathepsin L.  All were present at or below 
the 0.5% abundance level.  Sequences for the detected peptides are listed below the full sequence 
and the corresponding residues are underlined within the full amino acid sequence of Cathepsin L. 
No other proteases were detected in the above analyses.
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Cathepsin L is known to exist in three forms: a proenzyme running at ~37kD, 
a single chain intermediate at ~30kD, and a double chain mature form at ~25kD 
and ~5kD (Ishidoh et al., 1998).  The pro form must be cleaved to become active, 
whether by self-cleavage or by another enzyme (Turk et al., 2000); in contrast, 
both the “intermediate” and “mature” forms have been shown to be active (Mason 
et al., 1989).  The hydroxyapatite fractions of the stronger peak of activity (~21-
25) correlate with the detection of the mature form of Cathepsin L by immunoblot 
(Figure 4.5F, marked by asterisk), while the weaker activity fractions (~13-15) 
correlate closely with the detection of the intermediate form of Cathepsin L (Figure 
4.5F, marked by dot).  This correlation not only supports a causal relationship 
between the presence of Cathepsin L and the H3 cleavage activity, but also helps to 
explain the difference in elution and activity between the two peaks of H3 cleavage 
activity generated by the hydroxyapatite chromatography.
Fractions Enriched in H3 Cleavage Activity Exhibit Cathepsin L-like Activity
To validate further the identification of Cathepsin L as a histone H3 protease, I 
tested our enriched fractions with different classes of protease inhibitors in our H3 
cleavage assay.  As shown in Figure 4.8A, adding increasing amounts of serine 
protease inhibitor AEBSF produced a modest reduction in cleavage activity at a 
high concentration (20mM), but not at the lower concentrations tested (2mM and 
10mM).  However, when using the cysteine protease inhibitor E64, all cleavage 
was abolished at even the lowest concentration tested (10µM). 
Noting the strong inhibition of H3 cleavage activity by E64, an irreversible 
inhibitor that binds covalently to its substrate and has been shown to inhibit 
Cathepsin L (Barrett et al., 1982), I then took advantage of a commercially available 
E64-bound resin to test whether it could precipitate Cathepsin L from our active 
hydroxyapatite fractions and, subsequently, remove the soluble H3 cleavage 
activity.  Both E64 bound and control resins were added to fractions 20 (in which 
85
6
16
A
B
C
α-H3.cs1
α-HIS-HRP
6
16
+c
AEBSF E64
6
16 α-H3.cs1
(supernatant)
α-mCathL
(resin eluate)
22
36
frac 20 frac 20 frac 23frac 23
+E64 resin —E64 resin
6
16
α-H3.cs1
α-HIS-HRP
6
16
+ — + — + — + — + — + —
WT   K18Y  L20V L20E L20W A21T
D
α-mCathL
days +RA
22
36
 und  1   2   3   4   5
#
•
*
*
+ — + — + — + — + — 
A21L   K23S K23Q K27A S28A
α-H3.cs1
α-HIS-HRP
6
16
6
16
Figure 4.8: Cathepsin L cleaves histone H3 in vitro and associates with chromatin in vivo.
A. Hydroxyapatite fraction #23 (Figure 4.5E) was assayed +/- protease inhibitors in the H3 cleavage 
assay; cysteine protease inhibitor E64 is a potent inhibitor of the H3 protease activity.
B. Immobilized E64 was incubated with both an active hydroxyapatite fraction (23) and one without 
enzymatic activity (20); control resin was incubated with each fraction in parallel. Resins were then 
precipitated from solution, boiled in SDS sample buffer to remove bound proteins, and analyzed by 
immunoblotting (bottom panel); the supernatant was tested for H3 protease activity (top panel).
C. Hydroxyapatite fraction #23 (Figure 4.5E) was assayed with various rH3-HIS point mutants in the 
H3 cleavage assay; note that mutations in L20 abolished activity as assayed by both the HIS and 
H3.cs1 antibodies (top two panels) and that mutations in K23 abolished cleavage as assayed by the 
H3.cs1 antibody (bottom panel).
D. Chromatin from undifferentiated ESCs and ESCs differentiated +RA for the number of days 
indicated was digested with micrococcal nuclease and analyzed by immunoblotting with Cathepsin 
L antibody to assay whether or not Cathepsin L protein is associated with chromatin; note that 
Cathepsin L is associated with chromatin in differentiating ESCs, particularly the mature form (*).
little to no H3 cleavage activity detected) and 23 (in which strong H3 cleavage 
activity was detected), incubated to allow binding and potential inhibition, and then 
pelleted by centrifugation.  The cleared supernatant was subsequently tested for 
H3 cleavage activity.  As expected, E64 resin successfully removed H3 cleavage 
activity from fraction 23, while control resin did not (Figure 4.8B, upper panel). 
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Importantly, as shown using the cleavage-site specific H3.cs1 antibody, the activity 
removed by the E64 resin included the specific A21/T22 cleavage site activity.  In 
contrast, the specific H3 cleavage activity remained in the supernatant of fraction 
23 incubated with control resin (Figure 4.8B, upper panel). 
I then eluted any bound proteins from the E64 and control resins by boiling 
in SDS sample buffer and probed the eluates for the presence of Cathepsin L.  As 
hypothesized, mCathL was detected on the +E64 resin that had been incubated 
with fraction 23, but was not found on control resin nor on resin incubated with 
fraction 20 (Figure 4.8B, lower panel).  As a control, I also analyzed the above 
eluates by immunoblotting with an antibody to another cathepsin family member, 
Cathepsin B, but did not detect any immunoreactive species (data not shown). 
Taken together, the loss of activity from solution paired with the presence of 
Cathepsin L protein bound to the corresponding +E64 resin strongly suggests a 
causal relationship between this cysteine protease and the primary H3 protease 
activity characterized above (cleavage of H3 between A21/T22, H3.cs1).
Cathepsin L is also known to preferentially cleave proteins that contain 
hydrophobic residues in their P2 position (two residues N-terminal from the cleaved 
bond, as originally defined (Schechter and Berger, 1967)), specifically leucine and 
phenylalanine (Rawlings and Barrett; Rawlings et al., 2008). Importantly, and in 
keeping with this characteristic, the sequence surrounding the primary H3 cleavage 
site (H3cs.1) mapped from ES cells by both MS and Edman degradation includes 
a leucine at the P2 position (L20).  To verify the significance of this leucine in the 
H3 sequence and support the identification of Cathepsin L in fraction 23, I mutated 
this residue (L20V, L20E & L20W) and neighboring residues and tested the 
mutated recombinant proteins in our H3 cleavage assay (Figure 4.8C).  Although 
the more conservative L20V mutant showed little change in H3 cleavage, L20E 
and L20W mutants completely abolished H3 cleavage as assayed by both the 
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HIS and H3.cs1 antibodies (Figure 4.8C, top two panels).   Moreover, the loss 
of H3 cleavage upon mutation of L20, compared to little or no loss of signal upon 
mutation of neighboring residues (K18 or A21), suggests that L20 is particularly 
important to the enzymatic activity in fraction 23.  Together, this mutational analysis 
also supports the identification of Cathepsin L as the enzyme responsible for the 
histone H3 cleavage characterized in the above in vitro assays.
Interestingly, mutating K23 to either S or Q also had a significant effect 
on the H3 cleavage activity.  Although no difference was seen in H3 cleavage by 
assaying with HIS, these mutations greatly diminished the cleavage site recognized 
by the H3.cs1 antibody, suggesting a possible role for this residue in regulating the 
precision of H3 proteolysis by Cathepsin L.  It is interesting to note that none of 
the N-terminal peptides identified by MS were acetylated at K23 while C-terminal 
peptides acetylated at K23 were consistently detected (Figure 4.4).  Together, 
these data suggest the intriguing possibility that the acetylation of K23 may serve 
to inhibit cleavage at certain sites.
Cathepsin L Is Associated with Chromatin In Vivo
Although there is previous evidence that Cathepsin L and its activity exists in the 
cell nucleus of MEFs (Goulet et al., 2004), I wanted to document this nuclear 
localization in our ESC model using a biochemical approach: I isolated chromatin 
and then solubilized it by micrococcal nuclease digestion as described above 
(Figure 4.1C).  As shown by probing with Cathepsin L antibody, Cathepsin L 
was indeed associated with chromatin fragments released by nuclease digestion 
(Figure 4.8D).  Importantly, chromatin association only begins to appear upon 
differentiation and is not apparent in undifferentiated ESCs.  I note as well that the 
mature form of Cathepsin L (marked by asterisk) was enriched over the full length 
(hash) or intermediate (dot) forms.
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rCathepsin L Reproduces the In Vivo Histone H3 Cleavage Pattern
To further validate the identification of Cathepsin L as an H3 protease, I tested 
recombinant mouse Cathepsin L enzyme in our H3 cleavage assay (Figure 4.9). 
Since Cathepsin L displays optimal activity at the more acidic pH of the lysosome 
(i.e. ~pH 5, (Barrett et al., 2003)), and since I suspected that Cathepsin L is acting 
within the nucleus at a higher pH (~pH 7-8), I tested the recombinant enzyme in both 
pH environments.  Importantly, recombinant mouse Cathepsin L was able to cleave 
recombinant histone H3 at both pH 5.5 and pH 7.4.  Moreover, the recombinant 
enzyme cleaved H3 and created the specific epitope recognized by the cleavage 
site-specific H3.cs1 antibody (Figure 4.9A, lower panel).  To further characterize the 
sites of proteolytic cleavage, I sent the reaction products of rCathepsin L and rH3-
HIS to the Hunt Laboratory for analysis by MS.  Importantly, MS analysis revealed 
that the six sites of cleavage mapped in the endogenous H3 samples (Figures 4.3 
and 4.4) were also produced by rCathepsin L in vitro (Figure 4.9B).  Also observed 
in both reactions are five of the six complementary N-terminal peptides generated 
by rCathepsin L cleavage of H3 (left), and their abundances correlated with that 
of their C-terminal counterparts.  Furthermore, the most abundant site of cleavage 
in vitro was between A21 and T22, the same site that was shown to be most 
abundant in the MS analysis of endogenous histone H3.  In addition, the relative 
abundances of the in vivo H3 cleavage sites and those produced by Cathepsin L in 
vitro are highly correlative.  One exception is cleavage between residues K27 and 
S28, which is more abundant in the in vitro assay compared to that mapped from 
in vivo samples (the latter shows a preference for cleavage between residues R26/
K27 over K27/S28).  We speculate that the presence of histone modifications in 
vivo play a role in regulating the preferred cleavage site of Cathepsin L, particularly 
at sites surrounding H3K27, which was shown to be preferentially methylated on 
cleaved H3 by both immunoblot and MS analysis (Figure 4.1A and Figure 4.4). 
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Figure 4.9: rCathepsin L cleaves histone H3 in vitro.
A. Recombinant Cathepsin L cleaves rH3 in vitro at both pH 5.5 and pH 7.4 and generates a fragment 
that is recognized by both α-HIS-HRP (top panel) and α-H3.cs1 (middle panel) antibodies.
B. Recombinant mouse Cathepsin L was incubated with recombinant H3-HIS at both pH 5.5 and 
pH 7.4; after 2 hours, the reaction products were subjected to analysis by mass spectrometry. 
Both N-terminal (left) and C-terminal (right) fragments of the rH3 cleavage were detected; note 
the similarity to the pattern of in vivo cleavage shown in Figure 4.3C. Summed ion currents for all 
charge states of the unmodified sequences were employed to estimate the relative abundances of 
the six peptides beginning with the indicated residues as follows: T22 > K23, A24, and S28 > A25 
and K27. Also observed in both of the above digests are five of the six complementary N-terminal 
peptides generated by Cathepsin L cleavage of H3 (left panel) containing residues A1-A21, A1-
T22, A1-K23, A1-R26 and A1-K27. Relative abundances of these N-terminal peptides correlate, as 
expected, with their C-terminal counterparts: A1-A21 > A1-T22, A1-K23, A1-K27 > A1-R26.
C. Recombinant Cathepsins B, K, and L were pre-activated and incubated with recombinant H3-
HIS at both pH 5.5 and pH 7.4; after 15 minutes, the reactions were separated by SDS-PAGE and 
analyzed by immunoblotting.
Taken together, the above data support the conclusion that Cathepsin L is capable 
of generating all of the histone H3.2 fragments observed at day three following 
induction of ESC differentiation by retinoic acid.
 I then wanted to test other cathepsin family members in the H3 cleavage 
assay.  I chose to test rCathepsin B, one of the most abundant lysosomal proteases, 
and rCathepsin K, which is reported to have a significant preference for leucine in 
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the P2 position of its substrates much like Cathepsin L (Cathepsin S also shares 
this preference but was not found to have significant expression in our ESC model). 
Following pre-activation the recombinant enzymes, Cathepsins B, K and L were 
incubated with rH3-HIS at both pH 5.5. and pH 7.5, and the reactions were then 
analyzed by immunoblotting with both HIS and H3.cs1 antibodies.  As shown in 
Figure 4.9C, pre-activated Cathepsin L cleaves rH3-HIS robustly and produces a 
pattern that is similar to that observed in vivo.  In contrast, Cathepsin B cleaves 
rH3 with a distinct pattern from Cathepsins K or L and does not significantly 
produce the H3.cs1 epitope.  Cathepsin K produces a similar pattern to Cathepsin 
L under these assay conditions, although they appear to differ in their preferences 
for specific sites (e.g. the cleavage site recognized by the H3cs.1 antibody is less 
abundant in the Cathepsin K reactions).
Both RNAi-mediated and Chemical Inhibition of Cathepsin L Inhibits H3 
Cleavage In Vivo
I then sought to show that knockdown of Cathepsin L in vivo led to a decrease 
in H3 cleavage.  I first created heterogeneous (non-clonal) stable cells lines 
constitutively expressing short RNAi hairpins to both a control gene (a human gene 
whose hairpin sequence show no significant sequence homology to the mouse 
genome by BLAST) and the Cathepsin L gene (Ctsl) by puromycin selection.  I 
then differentiated these heterogeneous cell lines with RA, as usual, and harvested 
the cells at various time points.  As shown in Figure 4.10A and B, knockdown of 
Cathepsin L (shown by immunoblotting with Cathepsin L antibody, upper panels) 
led to reproducible decrease in H3 cleavage as detected by the H3 C-terminal 
antibody (lower panels).  In parallel, samples taken at day 3 post-induction with 
RA were also evaluated for knockdown efficiency and H3 cleavage by titration of 
sample (Figure 4.10B).
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To further assess whether Cathepsin L causes histone H3 cleavage in 
vivo, I treated differentiating ESCs with a commercially available, cell-permeable 
Cathepsin L specific inhibitor, Cathepsin L Inhibitor I.  Inhibition of Cathepsin L 
using a chemical inhibitor allowed me to assess the effect of Cathepsin L inhibition 
within a single, wild-type cell line rather than comparing individual cell lines created 
by drug selection.  Undifferentiated ESCs were treated with or without inhibitor for 
24 hours prior to plating for differentiation.  Cells were then differentiated with RA 
while either Cathepsin L Inhibitor I or DMSO alone was maintained in the media. 
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Figure 4.10: Both RNAi and chemical inhibition of Cathepsin L reduce histone H3 cleavage 
in vivo.
A. Control and Ctsl RNAi cells lines were differentiated with RA as usual and harvested at the 
indicated time points; WCEs were then separated by SDS-PAGE and analyzed for both Cathepsin 
L expression (upper panel) and histone H3 cleavage (lower panel) by immunoblotting.
B. A serial two-fold dilution of samples from day 3 +RA induction were resolved by SDS-PAGE gel 
and analyzed by immunoblotting as in A.
C. The addition of Cathepsin L Inhibitor I to the cell media of differentiating ESCs (left side) inhibits 
the processing of Cathepsin L itself (a) as well as that of histone H3 (b, c) as compared to DMSO 
alone treated control cells (right side). Loss of pluripotency marker Oct 3/4 was not affected (d) nor 
was the self-processing of another cathepsin family member, Cathepsin B (e).
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As shown in Figure 4.10C, cells treated with inhibitor showed significant failure to 
fully process Cathepsin L from its intermediate form (marked by dot) into its mature 
form (asterisk), demonstrating that its self-activating activity had been inhibited 
(Figure 4.10C, panel a, left).  In contrast, no significant accumulation of the 
intermediate form was seen in the DMSO alone treated cells (Figure 4.10C, panel 
a, right).  Notably, histone H3 cleavage also decreased significantly in the cells 
treated with the inhibitor, but not in cells treated with DMSO alone, as shown by 
probing immunoblots with both H3-general and H3.cs1 antibodies (Figure 4.10C, 
panels b and c).  Interestingly, all cleavage detected by the H3-general antibody 
was abolished in the cells treated with inhibitor, suggesting that Cathepsin L may 
be responsible for all sites of cleavage (supported by MS data in Figure 4.9). 
Importantly, neither Oct-3/4 nor Cathepsin B levels (Figure 4.10C, panels d 
and e) appeared to change upon addition of the inhibitor.  Since Oct-3/4 is a marker 
of pluripotency that is normally lost rapidly upon differentiation with RA (Figure 
4.1D), the fact that this pattern is unchanged in the presence of the Cathepsin L 
Inhibitor I indicates that the inhibitor does not alter the pluripotency or differentiation 
capacity of ESCs prior to the time point at which H3 cleavage is observed.  This 
conclusion is supported by Q-PCR data for the pluripotency marker Nanog (Figure 
4.11A), which also remains unaffected by Cathepsin L inhibition.  The consistency 
of Cathepsin B levels between those cells treated with Cathepsin L Inhibitor I and 
control cells suggests that the inhibitor is indeed specific for Cathepsin L.  Markers 
of cell lineage were also analyzed by Q-PCR and suggest some changes in neural/
ectodermal expression patterns and levels of endodermal marker expression 
between inhibitor treated and control cells (Figure 4.11B and C).  However, the 
changes observed were not statistically significant and, in fact, add more support to 
the conclusion that Cathepsin L I inhibitor does not globally affect the pluripotency 
or differentiation profile of ESCs.  Moreover, given that the inhibitor (or the RNAi 
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Figure 4.11: The effect of in vivo chemical inhibition of Cathepsin L on ESC differentiation.
A. Gene expression of pluripotency marker Nanog: cells were differentiated with RA in the presence 
of Cathepsin L I inhibitor or DMSO alone, as in Figure 4.10C; mRNA was then isolated, reverse 
transcribed into cDNA and assayed by Q-PCR with SYBRgreen. Data in panels A-C represent the 
mean ±SD of three independent experiments.
B. Q-PCR for Nestin, a neuronal/ectodermal marker, suggests its expression may increase with 
Cathepsin L I inhibitor on days 3, 4 and 5 of differentiation versus control cells. Other neuronal 
markers did not show this trend (Pax3, Musashi, HoxA1).
C. Q-PCR for Sox17, a marker of endoderm, showed some difference between inhibitor treated 
and control cells in level of expression (expression was higher in control cells, P ≈ 0.5 for days 4 
and 5); another endodermal marker, GATA6, did not show significant difference when averaged 
over three experiments.  Interestingly, Q-PCR for markers of mesodermal lineage, including Myf5 
and Fgf8, did not detect significant expression.
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Figure 4.11: The effect of in vivo chemical inhibition of Cathepsin L on ESC differentiation.
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hairpin) is not specific to the nuclear Cathepsin L enzyme and that the differentiation 
of ESCs with RA leads to a heterogenous population of cell types (despite being 
less heterogeneous than other differentiation methods), this type of experiment is 
unlikely to reveal the specific effects of H3 cleavage inhibition.
Histone Tail Modifications Can Modulate Cathepsin L Activity and Its 
Downstream Effects
I then asked whether known covalent modifications on the histone tail affect the 
cleavage activity of Cathepsin L.  As depicted in Figure 4.12A, several amino 
acids near the sites of Cathepsin L cleavage are known to be modified by either 
acetylation (triangles) or methylation (circles).  To test the potential effects of these 
modifications on the cleavage activity of Cathepsin L, I first turned to the H3 cleavage 
assay described in Figure 4.5.  Four different recombinant H3 substrates were 
prepared as follows: unmodified rH3 (1), rH3 dimethylated specifically at K27me2 
(2), rH3 “pan-acetylated” by treatment with acetic anhydride (3) and rH3 with 
both K27me2 and pan-acetylation (4).  These substrates were shown to have the 
specific modifications of interest depicted in Figure 4.12A by immunoblot (Figure 
4.12B) and were verified by MS (≥ 90%, data not shown).  As shown in Figure 
4.12A, this assay demonstrated that acetylation of lysine residues greatly reduced 
cleavage of H3 by rCathepsin L at both pH 7.5 and 5.5 (compare substrate 1 to 
3).  In contrast, K27me2 increases H3 cleavage (compare substrate 1 to 2; greater 
depletion of full-length rH3+K27me2 suggesting increased cleavage activity at pH 
5.5).
 In order to test the effect of the above modifications depicted in Figure 
4.12A more quantitatively and specifically, I synthesized a set of five peptides with 
identical backbone sequence flanking the H3 cleavage site (H3 15-31) modified as 
follows: unmodified, K18 acetyl, K23 acetyl, K18ac+K23ac, and K27me2.  I then 
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Figure 4.12: Covalent histone modifications modulate Cathepsin L activity and its downstream 
effects.
A. rCathepsin L was incubated with each of four rH3 substrates: 1= rH3 unmodified, 2= rH3 alkylated 
to K27me2, 3= rH3 pan-acetylated, 4= rH3+K27me2 pan-acetylated.
B. C-terminally HIS-tagged recombinant histone H3 was mutated to K27C and then alkylated to 
convert K27C to K27me2; an aliquot of this protein was then treated with acetic anhydride to 
acetylate all free lysines. These proteins were then assayed for the presence of K27me2, H3K18ac 
and H3K23ac by immunoblot..
C. H3 cleavage reactions were performed as in A using synthesized peptides that represent the 
H3 tail from amino acids 15 to 31. Reactions were incubated with ~250pmol peptide and quenched 
with 0.1% TFA before being plated in duplicate for ELISA with the H3cs.1 antibody. Signal was 
normalized to that of mock reactions for each peptide. Results represent the mean of three 
independent experiments ± standard deviation (SD).
D. Peptide pull-down assays were performed with recombinant mouse CBX7-chromodomain or 
rhBPTF-PHD finger and H3 peptides (sequences and methylation states indicated).
E. Fluorescence anisotropy Cbx7-CD protein binding to non-cleaved peptide (18-37) vs. cleaved 
peptide (22-37); binding decreases 3 fold with cleaved peptide, p<0.01. Kds are in µM±SEM. Data 
points represent the mean±SD.
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employed an ELISA based assay using the H3cs.1 antibody described previously 
(Figure 4.6) to quantitatively measure the H3cs.1 cleavage activity of rCathepsin 
L on these peptides.  As shown in Figure 4.12C, clear differences in rCathepsin 
L activity were observed at both pH 7.5 and pH 5.5.  As suggested by the rH3 
cleavage assay described above, K27me2 (magenta) strongly increases the ability 
of Cathepsin L to cleave at H3cs.1 as compared to the matched unmodified H3 
15-31 peptide (red).  Interestingly, acetylation at K18 (blue) also increases this 
activity, suggesting that the acetylation of another lysine or combination of lysines 
must be responsible for the abrogation of cleavage by acetylation demonstrated 
above.  Our data suggest that acetylation at K23ac is at least partly responsible for 
this effect, as the K23ac peptide shows very little cleavage activity at H3cs.1, both 
alone (green) and in combination with K18ac (black).
 I then asked what effect of the cleavage of the H3 tail might have on the 
binding of effector proteins.  Since K27 methylation is a well-documented binding 
site for the chromodomain-containing protein Polycomb (Pc) (Bernstein et al., 
2006b; Fischle et al., 2003), I sought to test the effect of H3 cleavage on Pc binding 
to H3K27 methyl.  Using peptides that mimicked either the “non-cleaved” H3 tail (H3 
18-37) or the “cleaved” H3 tail (H3 22-37), I assayed the effects of H3 cleavage on 
the ability for the chromodomain of Pc (mouse CBX7) to bind to K27 methyl (Figure 
4.12D); the PHD-finger of the known H3K4 methyl binding protein BPTF was used 
as a positive control and to demonstrate specificity (Figure 4.12D, lower panel). 
As shown in Figure 4.12D and quantified in Figure 4.12E, H3 cleavage greatly 
diminished the ability of CBX7 to bind to H3K27 methyl, suggesting that proteolytic 
modification introduced by Cathepsin L could lead to significant downstream 
effects.
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Chapter 4 Discussion
Here I show that ESCs employ regulated histone proteolysis in order to change 
their “epigenetic signature” upon differentiation.  Furthermore, I have identified 
Cathepsin L as a protease responsible for developmentally-regulated histone H3 
cleavage and demonstrated that its activity may be modulated by the modification 
of the histone tail itself.  This study reveals a novel nuclear function of this family 
of cysteine proteases in histone and stem cell biology and suggests that controlled 
histone proteolysis may be part of a mechanism for introducing variation into the 
chromatin polymer.
Despite remarkable progress made in documenting epigenetic signatures 
such as “bivalent domains” i.e. an H3 tail bearing both H3K4me3 and H3K27me3 
marks (Bernstein et al., 2006a), little is known as to what mechanisms may function 
to bring about the above changes at a chromatin level.  Our data suggest that 
mouse ESCs employ a novel, regulated histone H3 proteolysis mechanism that 
may serve to alter epigenetic signatures upon differentiation.  Other means of 
actively removing histone methyl marks have been well documented, including 
enzymatic demethylation (Anand and Marmorstein, 2007; Shi et al., 2004) and 
selective histone variant replacement (Ahmad and Henikoff, 2002).  However, 
until now considerably less evidence of endogenous histone proteolysis has been 
reported in mammalian cells, although N-terminal cleavage of the histone H3 tail 
has been shown in a ciliate model, Tetrahymena (Allis et al., 1980), in mammalian 
cells infected with the foot-and-mouth disease virus (Falk et al., 1990), and recently 
in the budding yeast s.cerevisiae (Santos-Rosa et al., 2009).
The finding that Cathepsin L cleaves histone H3 in mouse ES cells was 
unexpected as this enzyme was originally described as a lysosomal protease 
(Barrett et al., 2003).  However, Cathepsin L has been shown to localize to nuclei 
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where it plays a role in the proteolytic processing of transcription factor CDP/Cux 
(Goulet et al., 2004).  Notably, my data show that the activities of both fraction 23 and 
recombinant Cathepsin L are higher at pH 5.5 than at pH 7.4 (Figure 4.9); however, 
as noted in Goulet et al, this may in fact be an important feature in the regulation of 
its activity in the nucleus.  Biochemical studies have also shown that pro-Cathepsin 
L is localized to the nucleus in ras-transformed mouse fibroblasts (Hiwasa and 
Sakiyama, 1996).  In addition, evidence of endogenous, nuclear serpin inhibitors 
with the ability to inhibit Cathepsin L activity, e.g. MENT (Bulynko et al., 2006) and 
Cystatin B (Riccio et al., 2001), further supports the notion that Cathepsin L, and 
potentially other cysteine proteases, play important but poorly understood roles 
in regulated nuclear proteolysis.  As far as I am aware, transcription factor CDP/
Cux is the only nuclear substrate of Cathepsin L identified to date, and histones 
have not yet been identified as substrates of this class of proteases in mammalian 
cells.  Interestingly, however, recent studies in sea urchin have suggested that 
a Cathepsin L-like cysteine protease may be responsible for the degradation of 
sperm histones during a key chromatin remodeling event after fertlization (Morin et 
al., 2008).  My data support other studies that demonstrate the nuclear localization 
of Cathepsin L and provide the first indication that cellular histones, H3 in particular, 
are key substrates of this family of proteases in mammalian cells.
The finding that Cathepsin L is an H3 protease is interesting when considering 
the phenotype common to the Cathepsin L knockout mouse (Nakagawa et al., 
1998) and the furless mouse, which has been shown to have a spontaneous 
mutation in the Cathepsin L gene (Roth et al., 2000).  These mice exhibit periodic 
hair loss due to the improper cycling and morphogenesis of their hair follicles. 
Roth et al conclude that upon the loss or mutation of Cathepsin L “the balance 
between proliferation and differentiation seems to be shifted toward proliferation,” 
and subsequently causes the observed phenotype.  Since skin cells derive from 
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an ectodermal lineage and also maintain a degree of “stemness” in their ability 
to both proliferate and differentiate, it is interesting to speculate that perhaps the 
role of Cathepsin L in histone H3 cleavage is repeated again in other models of 
differentiation.  Cathepsin L knockout mice are viable and fertile, however, indicating 
that its functions are nonessential and/or redundant.  That said, these mice have 
been reported to show defects in spermatogenesis (Wright et al., 2003), which is 
interesting in light of the above mentioned cathepsin-mediated degradation of sea 
urchin sperm histones.  
Notably, Cathepsin L/Cathepsin B double knockout mice exhibit severe brain 
atrophy and die two to four weeks after birth (Felbor et al., 2002).  The severity 
and selectivity of this phenotype suggests that these two enzymes overlap in their 
specific functions.  Although I did not observe significant inhibition of Cathepsin 
B upon in vivo chemical inhibition of Cathepsin L, nor did I observe the same 
pattern of H3 cleavage with recombinant Cathepsin B compared to Cathepsin L 
in vitro, I cannot exclude the possibility that redundancy in H3 cleavage function 
may exist between these or other related enzymes at other stages or lineages 
of differentiation.  One potentially interesting source of redundancy might be a 
poorly studied family of cathepsins known as the placental cathepsins (Barrett et 
al., 2003).  In rodents, a series of tandem duplications of the Cathepsin L gene 
(ctsl) has produced a family of eight additional cathepsin genes on chromosome 
13.  Originally cloned from the placenta of rat and mice (Conliffe et al., 1995; Sol-
Church et al., 2000a; Sol-Church et al., 2000b, c), these Cathepsin L-related genes 
are differentially expressed and may have distinct roles both within the placenta 
and other tissues (Barrett et al., 2003).
These findings require a revaluation as to the function of this family of 
enzymes in transcriptional and epigenetic regulation; many important questions 
remain.  First, how is the protease cleavage activity regulated?  Along this line, 
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I showed that covalent modifications (i.e. acetylation and methylation of nearby 
lysines) serve to regulate, positively and negatively, the H3 proteolytic processing 
event (Figure 27).  Also note that proteolytic processing of H3 in the ciliate model 
occurs selectively in a hypoacetylated, transcriptionally silent (micronuclear) 
genome, while processing of H3 fails to occur in hyperacetylated, transcriptionally 
active macronuclei (Allis et al., 1980).  These data raise the question as to 
whether other chromatin-modifying enzyme complexes, such as HATs, HDACs, or 
ubiquitinating enzymes, play a role in regulating histone proteolysis.
Second, by what mechanism is the cleaved H3 replaced, and is DNA 
replication and chromatin assembly required?  Although it is possible that the cell 
would leave those loci in a permanently changed state, one would imagine that the 
cell would have a mechanism to reverse the effect of cleavage.  My data supports 
this in that I do not observe the cleaved H3 product in ESCs beyond 4 days of 
RA induction.  In fact, the cell has a few different mechanisms that might resolve 
this issue.  For example, since not every H3 molecule will have been cleaved 
(or even serve as a substrate for the enzyme), the cell could use remodeling 
mechanisms to remove the cleaved H3 nucleosomes and replace it with those 
from other regions of the genome.  Additionally, the proteolyzed molecule of H3 
may be removed from the chromatin and replaced by a full-length H3 molecule, 
either by any H3 isoform during S phase or by H3.3 outside of S phase (Loyola 
and Almouzni, 2007).  As I described in my work with Sandra Hake in Chapter 3, 
the ratios between H3 isoforms change as ESCs differentiate, suggesting that H3 
replacement mechanisms in ESCs are highly robust and could rapidly replace a 
tail-less H3 molecule.  My findings with the Hunt laboratory also show that the 
histone variant H3.2 is preferably cleaved as compared to H3.3, supporting the 
idea that S-phase/replication-coupled replacement may be involved.  Along this 
line, I also note that proteolytic processing of transcription factor CDP/Cux by 
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Cathepsin L occurs during the G1/S-phase transition and is coupled to cell cycle 
progression (Goulet et al., 2004). Whether proteolytic processing of H3 is cell cycle 
dependent remains unclear, although it is interesting to note that my studies were 
done in ESCs, which cycle rapidly and spend a high percentage of time in S-phase 
as measured by flow cytometry (Figure 3.2D).
 Third, and more broadly, does this proteolytic mechanism apply to other 
histone substrates or to other cathepsin family members or cathepsin-like proteases, 
and is the general mechanism conserved in other organisms or operating in other 
stages of development or differentiation?  Although Cathepsin L is the only member 
of this family shown to localize to the nucleus, the conservation in genomic structure 
and sequence between this protease and its related family members suggest 
that other cathepsins may function similarly.  As with other chromatin-modifying 
enzymes/complexes, I suspect that the particular enzyme system and mechanism 
may not be universal, but rather specific to a particular developmental time and/
or genomic locus.  Moreover, it is possible, if not likely, that histone H3 is only a 
substrate of Cathepsin L during a particular window of time and space, dictated 
by multiple modes of regulation that may include the presence of endogenous 
protease inhibitors (e.g. MENT (Bulynko et al., 2006)) and the modification of the 
H3 tail itself.
Finally, the major outstanding question is: what is the downstream biological 
function of histone H3 tail cleavage?  In order to assay for the downstream effects 
of H3 proteolysis, this event must be separated from the effects of its cleavage of 
other Cathepsin L substrates. Experimentally, this is quite difficult, since there is 
at least one other known nuclear substrate, transcription factor CDP/Cux (Goulet 
et al., 2004).  One possibility would be if the structure of mammalian Cathepsin 
L + H3 peptide revealed unique interactions that would then allow for the over-
expression of a mutant protein that only affected its activity toward histone H3. 
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Another possibility would be to replace all copies of H3 with a non-cleavable protein, 
such as one of the mutants in Figure 4.8; however, given that mammalian cells 
have many (>10) copies of the histone H3 gene in their genome, this experiment 
may not be feasible.  It would also be interesting to test the hypothesis that H3 
proteolysis leads to the regulated replacement of that histone at specific genomic 
loci.  In order to do this, it would be necessary to develop ChIP methods to assay 
the removal of cleaved H3 and its replacement (e.g. w/H3.3).  Although I did make 
several attempt to ChIP differentiating ESC chromatin with the H3cs.1 antibody 
I developed, I never found significant enrichment at specific genes.  It might be 
necessary to generate new antibodies and screen for ones that are ChIP-grade. 
Once a map is generated of the loci at which H3 is cleaved, it would then be 
possible to develop ChIP approaches to detect its replacement.  Another obstacle 
to this experiment will be the lack of H3 antibodies that can distinguish between 
the three H3 isoforms.  However, once the genomic targets of H3 cleavage are 
known it would be possible to try using epitope tagged H3 isoforms to analyze their 
presence at these loci before and after H3 cleavage.
Limited proteolysis of nuclear proteins is an important means of regulating 
transcription and other cell processes (Goulet and Nepveu, 2004; Vogel and 
Kristie, 2006).  Here I show that limited proteolysis of histone H3 by Cathepsin L 
occurs during the differentiation of ESCs and may be regulated both positively and 
negatively by covalent modifications on the H3 tail itself.  Despite the technical 
difficulties in assaying its function, the identification and characterization of 
H3 cleavage by Cathepsin L during ESC differentiation is an important step in 
understanding limited nuclear histone proteolysis as a mode of transcriptional 
regulation.  It is possible that H3 cleavage serves to remodel chromatin and/or 
regulate gene expression, perhaps by removing certain covalent modifications, 
and/or creating a new N-terminal H3 tail (as well as a new sequence context for 
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binding modules), and/or altering the structure of selected nucleosomes (affecting 
their compaction and stability).  I will address these questions and other possible 
far-reaching implications of regulated histone proteolysis in the General Discussion 
in Chapter 5.
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Chapter 5: General Discussion
 A rapidly growing literature demonstrates that cells undergo dramatic 
developmentally-regulated changes in gene expression and cellular morphology 
upon transition from undifferentiated stem cells to specific lineages (Giadrossi et al., 
2007; Kim et al., 2008; Murry and Keller, 2008).  Chromatin proteins provide cells 
with layers of gene regulation that are independent of genomic sequence.  Here 
I have described just a few of the many chromatin mechanisms that cells use to 
control differentiation and development.  In particular, my work focuses on changes 
that involve histone H3 during the differentiation of mouse Embryonic Stem Cells 
(ESCs).  Below I will discuss some of the potential far-reaching implications of this 
work.  I will focus mainly on the study of H3 proteolysis during ESC differentiation 
(described in Chapter 4), since this work was the major focus of my graduate 
studies; however, I will discuss how other aspects of H3 regulation during ESC 
differentiation, including histone replacement and the recruitment of specific 
histone-binding proteins, may converge into common regulatory mechanisms.
 There is now growing evidence supporting the idea that histones, particularly 
histone H3, are proteolytically cleaved in the course of normal growth and 
development.  Past studies cell-cycle documented the cell-cycle regulated, nuclear 
cleavage of H3 in the ciliate Tetrahymena (Allis et al., 1980) and the proteolysis of 
H3 in mammalian cells infected with the foot-in-mouth-disease virus (FMDV) (Falk 
et al., 1990).  More recent work includes the study described here (in Chapter 4) 
demonstrating H3 cleavage in differentiating mouse ESCs (Duncan et al., 2008) and 
a report of N-terminal H3 proteolysis in budding yeast (Santos-Rosa et al., 2009). 
Interestingly, the major site of cleavage is conserved in these last two studies 
(between alanine 21 and threonine 22), suggesting that such regulated proteolysis 
may be evolutionarily conserved.  Here, I show that H3 cleavage in differentiating 
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ESCs can be performed by the papain-like cysteine protease Cathepsin L and 
that its activity toward H3 is affected by modifications on the histone tail itself. 
Nevertheless, many questions remain regarding the regulation and mechanism 
of this particular H3 proteolysis and, more broadly, the potential functions and 
downstream effects of regulated histone proteolysis in general.  Below I will discuss 
some of the possible mechanisms and functions of regulated histone proteolysis 
and how they may cooperate with other mechanisms of chromatin remodeling to 
affect epigenetic regulation.
Substrate Recognition by Cathepsin L
One outstanding question about the regulated H3 proteolysis observed in mouse 
ESCs concerns the selective cleavage of the H3 tails.  Three observations described 
in Chapter 4 suggest that H3 cleavage in differentiating ESCs occurs preferentially 
on a subset of H3 tails: 1) only a small percentage of H3 is cleaved, 2) H3 variant 
H3.2 is preferentially cleaved over H3.3 and possibly H3.1, and 3) the cleaved H3 
is enriched in certain histone modifications, particularly H3K27me2.  Although it is 
possible that other proteins mediate this preference as part of a protease complex, 
it is also feasible that the enzyme itself, specifically Cathepsin L, directs this 
selectivity.  One way to investigate this possibility is through a structural analysis 
of the Cathepsin L enzyme in complex with H3 peptides, in the same way that the 
structural studies described above on the PHD finger of BPTF revealed the nature 
of its ability to bind H3K4me3.  Dr. Patel and colleagues (MSKCC) are currently 
trying to obtain crystal structures of Cathepsin L + H3 peptide complexes; however, 
they have successfully obtained crystal structures of the cathepsin enzyme alone 
and used this data to model its recognition of H3 peptides.  As shown in Figure 
5.1, these models not only strongly support other data showing that Cathepsin L 
cleaves histone H3 between alanine 21 and threonine 22 (Figure 5.1A and B), 
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Figure 5.1: Cathepsin L may recognize dimethylated H3K27.
A. Electrostatic surface representation (red = negatively charged and blue = positively charged 
surface) of the crystal structure of Cathepsin L with an unmodified H3 (aa 18-27) peptide modeled 
into the complex; the peptide is shown in a space filling representation.  The black arrow indicates 
the cleavage site.
B. An expanded view of the cleavage site in A.
C. The model in A rotated 90 degrees to show the accommodation of the unmodified K27.
D. The structure shown in A with an H3 (aa 18-27) K27me2 peptide modeled into the complex; 
the black arrow indicates the dimethyl K27 and the circle highlights the potential “cage” that 
accommodates the methylammonium group.  (Images in A-D produced by Haitao Li and used with 
permission.)
but also suggest that the enzyme may have an aromatic cage, similar to those 
described above found in chromodomains (CDs) and PHD fingers, that could 
engage K27me2 if it assumes certain conformations (Figure 5.1C and D).
 These exciting structural studies could play an important role in forming 
hypotheses and guiding future functional experiments.  Importantly, they will help 
to better define not only how H3 is cleaved at specific sites, but also how it is 
recognized by Cathepsin L and potentially other papain-like cysteine proteases. 
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Such information could potentially lead to the discovery of new small-molecule 
inhibitors (or activators) that perturb this activity with greater specificity than those 
currently available.  It could also pinpoint the structural features critical to H3 
recognition, which could guide mutagenesis studies that aim to dissect the function 
of Cathepsin L activity toward histone H3 versus its other nuclear substrate(s).
Histone Proteolysis and Chromatin Remodeling
Another outstanding question about H3 proteolysis during ESC differentiation, and 
histone proteolysis in general, is: what are the downstream effects?  Although this 
question is still largely unanswered, data presented here and in other studies (Allis 
et al., 1980; Santos-Rosa et al., 2009) offer some hints and possibilities.
 As shown in Figure 5.2, H3 cleavage could impact chromatin function at the 
level of the histone tail (Figure 5.2A), the nucleosome, or the organization of the 
chromatin fiber (Figure 5.2B).  In Chapter 4, I showed evidence that cleavage of 
the H3 tail by Cathepsin L significantly decreases the binding affinity of mammalian 
Polycomb protein CBX7 for H3K27me3.  This effect is not surprising since structural 
studies of the CD of Drosophila Polycomb in complex with an H3 peptide (Min et al., 
2003) show that it makes contacts with amino acids N-terminal to the cleavage site 
mapped in differentiating ESCs (represented by the star shape in Figure 5.2A-1). 
It is also the case that Polycomb (and mammalian Pc CBX7) has a higher affinity 
for H3 trimethylated at K27, while the cleaved H3 is preferentially dimethylated 
at K27.  That said, CBX7 does bind with some affinity to H3K27me2, and it is 
unclear whether in vitro binding affinities directly translate to in vivo preferences 
for methylation state.  In any case, this evidence supports the idea that histone 
cleavage can impact downstream cellular function by affecting the binding of 
effector proteins such as Polycomb.
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Figure 5.2: Histone cleavage may affect chromatin function through mechanisms operating 
at the tail and/or nucleosome levels.   
A. Cleavage of the H3 tail has been shown to decrease the binding affinity of mammalian Polycomb 
(Pc) for K27 methylation (1); it may also create a new context for different binding proteins that 
could not bind prior to cleavage due to steric effects (2).
B. H3 cleavage may lead to histone replacement, perhaps mediated by H3.3 chaperone HIRA; 
such a mechanism might lead to H3.3 accumulation at specific genomic loci (1). Histone proteolysis 
may also affect nucleosome stability and lead to their eviction; this would then allow greater access 
of the DNA to transcription factors (TFs), leading to increased transcription at those loci.
 The fact that histone cleavage can impact the affinity of known histone 
methyl-binding proteins also raises the question as to whether such cleavage 
could also lead to the recruitment of new effector proteins.  Given that the CD of 
Polycomb and the binding domains of other chromatin-interacting proteins (e.g. 
the PHD finger of BPTF) are known to contact and recognize both the methyl 
modification on a particular lysine and the backbone sequence surrounding it, as 
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demonstrated in Min et al and depicted in Figure 5.2A-1, it is also likely that the 
“new” histone tail produced by its cleavage presents the appropriate context for 
different chromatin-interacting proteins to bind the same modification.  Moreover, 
the PHD finger of BPTF makes specific contacts with the amino terminus of the 
H3 tail (as shown in Figure 2.6C) leading Ruthenburg et al to hypothesize that the 
proximity of a given modification to the end of that tail may also affect the ability 
of particular proteins to bind (e.g. an “end-rule”), in addition to the modification 
itself and its immediate sequence context (Ruthenburg et al., 2007).  In Figure 
5.3 I show some unpublished data suggesting that there are indeed proteins in 
the nuclei of differentiating ESCs that prefer to bind H3K27me2 and K27me3 in 
the context of the cleaved peptide (H3 22-37) but not an “uncleaved” peptide (H3 
18-37).  Using the method established in our laboratory and depicted in Figure 
5.3A, I performed a screen for such cleaved-histone-methyl-binding proteins and 
found that many proteins did preferentially associate with the shorter methylated 
peptides (Figure 5.3B).  Unfortunately, this experiment did not purify significant 
quantities of protein for mass spectrometry identification, but it does suggest that 
such experiments are promising and worth pursuing in future studies.
 It is also possible that histone cleavage leads to downstream effects by 
causing changes at the nucleosome level.  Studies have shown that nucleosome 
composition and positioning on DNA affacts gene expression, but the functional 
roles of such mechanisms in development and differentiation are not yet fully 
understood (Rando and Ahmad, 2007).  As shown in Figure 5.2B and Figure 
1.5A, cleavage of histone tails (such as that of H3 by Cathepsin L) could initiate 
other mechanisms of chromatin remodeling, such as histone replacement (Figure 
5.2A-1 and Figure 1.5A) and/or nucleosome eviction (Figure 5.2B-2). Chromatin 
Immunoprecipitation (ChIP) studies using cleavage-site-specific antibodies and 
epitope tagged H3 variants, such as those suggested in the Chapter 4 discussion, 
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Figure 5.3: H3 peptides mimicking H3 cleavage associate with a unique group of proteins
A. A schematic depicting the peptide pulldown method used to identify novel histone modification 
binding proteins (Wysocka, 2006).
B. A preliminary experiment showing that cleaved H3 peptides may interact with histone binding 
proteins that cannot bind to peptides that contain residues amino to the H3 cleavage site.
could address the possibility that histone cleavage leads to histone replacement 
at specific genomic loci, as depicted in Figure 5.2B-1.  In the long term, once the 
functional roles of histone variant H3.3 in ESC differentiation are better understood, 
it would be interesting to test whether the perturbation of histone cleavage activity 
affects some of these downstream functions; such an experiment would address 
whether there is a functional, mechanistic link or merely a correlative one.
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It may also be possible to test this histone replacement hypothesis in 
Drosophila.  Preliminary evidence produced by the Kuroda Laboratory at Harvard 
Medical School suggests that the cleavage site mapped in differentiating mouse 
ESCs (Figure 4.3) may be conserved in the fly as well.  Using the cleavage-
specific antibody H3cs.1 in immunofluorescent (IF) labeling of squashed Drosophila 
polytene chromosomes, they observe a pattern that not only suggests the H3cs.1 
epitope is present, but also that it is non-randomly distributed (Figure 5.4 and 
personal communication with Gortchakov and Kuroda).  Their IF labeling also 
indicates that only a minor fraction of chromatin is recognized by the H3 cleavage 
site antibody, which agrees with the data on differentiating ESCs.  Since H3 variant 
replacement was originally documented in Drosophila and the fly is a genetically 
tractable organism, these results suggest that this may be a very useful model 
in which to test the histone replacement hypothesis described in Figure 5.2B-
1.  Although it is still unclear whether this particular antibody can be optimized 
for ChIP, the preliminary IF results shown in Figure 5.4 are suggest that such 
experiments may be possible. 
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Figure 5.4: The cleavage-specific antibody H3cs.1 labels Drosophila polytene chromosomes 
in a non-random pattern.
A. Immunofluorescent (IF) staining of squashed Drosophila polytene chromosomes with the H3 
cleavage-specific antibody (α-H3cs.1, shown in red).  DNA is stained with DAPI (blue).
B.  A second IF image of a chromosome squash (as described in A) providing a closer view of 
the distribution of α-H3cs.1 (red).  DNA is stained with DAPI (blue). (Images in A&B produced by 
Andrey Gortchakov and used with permission.)
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Another interesting model depicting a potential downstream effect of histone 
cleavage is presented in Figure 5.2B-2.  Although the mechanistic details are not 
clear, this model is supported by experiments done in S. cereviseae (Santos-Rosa 
et al., 2009).  In their study, Santos-Rosa et al use amino (N) and carboxy (C) 
terminal epitope tagged H3 proteins to perform ChIP studies, which suggest that H3 
tails are cleaved at gene promotors (measured by N-terminal-H3-tag ChIP signal 
reduction) prior to the depletion of the histone core (measured by a decrease in 
the C-terminal-H3-tag ChIP signal).  They also show that yeast strains expressing 
a mutant copy of H3 (L20A) do not properly activate genes that normally increase 
in expression under specific conditions (i.e. stationary phase and sporulation). 
As shown in Figure 5.2B-2, histone cleavage might lead to gene activation by 
causing nucleosome eviction and therefore allowing the underlying DNA sequence 
to become more accessible to transcription factors (TFs) and, ultimately, RNA 
polymerase.  Their studies also suggest that the yeast H3 cleavage enzyme 
discriminates against H3 proteins modified with the activating mark H3K4me3, 
although it is not clear whether this modification directly inhibits the protease itself 
or is mediated indirectly through other proteins and/or activities in the yeast nuclear 
extract.
Although the identity of the yeast H3 cleavage enzyme(s) is still unknown, 
its discovery will be an important step in studying the downstream effects of histone 
proteolysis.  Since yeast are a genetically tractable system, it will be much easier 
to test hypothetical models, such as those depicted in Figure 5.2, using knockout 
and mutagenesis strategies that are possible in this model organism.
Unique Histone Modification Patterns in Embryonic Stem Cells
As described in Chapter 3, the chromatin of ESCs bears a unique modification 
pattern that may be critical to their maintenance of pluripotency and ability to 
differentiate.  At the moment, only one specific ESC pattern of modifications has 
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been identified: termed “bivalent domains,” this pattern is not only unique in that 
it correlates with pluripotency but also because it is defined by a combination of 
marks, H3K4me3 and H3K27me3, that were previously thought to be mutually 
exclusive (Bernstein et al., 2006).  The fact that these modifications are both 
enriched at genomic loci in ESC chromatin is also significant because they 1) occur 
in regions that are enriched for genes encoding transcription factors associated 
with embryonic development and 2) are catalyzed by key developmental proteins, 
trithorax Group (trxG) and Polycomb Group (PcG) proteins, respectively (depicted 
in Figure 5.5A) (Bernstein et al., 2006).  Nevertheless, the question remains as to 
whether other unique modification patterns exist in ESCs and, if so, whether they 
have redundant or specialized roles.
 Since genes within these bivalent domains are expressed at a very low 
level, Bernstein et al suggest that the H3K4me3+H3K27me3 bivalent domain 
maintains genes in a “poised” state.  Work by Azuara et al supports this theory 
by showing that ESCs defective in H3K27 methylation display improper gene 
expression at these loci (Azuara et al., 2006).  One hypothesis might be that ESCs 
do have additional unique modification patterns, whether on another single tail or 
in a cross-talk across different histones and that such redundancy would make the 
mechanism of maintaining “poised” genes more robust.  As shown in Figure 5.5, 
such a dual pattern system might then have further implications when histone H3 
is cleaved during ESC differentiation.  In cleaving the histone tail, a “irreversible” 
post-translational modification, the cell can both quickly remove modifications 
(e.g. H3K4me3) and “lock in” the chromatin states dictated by the redundant mark 
(yellow boxes, Figure 5.5B).  The function of this mark may be reinforced by the 
loss of effectors such as Pc and/or by the recruitment of different binding proteins to 
the new amino terminus of H3.  Such a mechanism might only exist during a small 
window of time during development, such as when an ESC loses its pluripotency, 
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Figure 5.5: The functions of ESC specific modifications may be affected by histone 
cleavage.
A. A schematic depicting the known ESC-specific modification pattern (H3K4me, represented by 
the green circle and H3K27me, represented by the red circle) and a potentially unidentified mark.
B. A schematic showing some of the potential downstream effects on the chromatin status depicted 
in A after H3 tail cleavage.
and allow it to “reset” its epigenetic profile before it proceeds to differentiate toward 
a specific lineage.  It is also possible that this cleavage mechanism is repeated in 
other instances of stem cell differentiation, such as the differentiation of multipotent 
skin stem cells (see Chapter 4 discussion), and/or that it occurs on other histone 
tails, such as H2A.
 Many questions still remain as to the function, mechanisms and far-reaching 
implications of histone proteolysis in both ESCs and other cell types and organisms. 
Most importantly, these studies have focused exclusively on the “normal” state of 
cellular growth, differentiation and development.  In the future, it will be important 
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to address whether this activity exists in disease states and, if so, how it differs 
from that of normal cells.  It is possible that histone cleavage, whether of H3 or 
other histone tails, could be a clinical marker of certain pathologies and/or lead 
to testable treatments of such pathologies through the use of enzyme inhibitors. 
Another important context in which histone cleavage may figure is the recently 
developed induced Pluripotent Stem cells (iPS), in which differentiated cells are 
converted to stem cells by the expression of three or four transcription factors 
(Takahashi and Yamanaka, 2006).  The efficiency with which differentiated cells 
convert to stem-like cells in this process is still quite low, and it is often suggested 
that this inefficiency is due to the inability of these transcription factors to change 
the epigenetic state of chromatin.  Given that histone cleavage occurs in the 
process of differentiating pluripotent cells, it may also play a role in the reversal of 
this process.  These questions, and others not raised here, will be the subject of 
future studies.
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Chapter 6: Materials and Methods
Recombinant Protein Preparation
CBX-CDs
CBX CDs (aa 1-62) and full length CBX7 were cloned into pGEX-6P-1 (Amersham); 
GST fusion proteins were produced in BL21 E. coli.  Bacterial lysates were purified 
over Glutathione Sepharose 4B (Amersham) as recommended by the manufacturer. 
6x His-tagged human HP1β and Drosophila Pc proteins were a gift of W. Fischle 
(aa 15-72 and aa 15-77, respectively, both cloned into pET-11a; Promega).  Point 
mutations of caging aromatic residues in CBX7 were created using QuikChange 
site–directed mutagenesis (Stratagene). BPTF PHD Fingers
Wild type and mutant PHD fingers from human BPTF (residues 2583-2640) were 
expressed and purified as described previously (Li et al., 2006).  Briefly, the PHD 
finger (residues 2583-2640) from human BPTF was cloned into pGex6p vector 
with an N-terminal glutathione S-transferase (GST) tag.  The protein was over-
expressed in the Escherichia coli host cell Rossetta2 (Novagen) by induction 
with 0.4 mM isopropyl β-D-thiogalactoside overnight at 20º C in LB medium 
supplemented with 0.1 mM ZnCl2.  After cell lysis and centrifugation, the GST-
fusion protein was purified by GST affinity column, followed by tag cleavage using 
PreScission protease (Amersham Biosciences), and purification by size-exclusion 
chromatography on Superdex 75.  Point mutants of PHD fingers were made using 
the QuickChange site-directed mutagenesis kit (Stratagene) and were verified by 
DNA sequencing.  All mutants were purified as described for the native protein.
L3MBTL1 MBT repeats
Wild type and mutant 3MBT (residues 197-526 of human L(3)MBTL1, gi: 23396689) 
were expressed and purified as described previously (Wang et al., 2003).
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Histone H3-HIS
A PCR fragment of the complete mouse histone H3.2 ORF was cloned into the 
pET30a plasmid vector to add a C-terminal HIS tag to the coding sequence. 
Mutations were made using the Quick-Change Mutagenesis II kit (Stratagene). 
Plasmids were transformed into BL21 E.coli and rH3-HIS protein was purified 
from inclusion bodies using both Ni2+-NTA and C8 columns (RP-HPLC).  Acetic 
anhydride treatment was performed as described previously (Garcia et al., 2007). 
rH3-HIS was converted to rH3-HIS+K27me2 by first mutating K27 to C and C110 
to A and then alkylating the cysteine to dimethyl by published methods (Simon et 
al., 2007).
Peptide Synthesis
Peptides were synthesized either at The Rockefeller University Proteomics 
Resource Center, the Memorial Sloan-Kettering Cancer Center for Microchemistry, 
or the Baylor College of Medicine Protein Chemistry Facility.  The methylation state 
of each peptide was confirmed by mass spectroscopy.  Peptides were extensively 
lyophilized and resuspended in milli-Q water before use.  5-Carboxyfluorescein 
(5-FAM) or biotin groups were coupled directly to the N-terminus (for H3 aa 19-35 
series) or C-terminus (for H3 aa 1-15 series).
Fluorescence polarization
Fluorescence polarization assays were performed essentially as described (Fischle 
et al., 2003).  All mouse Pc CDs were analyzed using buffer containing 20mM 
imidazole, 25 mM NaCl, and 2 mM DTT and mHP1α was performed using a buffer 
containing 50mM Na2HPO
4, pH=7, 25mM NaCl, 1mM MgCl2, 2mM DTT. The wild-
type and mutant PHD fingers were assayed using buffer containing 10mM HEPES 
pH 7.5, 150 mM NaCl, 0.005% NP-20 and 2 mM DTT.  The assays on L3MBTL1 
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were performed under conditions of 20 mM imidazole, 25 mM NaCl, 2 mM DTT 
(pH 8.0) or 25 mM Tris-HCl, 2 mM DTT (pH 8.0).  50ml reactions were incubated 
with 100 nM C-terminally fluorescein-labeled peptide for 15 minutes on ice (Pc/
HP1-CDs) or 1 hour at room temperature (PHD and L3MBTL1); fluorescence 
polarization was then measured in the Hidex Chameleon plate reader, at room 
temperature.
Fluorescence polarization statistical analysis
For all fluorescence polarization experiments, three independent batches of 
protein were purified and used in 2-4 replicate binding assays per batch (unless 
stated otherwise in the text or figure fegend).  Anisotropy results for each replicate 
were normalized and then plotted; binding curves were fit to all normalized data 
points to determine Kds and error (SEM).  Normalized results for all replicates were 
averaged and plotted using the Kalidograph software package, with error bars 
representing standard deviation when included.  P value was calculated using the 
Student’s t-test.
Peptide pull-down assays
Peptide pull-down assays were performed as described (Wysocka, 2006) using 
biotinylated peptides conjugated to streptavidin agarose beads (Pierce 20349). 
~5ug of recombinant protein plus 20-fold excess of BSA (internal control) or nuclear 
extracts from ESCs were incubated with the peptide-conjugated beads in assay 
buffer (150mM KCl, 20mM Hepes and 0.2% TritonX-100) for 1-4 hours at 4°C; the 
beads were then washed 6-8x in assay buffer.  Elutions were loaded onto 10 or 
15% SDS-PAGE gels and silver stained.
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Crystallization, data collection and structure determination of BPTF-PHD
Crystallization, data collection and structure determination of the PHD finger of 
BPTF in complex with H3K4me3 peptide were performed as described previously 
(Li et al., 2006).  Briefly, crystals of the complex between SeMet-labeled PHD 
finger-bromodomain and H31-15K4me3 were obtained using Crystal Screen Cryo 
Kit (Hampton Research) condition #41.  The protein and peptide were mixed with 
a ratio of 1:1.2 at ~15 mg/ml and put on ice for ~30 min prior to use.  Overnight-
grown crystals were briefly cryo-protected by the reservoir solution and frozen 
under liquid nitrogen.  The diffraction data was collected at wavelength 1.3477 
Å at the Advanced Photon Source (APS) beam line 23ID-D, Argonne National 
Laboratory.  Due to crystal decay, two data sets from different regions of one crystal 
were collected with 250x0.5º and 180x1º frames each, and merged for structure 
determination.  All data were processed with HKL2000 (http://www.hkl-xray.com/).
Crystallization, data collection and structure determination of the Y17E PHD finger 
mutant in complex with H3K4me2 peptide were performed as described previously 
(Li et al., 2007).  Briefly, crystallization was performed by vapor diffusion at 20°C. 
Y17E sample (16.5mg/ml, 20mM Tris-HCl pH 7.5, 50mM KCl) was pre-incubated 
with three-fold molar excess of H3(1-9)K4me2 peptide in the presence of 5mM 
MgCl2 for ~30 min on ice.  Crystals were flash-frozen in liquid nitrogen with the 
reservoir solution as cryoprotectant.  Diffraction data of both crystals were collected 
at beam line NE CAT 24ID-C, the Advanced Photon Source (APS), Argonne 
National Laboratory, and were processed with HKL2000 (http://www.hkl-xray.com). 
The phases of both crystals were determined by molecular replacement using the 
program Molrep associated with the CCP4 software package (http://www.ccp4.
ac.uk/html/molrep.html).
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Immunoblots
Samples were separated on SDS/PAGE mini gels and transferred onto polyvinylidene 
difluoride (PVDF) membranes (Millipore); membranes were often then stained with 
Ponceau S (Sigma) or Amido Black (Sigma) to ensure proper protein transfer. 
After incubation with primary antibody and addition of a horseradish peroxidase-
conjugated secondary antibody (Anti-Rabbit HRP Immunoglobulins, Dako P0399; 
ECL HRP-Linked Mouse IgG whole Ab, GE NA931V; Polyclonal Rabbit Anti-Goat 
Immunoglobulins, Dako P0449), membranes were incubated with ECL-Plus 
substrate (Amersham Pharmacia), and proteins were detected by exposure to 
x-ray film or using the Fujifilm LAS4000 Imager.
Antibodies
The following antibodies were purchased from commercial vendors: monoclonal 
α-Flag (M2, Sigma), H3K27me2 (Active Motif 07-452), H3K27me3 (Active 
Motif 07-449), monoclonal α-Hp1β (Active Motif), monoclonal α-GFP (Roche); 
Cathepsin L (R&D Systems AF1515), Cathepsin B (R&D Systems AF965), Penta-
HIS HRP Conjugate Kit (Qiagen 34460), Oct3/4 (BD Transduction Laboratories 
611202), H3gen (Abcam 1791), and H3K4me3 (Abcam 8580). WDR5 was a gift 
from J. Wysocka and monoclonal H3K27me3 for IF a gift from D. Reinberg.  The 
cleavage-specific H3.cs1 antibody was generated as follows: a 2x branched peptide 
corresponding to mammalian histone H3 sequence 22-26 was conjugated to KLH 
and injected into rabbits (Covance).  The N-terminal H3gen antibody was generated 
as follows: a peptide corresponding to mammalian histone H3 sequence 1-6 was 
conjugated to KLH and injected into rabbits (Covance). Serum was collected and 
specificity is shown in Figure 4.6.
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ELISA
Peptides (untreated or those used as substrates in H3 cleavage reactions) were 
plated onto clear, high-binding ELISA plates in duplicate.  Standard curves were 
generated by plating positive control peptides in duplicate in serial dilutions.  Plates 
were then incubated overnight at 37°C to allow peptides to bind.  Each well was 
then washed 3x with 1X phosphaste buffered saline (PBS).  Blocking solution [1% 
bovine albumin serum (BSA) in 1X PBS + 0.5% Tween-20(PBST)] was then added 
to each peptide-containing well and the plates were incubated for 1 hour at 37°C. 
Blocking solution was then removed and replaced with primary antibody diluted in 
PBST (at a dilution previously optimized for immunoblotting or at several dilutions 
if optimization is necessary) and incubated for 2-3 hours at 37°C.  The wells were 
then washed 3x with PBST.  HorseRadish-Peroxidase (HRP) conjugated secondary 
antibody was then diluted in 1XPBST, added to each well (1:5000 dilution used for 
anti-rabbit secondary antibody in ELISAs with H3cs.1 antibody), and incubated 
for 1-2 hours at 37°C.  Wells were then washed 3x with 1XPBST.  To develop the 
assay, OPD tablets (Sigma-Aldrich) were dissolved in MilliQ water and the solution 
was added to each well and incubated at room temperature for 5-10 minutes (until 
solution turned yellow in positive control wells).  The reactions were then quench 
by added an equal volume of 1M HCl and absorption measured at 495nm on the 
Hidex Chameleon plate reader.
Preparation of Histones
Nuclei and histones were isolated as described (Shechter et al., 2007).  Cell nuclei 
were isolated by hypotonic lysis in buffer containing 10 mM Tris-HCl, pH 8.0, 1 
mM KCl, 1.5 mM MgCl2, 1 mM DTT, 0.4 mM PMSF, protease and phosphatase 
inhibitors.  Pelleted nuclei were acid extracted using 0.4 N sulfuric acid followed by 
precipitation with trichloroacetic acid or dialysis.
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H3 Variant separation by Reverse Phase HPLC (RP-HPLC)
Separation of mammalian core histones by RP-HPLC was done as described 
(Shechter et al., 2007).  Briefly, acid-extracted histones were separated by RP-
HPLC on a C8 column (220 by 4.6 mm Aquapore RP-300, Perkin Elmer) using a 
linear ascending gradient of 35-60% solvent B (solvent A: 5% acetonitrile, 0.1% 
TFA, solvent B: 90% acetonitrile, 0.1% TFA) over 75 minutes at 1.0 ml/min on a 
Beckman Coulter System Gold 126 Pump Module and 166/168 Detector.  Under 
these conditions histones H3 split into two peaks.  The H3 containing fractions were 
dried under vacuum and stored at –80ºC.  RP-HPLC fractions were resuspended 
in water, analyzed by SDS/PAGE and control-stained with Coomassie brilliant 
blue.  The so identified fractions were then subjected to mass spectrometry (MS) 
analysis.   
Sample Preparation and MS of Histone H3 Variants
Purified histone H3 protein from pooled RP-HPLC fractions were derivatized by 
treatment with propionyl anhydride reagent (Johnson et al., 2004).  The reagent 
was created using 75 µL of MeOH and 25 µL of propionic anhydride (Aldrich, 
Milwaukee, WI).  Equal volumes of reagent and each H3 variant were mixed and 
allowed to react at 51oC for 15 min.  Propionylated histone H3s were then digested 
with trypsin (Promega, Madison, WI) at a substrate:enzyme ratio of 20:1 for 5 hours 
at 37oC after dilution of the sample with 100 mM ammonium bicarbonate buffer 
solution (pH = 8).  The reaction was quenched by the addition of concentrated 
acetic acid and freezing.  A second round of propionylation was then performed 
to propionylate the newly created peptide N-termini.  Propionylated histone digest 
mixtures were then loaded onto capillary precolumns (360 µm o.d. x 75 µm i.d., 
Polymicro Technologies, Phoenix, AZ) packed with irregular C18 resin (5-20 µm, 
YMC Inc., Wilmington, NC) and washed with 0.1% acetic acid for 10 minutes. 
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Precolumns were connected with Teflon tubing to analytical columns (360 µm o.d. 
x 50 µm i.d., Polymicro Technologies, Phoenix, AZ) packed with regular C18 resin 
(5 µm, YMC Inc., Wilmington, NC) structured with an integrated electrospray tip as 
previously described (Martin et al., 2000).  Samples were analyzed by nanoflow 
HPLC-µ-electrospray ionization on a linear quadrupole ion trap-Fourier Transform 
Ion Cyclotron Resonance (LTQ-FT-ICR) mass spectrometer (Thermo Electron, 
San Jose, CA).  The gradient used on an Agilent 1100 series HPLC solvent delivery 
system (Palo Alto, CA) consisted of 0-40% B in 60 min, 45-100% B in 15 min 
(A = 0.1% acetic acid, B = 70% acetonitrile in 0.1% acetic acid) or other similar 
gradients.  The LTQ-FT mass spectrometer was operated in the data-dependent 
mode with the 10 most abundant ions being isolated and fragmented in the linear 
ion trap.  All MS/MS spectra were manually interpreted.
2 Dimensional Triton-Acid-Urea (2D TAU) Gels 
Total histones were dried under vacuum and resuspended in loading buffer (6 M 
urea, 0.02% (w/v) Pyronin Y, 5% (v/v) acetic acid, 12.5 mg/ml protamin sulfate). 
Samples were separated on TAU mini-gels (15% PAGE, 6 M urea, 5% acetic acid, 
0.37% Triton X-100; 300 V in 5% acetic acid for 1.5 h).  Lanes containing the 
samples were cut out, adjusted in 0.125 M Tris, pH 6.6 and the TAU gel slice was 
assembled on top of a 15% SDS/PAGE mini gel.  After the run, the gel was stained 
with Coomassie and destained with 5% methanol, 7.5% acetic acid overnight.  The 
gels were scanned and quantified using Image Gauge software (Science Lab), 
with the subtraction of background staining.
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Histone purification, Edman degradation and MS-MS mapping of H3 cleavage 
sites
Histones were acid extracted from nuclei and purified by RP-HPLC using a C8 
column as described (Shechter et al., 2007).  RP-HPLC fractions containing the 
H3 sub-band were pooled and repurified by RP-HPLC using a C18 column.  Equal 
amounts of fractions 52-55 were pooled, separated by SDS-PAGE, and blotted 
onto 0.2µm pore size membrane (Millipore ISEQ00010); H3 sub-bands were 
excised and subjected to Edman degradation as described previously (Strahl et 
al., 1999) using a Procise 492 cLC Sequencer from Applied Biosystems.  Fraction 
54 was digested with endoproteinase GluC (Roche Diagnostics, Indianapolis, IN) 
for 4 hours at 37oC (1:20 wt: wt) and loaded onto a C18 packed capillary column 
as previously described (Martin et al., 2000). Samples were analyzed by nanoflow 
HPLC-microelectrospray ionization on a linear quadrupole ion trap-Fourier 
transform mass spectrometer (LTQ-FT; Thermo Electron) for accurate mass and 
a Thermo LTQ instrument modified for electron transfer dissociation (ETD) and 
proton transfer charge reduction (PTR) for adequate tandem mass spectrometry 
(MS/MS) as previously described (Coon et al., 2005; Syka et al., 2004a; Syka et 
al., 2004b).  Data was manually interpreted, as well as searched against an H3 
database using OMSSA (Geer et al., 2004).
In vitro H3 cleavage assay
Extracts were incubated in buffer (10mM HEPES, 10mM KCl, 1.5mM MgCl2, 
0.34M sucrose, 10% glycerol, 5mM β-mercaptoethanol, all final) with 0.1µg/µl rH3-
HIS (purified from E. coli) and incubated at 37°C for 1-3 hours.  Reactions were 
stopped by addition of 5X SDS sample buffer and boiling; results were analyzed by 
immunoblotting with HIS-HRP and/or H3.cs1 antibody.  For MS analysis, reactions 
were quenched by addition of 0.1% (final) TFA.  rCathepsin L (R&D Systems 1515-
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CY-010), rCathepsin B (R&D Systems BAF965), and rCathepsin K (Calbiochem 
342001) were purchased from commercial sources and tested in the assay with 
rH3-HIS.
Enzyme enrichment and identification
3 days +RA differentiating ESC chromatin pellets were solubilized by sonication 
in buffer A (80mM NaPO-4, 200mM NaCl), injected onto a 2 or 5mL hydroxyapatite 
column (BioRad), and fractionated with a 200mM to 2M NaCl gradient.  Each 
fraction was then assayed as described above; both active and inactive fractions 
were reduced with 1mM DTT at 51oC for 1 hr and alkylated with 2mM iodoacetamide 
in the dark at RT for 45 mins, followed by digestion with trypsin (Promega Corp., 
Madison, WI) at an enzyme to substrate ratio of 1:20 (wt:wt) for 6 hrs at 37 oC; 
digest was then acidified with glacial acetic acid and aliquots of samples were 
analyzed using an LTQ-FT as described above.  Data was searched against a 
mouse database using SEQUEST (Eng et al., 1994).  All spectra of interest were 
manually validated.
Cellular extract preparation
Whole cell extracts were prepared by resuspending cell pellets in SDS-Laemmli 
sample buffer and boiling immediately.  Chromatin extracts were prepared by 
sonicating chromatin pellets in buffer (10mM HEPES, 10mM KCl, 1.5mM MgCl2, 
0.34M sucrose, 10% glycerol, 5mM β-mercaptoethanol) after isolation by various 
methods (high salt extraction, (Dignam et al., 1983), chromatin fractionation, 
(Mendez and Stillman, 2000)).  Briefly, cells were swelled in low salt buffer and 
then lysed by either mechanical disruption (Dignam method) or detergent (Stillman 
method); soluble nuclear proteins were then either extracted with high-salt 
(Dignam) or released by incubation in no salt buffer and mechanical disruption 
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(Stillman), leaving behind the chromatin pellet.  Protease inhibitors were omitted 
from extract preparations used for activity assays.  Digestion of chromatin fractions 
into mononucleosomes was accomplished by treatment with microccocal nuclease 
as described (Wysocka et al., 2001).
Chromatin fractionation and RNAse treatment
Biochemical fractionation was performed by centrifugation as described (Mendez 
and Stillman, 2000; Wysocka et al., 2005) and depicted in Figure 2.4A.  Chromatin 
from female ESCs was prepared at day 6 of differentiation as described above, 
resuspended in low salt buffer (10mM Hepes, 10mM KCl, and 1.5mM MgCl2), and 
treated with RNase A at 0, 2, or 5 µg per 100ul of chromatin.  Samples were incubated 
at 37°C for 10 min. and chromatin was run on SDS-PAGE for immunoblots.
Chromatin ImmunoPrecipitation (ChIP)
Chromatin ImmunoPrecipitations were performed essentially as described 
previously (Lee et al., 2006).  Briefly, ESCs were trypsinized, resuspended in warm 
serum-containing media, and then cross-linked and fixed with 1% paraformaldehyde 
(final) for 30 minutes at room temperature.  The cells were then pelleted and lysed in 
buffers containing protease inhibitors (Complete Mini tablet, Roche), and sonicated 
in the Bioruptor (Diagenode) to shear the chromatin.  1/10 volume of 10% Triton 
X-100 was then added to the sonicated lysates, followed by centrifugation to clear 
any non-solubilized material.  The supernatants were then aliquoted into input and 
ChIP samples.  Pre-antibody-bound Protein A and/or Protein G magnetic beads 
(Dynabead) were then added to the ChIP samples and incubated overnight at 4°C. 
The beads were then washed several times and the chromatin fragments eluted. 
The eluates were then treated to reverse the protein-DNA cross-linking and digest 
the remaining protein and RNA.  The remaining genomic DNA was then purified 
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using the Qiagen PCR purification kit and split into aliquots for QPCR and Solexa 
sequencing.  Those aliquots to be sent for sequencing were prepared by first using 
the Epicentre DNA ENDRepair kit (Epicentre Biotechnologies, Cat. # ER0720) to 
generate blunt-ended DNA, then treated with the Klenow enzyme (New England 
Biolabs) to add adenines to the 3’ ends, ligated to the Solexa adapter using T4 
ligase (New England Biolabs), and amplified by PCR.  Amplified DNA was then 
sequenced using the Ilumina Genome Analyzer (Solexa) in the Genomics Resource 
Center at The Rockefeller University.
RNA gel shifts
RNA was in vitro transcribed with T7 Megascript (Ambion) and 32P-UTP.  100 
and 500 nt fragments of cyclin E were used as a template for single and double-
stranded RNAs. RNAs were gel purified.  Cyclin E DNA was labeled with 32P γ-ATP 
using T4 Polynucleotide kinase. Increasing amounts of protein (10-500 pmol) were 
incubated in buffer containing 20mM Hepes, 100mM KCl, 2mM EDTA, 0.01% NP-
40, 1mM DTT, 3ug tRNA for RNA gel shifts (Ambion), 1ug poly (dI-dC) for DNA 
gel shifts (Amersham), RNasin (Promega) and 10,000 cpm of RNA or DNA in a 
total reaction volume of 20 µl.  Reactions were incubated on ice for 30 min.; 5% 
native 0.5xTBE gel was pre-run at RT; gels were run at 4°C for 3 hours at 250v and 
imaged with FLA-5000 phosphorimager (Fujifilm).
Cell Lines and Culture
All mammalian cell lines, with the exception of mouse LF2 cells were grown in 
Iscove’s DMEM supplemented with 10% fetal calf serum and penicillin/streptomycin 
at 37ºC and 5% CO2.  The following cell lines were used in this study: HeLa (human 
cervical epithelium, gift from Lisa K. Denzin, MSKCC), HT-29 (human colon 
cancer, gift from Petr Protiva, Cornell University), Raji (human Burkitt’s lymphoma, 
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gift from Lisa K. Denzin, MSKCC), CEM (human T cell leukemia lymphocyte, 
gift from Lisa K. Denzin, MSKCC), HEK293 (human embryonic kidney), U2OS 
(human osteosarcoma, ATCC#: HTB-96), MEF (mouse embryonic fibroblast, gift 
from Andre Nussenzweig, NCI), LF2 (mouse embryonic stem cell, gift from Austin 
Smith, CSCR, UK), N2a (mouse neuronal stem cell-like, gift from Robert Darnell, 
Rockefeller University), P-CUT MEF and 10T1/2 (mouse embryonic fibroblast).
 ESCs (LF2 line, see above) were cultured as previously described 
(Bernstein et al., 2006; Smith, 1991).  Cells were grown on gelatin-coated plates 
without feeder cells and maintained in an undifferentiated state through culture 
in KODMEM (Invitrogen 1082-9018), 2mM L-glutamine (Sigma G7513), 15% ES 
grade fetal bovine serum (Gibco 10439-024), 10-4 mM 2-mercaptoethanol, and 
leukemia inhibitory factor (LIF).  Cells were plated and maintained at 60-80% 
density, requiring passage every 2-3 days and checked for the expression of 
positive stem cell markers by immunoblot periodically.  To differentiate, cells were 
plated at ~1*104 cells/cm2 and differentiated with LIF-free media ± 100nM all-trans-
RA (Sigma R2625).  Differentiation ES medium was changed every day for the 
first three days, during which time RA was maintained.  After three days, RA was 
removed and cells cultured with differentiation ES medium that did not contain 
RA.  Embryoid bodies were formed by splitting partially trypsinized cells onto non-
treated petri dishes and allowing cells to cluster.  Cathepsin L was chemically 
inhibited by adding 10uM [final] Cathepsin L I inhibitor (Calbiochem 219402) to the 
cell media. 
CBX cDNA fusions
CBX cDNAs were cloned BglII/SalI into EGFP-N1 (BD Biosciences) producing 
C-terminal EGFP fusion proteins.  CBX2 cDNA was a gift of M. Narita. CBX4 cDNA 
was cloned from female ES cell line HP310 by RT-PCR; cDNAs for CBX6 and 
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CBX8 were purchased from Open Biosystems; CBX7 cDNA previously described 
(Gil et al., 2004).  All CBX cDNAs were verified.  Point mutations in CBX7-EGFP 
were created as for recombinant proteins.  The CBX4 CD swap into CBX7 was 
made by staggered PCR by incorporation of overlapping oligos and the chimeric 
cDNA was cloned into EGFP-N1.
Immunofluorescence and RNase treatment
LF2 cells were transiently transfected at day 2 of differentiation with Lipofectamine 
2000 (Invitrogen) and on day 3, cells were stained as previously described 
(Chaumeil et al., 2002).  Line histograms were made with processing software, 
MetaMorph Offline.  RNase treatments on living LF2 cells were performed as 
described (Muchardt et al., 2002).  In brief, 24 hours post-transfection, cells were 
incubated on ice for 10 minutes in PNS-0.3% Triton X-100 (PNS=20 mM PIPES 
pH 6.8, 200 mM NaCl, 600 mM sucrose).  Cells were incubated for 1 hour on ice in 
PNS +/- RNase A (1 mg/ml) and fixed in 4% paraformaldehyde.  IF was performed 
as above.
Cell Cycle Analysis by FACS
1x106 cells were collected, washed with PBS and fixed overnight at -20ºC in 70% 
Ethanol, diluted in PBS.  The next day, cells were washed with PBS and incubated 
for 30 min at 37ºC in PBS containing RNaseA (10µg/ml), followed by the addition 
of propidium iodide (10µg/ml) and another incubation for 30 min at 37ºC.  Stained 
cells were analyzed on a FACSort instrument (BD Immunocytometry Systems) with 
the exclusion of doublets.  Analysis of the results was performed with CellQuest 
software (BD Bioscience).
131
RNAi knockdown
Short hairpins to both a control gene (a human gene that does not share sequence 
homology to the mouse genome) and the Ctsl gene were purchased from Open 
Biosystems (RHS3979-9628371 and RMM3981-9597987) and transfected into 
293T cells to produce Lentiviral particles.  ESC lines were created by infection and 
selection with puromycin.  Heterogeneous cell populations expressing either the 
control or Ctsl RNAi were then differentiated with RA.
RNA isolation, reverse transcription and Q-PCR with SYBRgreen
RNA was isolated from cells using Trizol reagent (Invitrogen) following the 
recommended protocol.  RNA quality was assessed using the Nanodrop 
Spectrophotometer (Thermo Scientific) by measuring the 260nm wavelength 
absorption to ensure that it produced a regular peak, and the 260/280nm ratio 
to the to ensure that it was > 1.8.  RNA that met these requirements was then 
reverse transcribed into cDNA using oligo dT primer and the SuperScript III First-
Strand Synthesis Kit (Invitrogen).  Reverse transcribed cDNA was then used in 
quantitative PCR (Q-PCR) reactions with SYBRgreen reagent and the incorporated 
fluorescence was measured by the Stratagene Mx3000P QPCR System.  Standard 
curves were generated for each primer pair using serial dilutions of cDNA, and each 
standard and sample was measured in duplicate.  The sequences of all primers 
used to amplify specific genes are listed in the table below.
Gene Forward seq (5’-3’) Reverse seq (5’-3’) Ann
Tmp C
Nanog CCTTCCCTCGCCATCACACT AGAGGAAGGGCGAGGAGAGG 57
Nestin TCGGGAGAGTCGCTTAGAG AGTTGCTGCCCACCTTCC 57
Pax3 CCATCGGCGGCAGCAAACC GATCCGCCTCCTCCTCTTCTCCTT 57
Musashi GCGGCGGCGGCAGCTGTAGTTCG CGGGGCTGGCGGCGCTGATGTAA 59
HoxA1 AGCCACCAAGAAGCCTGTCGTT TCTGTGAGCTGCTTGGTGGTGAAA 57
Sox17 CGCGCTCGACGGCTACC GCGGGCGGCTCTACGGACACT 59
GATA6 TGCCTCGACCACTTGCTATGAAAA CACTGATGCCCCTACCCCTGAG 55
Table 1.  Sequences of primers used in Q-PCR with SYBRgreen
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refID chr strd ES_exp und 3RA name
NM_026690 chr7 + 3.819966333 1 0 0610012D14Rik
NM_026886 chr5 - 7.750643333 1 0 1500001A10Rik
NM_028156 chr11 - 9.438215 1 0 1700001P01Rik
NM_030141 chr17 + 35.90888333 1 0 1700061G19Rik
NM_183097 chr8 + 53.16986667 1 0 1700067K01Rik
NM_053216 chr9 + 17.0918 1 0 1700102P08Rik
NM_029607 chr2 + 339.7533333 1 0 2310003C23Rik
NM_029747 chr17 - 28.9215 1 0 2410137M14Rik
NM_175381 chr19 + 51.4109 1 0 2700081O15Rik
NM_001033547 chr1 - 6.88332 1 0 4922505E12Rik
NM_001014836 chr10 - 6.98401 1 0 4930404N11Rik
NM_026296 chr5 + 13.41806333 1 0 4930548H24Rik
NM_027633 chr6 - 2.120500667 1 0 4931417G12Rik
NM_027519 chr5 + 6.018168333 1 0 6330406I15Rik
NM_177265 chr7 - 2.066853333 1 0 6330512M04Rik
NM_183152 chr10 + 53.06503333 1 0 6330514A18Rik
NM_021477 chr16 + 3.638213333 1 0 A2bp1
NM_173008 chr7 + 4.681863333 1 0 A430110N23Rik
NM_178656 chr11 + 10.3785625 1 0 A530088H08Rik
NM_001013793 chr17 + 23.8078 1 0 AA388235
NM_011920 chr6 + 697.8356667 1 0 Abcg2
NM_001033163 chr17 - 20.61596667 1 0 Abhd9
NM_198018 chr11 - 74.74003333 1 0 Abr
NM_134247 chr12 + 3.3122785 1 0 Acot4
NM_145444 chr12 + 3.399465333 1 0 Acot5
NM_172845 chr1 + 18.04867 1 0 Adamts4
NM_197985 chr6 - 389.27725 1 0 Adipor2
NM_009646 chr10 - 184.5286667 1 0 Aire
NM_001029876 chr8 + 387.8326667 1 0 AK122209
Appendix: genes marked differentially by H3K4me3
refID = refSeq gene ID; chr = chromosom; strd = DNA strand; ES_exp = ESC 
sample expression; und = undifferentiated ESC sample; 3RA = 3 days +RA 
differentiating cell sample; 0 = non-significant sequence representation; 1 = 
significant sequence representation; name = gene name
genes enriched in H3K4me3 in und ESCs (und = 1) are listed first followed by 
those enriched in H3K4me3 in 3RA ESCs (3RA = 1); within each sub-list, genes 
are listed in ascending alphabetical order according to gene name
Table 2.  Genes marked differentially by H3K4me3 - (pages 132-154)
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refID chr strd ES_exp und 3RA name
NM_028270 chr4 + 107.8928 1 0 Aldh1b1
NM_145684 chr11 - 19.08561667 1 0 Alox12e
NM_007441 chr3 + 7.171318833 1 0 Alx3
NM_019871 chr11 - 17.45036667 1 0 Amac1
NM_001012450 chr4 - 60.79077778 1 0 Ankrd6
NM_009676 chr1 + 8.509 1 0 Aox1
NM_031159 chr6 - 78.0922 1 0 Apobec1
NM_001005508 chr1 + 20.61983889 1 0 Arhgap30
NM_001002897 chr5 - 16.90213333 1 0 Atg9b
NM_026094 chr10 - 27.743845 1 0 Atp8b3
NM_001080935 chr11 + 39.98044233 1 0 B230217C12Rik
NM_001033308 chr4 - 28.25383333 1 0 BC013712
NM_144869 chr19 - 61.15306667 1 0 BC021614
NM_153513 chr3 - 49.95230178 1 0 BC028528
NM_009747 chr12 + 2.353836667 1 0 Bdkrb2
NM_001033539 chr16 + 1.567877 1 0 Bex6
NM_010800 chr5 + 17.69241333 1 0 Bhlhb8
NM_175235 chr9 + 7.282936667 1 0 Brunol6
NM_001017525 chr10 + 98.18878889 1 0 Btbd11
NM_001039231 chr5 - 22.27236 1 0 C230055K05Rik
NM_175427 chr2 - 6.553708333 1 0 C630035N08Rik
NM_013879 chr5 - 40.4871 1 0 Cabp1
NM_007583 chr15 - 8.57833 1 0 Cacng2
NM_133746 chr19 - 21.05016667 1 0 Calhm2
NM_011797 chr3 - 12.25247667 1 0 Car14
NM_001033243 chr7 + 12.38032667 1 0 Ccdc114
NM_153784 chr17 + 9.480913333 1 0 Ccdc64b
NM_177600 chr2 + 1.483516667 1 0 Ccdc73
NM_009913 chr9 + 3.231558222 1 0 Ccr9
NM_007645 chr7 - 10.2986 1 0 Cd37
NM_007646 chr5 + 73.28866667 1 0 Cd38
NM_009853 chr11 - 236.2413333 1 0 Cd68
NM_133974 chr9 - 69.13226667 1 0 Cdcp1
NM_019707 chr8 + 7.985309583 1 0 Cdh13
NM_133709 chr7 + 10.03623333 1 0 Chrdl2
NM_145129 chr9 - 4.122701833 1 0 Chrna3
NM_001081104 chr5 + 20.07288167 1 0 Chrna9
NM_019500 chr16 - 14.66071667 1 0 Cldn14
NM_025809 chr12 - 2.062456 1 0 Clec14a
NM_177129 chr1 - 11.78899917 1 0 Cntn2
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refID chr strd ES_exp und 3RA name
NM_007742 chr11 + 32.236045 1 0 Col1a1
NM_031163 chr15 - 24.47193333 1 0 Col2a1
NM_009946 chr13 + 22.50726111 1 0 Cplx2
NM_170673 chr6 + 57.92613333 1 0 Cpne9
NM_026682 chr11 - 103.5890167 1 0 Cpsf4l
NM_028798 chr3 - 15.19594333 1 0 Crct1
NM_172122 chr4 - 37.48393333 1 0 Crocc
NM_007795 chr7 + 52.33413333 1 0 Ctf1
NM_010009 chr10 + 6.15731 1 0 Cyp27b1
NM_145548 chr4 - 8.25364 1 0 Cyp2j13
NM_028979 chr4 - 12.4709 1 0 Cyp2j9
NM_178727 chr4 - 10.11254667 1 0 D630039A03Rik
NM_007584 chr17 - 66.27872671 1 0 Ddr1
NM_010043 chr1 + 51.33761333 1 0 Des
NM_010056 chr6 - 1.538752667 1 0 Dlx5
NM_001081330 chr11 - 10.69015 1 0 Dnahc2
NM_019874 chr4 + 52.07904444 1 0 Dnajb5
NM_153743 chr12 + 135.4267439 1 0 Dnmt3a
NM_001081695 chr10 + 751.661 1 0 Dnmt3l
NM_010077 chr9 + 4.800603333 1 0 Drd2
NM_025869 chr8 + 11.93795667 1 0 Dusp26
NM_001033344 chr1 - 63.86603333 1 0 Dusp27
NM_007904 chr14 - 8.420666667 1 0 Ednrb
NM_007911 chr11 - 33.2705 1 0 Efnb3
NM_019397 chrX - 9.15442 1 0 Egfl6
NM_025499 chr10 + 5.099154667 1 0 Eid3
NM_207685 chr4 - 429.9138667 1 0 Elavl2
NM_013514 chr14 - 109.5730167 1 0 Epb4.9
NM_144848 chr15 - 123.0061333 1 0 Eppk1
NM_019585 chr4 - 15.42566833 1 0 Espn
NM_176846 chr9 + 1.076221333 1 0 Exph5
NM_010164 chr1 - 13.02519 1 0 Eya1
NM_007977 chrX - 11.03175333 1 0 F8
NM_015798 chr18 + 2274.693333 1 0 Fbxo15
NM_001077189 chr1 - 20.10631807 1 0 Fcgr2b
NM_033522 chr12 + 5.125443 1 0 Ferd3l
NM_010194 chr7 - 13.76045 1 0 Fes
NM_080433 chr14 - 5.802793333 1 0 Fezf2
NM_010199 chr16 - 4.5063785 1 0 Fgf12
NM_020013 chr7 - 4.966183333 1 0 Fgf21
135
refID chr strd ES_exp und 3RA name
NM_010208 chr4 + 20.81738333 1 0 Fgr
NM_033571 chr5 - 41.32363333 1 0 Fkbp6
NM_008051 chr7 + 1.031342 1 0 Fut1
NM_008082 chr18 - 4.590435444 1 0 Galr1
NM_008105 chr13 + 111.950565 1 0 Gcnt2
NM_144891 chr2 + 8.3071505 1 0 Gdap1l1
NM_008110 chr11 + 25.21456667 1 0 Gdf9
NM_008120 chr4 - 17.36186667 1 0 Gja4
NM_008126 chr4 - 427.013 1 0 Gjb3
NM_183427 chrX - 3.7543115 1 0 Glra2
NM_001033452 chr2 - 37.79986667 1 0 Gm1967
NM_010317 chr13 + 6.872251111 1 0 Gng4
NM_021610 chr1 + 90.2146 1 0 Gpa33
NM_146250 chr1 - 17.50173333 1 0 Gpr1
NM_010951 chrX + 3.08802 1 0 Gpr143
NM_007412 chr10 - 19.67506667 1 0 Gpr182
NM_173410 chr7 + 5.955345 1 0 Gpr26
NM_011825 chr1 - 24.9065 1 0 Grem2
NM_026960 chr15 + 38.3199 1 0 Gsdmd
NM_029555 chr6 + 70.83673333 1 0 Gstk1
NM_026619 chr19 + 15.7455 1 0 Gsto2
NM_008185 chr10 - 55.99386667 1 0 Gstt1
NM_010398 chr17 - 19.94946667 1 0 H2-T23
NM_013548 chr13 + 214.3566667 1 0 Hist1h3f
NM_172563 chr11 - 8.236425 1 0 Hlf
NM_027521 chr10 + 40.827 1 0 Hmha1
NM_175606 chr5 - 62.11116444 1 0 Hopx
NM_026489 chr3 + 121.3566667 1 0 Hormad1
NM_010475 chr11 + 24.44636667 1 0 Hsd17b1
NM_025330 chr7 + 90.38643333 1 0 Hsd17b14
NM_001040684 chr7 + 156.185 1 0 Hsd3b7
NM_008310 chr16 - 2.827358833 1 0 Htr1f
NM_027320 chr11 + 65.4837 1 0 Ifi35
NM_026820 chr7 + 3796.616667 1 0 Ifitm1
NM_025378 chr7 - 3844.43 1 0 Ifitm3
NM_008340 chr17 + 22.32913333 1 0 Igfals
NM_008344 chr15 + 15.3358 1 0 Igfbp6
NM_198610 chr4 - 91.6409 1 0 Igsf21
NM_011772 chr10 - 11.949744 1 0 Ikzf4
NM_016671 chr8 - 4.792233333 1 0 Il27ra
136
refID chr strd ES_exp und 3RA name
NM_134109 chr16 + 74.39956667 1 0 Ildr1
NM_001033354 chr6 - 28.59006667 1 0 Iqsec3
NM_010592 chr8 + 172.21201 1 0 Jund
NM_021275 chr2 + 6.861653333 1 0 Kcna4
NM_032397 chr8 - 19.99056667 1 0 Kcnn1
NM_001081403 chr18 - 0.993792667 1 0 Klhl14
NM_175174 chr5 + 25.53080844 1 0 Klhl5
NM_001039042 chr7 + 10.86359 1 0 Klk13
NM_010663 chr11 - 14.08779667 1 0 Krt17
NM_027221 chr5 + 109.9396667 1 0 Krtcap3
NM_008479 chr6 - 13.45605667 1 0 Lag3
NM_027570 chr8 - 12.84734833 1 0 Ldhd
NM_144862 chr18 + 29.6078 1 0 Lims2
NM_001031772 chr10 - 29.90056667 1 0 Lin28b
NM_175271 chrX + 16.45565778 1 0 Lpar4
NM_008511 chr6 + 19.91353333 1 0 Lrmp
NM_027941 chr3 - 1307.973333 1 0 Lrrc34
NM_028175 chr8 + 7.151696667 1 0 Lrrc8e
NM_010734 chr17 - 17.76182 1 0 Lst1
NM_027366 chr17 + 372.157 1 0 Ly6g6e
NM_008535 chr8 + 13.68592 1 0 Lyl1
NM_001080390 chr19 - 77.78282222 1 0 Mark2
NM_001045484 chr8 + 44.2102 1 0 Mef2b
NM_008584 chr12 + 2.677003667 1 0 Meox2
NM_020021 chr4 - 1.910684 1 0 Mos
NM_001081361 chr1 - 11.53505167 1 0 Mosc1
NM_175534 chr7 - 16.04576667 1 0 Mrgpre
NM_018857 chr17 - 29.8378 1 0 Msln
NM_028069 chr7 - 12.30094667 1 0 Mupcdh
NM_146189 chr7 - 18.81796667 1 0 Mybpc2
NM_016754 chr7 + 735.4426667 1 0 Mylpf
NM_028016 chr6 + 2832.333333 1 0 Nanog
NM_201355 chr7 + 15.00292 1 0 Nat14
NM_007789 chr8 - 29.49239 1 0 Ncan
NM_010877 chr1 + 38.15966667 1 0 Ncf2
NM_013609 chr3 + 11.99053 1 0 Ngf
NM_008703 chr10 + 1.38555 1 0 Nmbr
NM_019401 chr2 - 30.72056667 1 0 Nmi
NM_010929 chr17 + 49.09722556 1 0 Notch4
NM_001029877 chr7 + 28.84873833 1 0 Nova2
137
refID chr strd ES_exp und 3RA name
NM_013839 chr2 - 10.10094667 1 0 Nr1h3
NM_010947 chr17 - 1.794152667 1 0 Ntn2l
NM_019738 chr7 - 310.5866667 1 0 Nupr1
NM_001024141 chrX - 2.191649333 1 0 Nxf3
NM_011025 chr2 + 63.6228 1 0 Oxt
NM_001038839 chr5 + 14.06871889 1 0 P2rx7
NM_011862 chr15 - 802.9116667 1 0 Pacsin2
NM_001033254 chr2 + 9.622628333 1 0 Pak6
NM_019943 chr5 - 9.172696667 1 0 Papolb
NM_011040 chr2 - 9.763525 1 0 Pax8
NM_001003671 chr18 + 4.43982075 1 0 Pcdhac1
NM_008788 chr5 - 670.69 1 0 Pcolce
NM_013628 chr13 + 13.45308333 1 0 Pcsk1
NM_211138 chrX + 57.02986667 1 0 Pcyt1b
NM_145978 chr14 - 56.55536667 1 0 Pdlim2
NM_018863 chr2 - 6.509916667 1 0 Pdyn
NM_021453 chr19 - 180.5266667 1 0 Pga5
NM_001042623 chr6 - 2727.77 1 0 Phc1
NM_008952 chr11 - 415.5423333 1 0 Pipox
NM_011987 chr16 - 307.1746667 1 0 Pla2g10
NM_011107 chr5 + 236.5109293 1 0 Pla2g1b
NM_177845 chr2 - 14.1262 1 0 Pla2g4e
NM_019588 chr19 + 21.96623333 1 0 Plce1
NM_177355 chr15 + 5.588176667 1 0 Plcxd3
NM_201394 chr15 - 113.3467208 1 0 Plec1
NM_001033253 chr10 - 35.55724667 1 0 Plekhg1
NM_001004156 chr4 + 95.6651 1 0 Plekhg5
NM_153169 chrX + 2.917573333 1 0 Pnma3
NM_001081209 chr1 - 285.2516667 1 0 Prdm14
NM_027230 chr2 - 123.2719533 1 0 Prkcbp1
NM_001039079 chr4 - 85.09287111 1 0 Prkcz
NM_001081374 chr7 - 122.882 1 0 Prss36
NM_177611 chr2 + 12.58479167 1 0 Psd4
NM_008969 chr2 + 5.123938333 1 0 Ptgs1
NM_008973 chr6 - 7.581533167 1 0 Ptn
NM_013545 chr6 - 137.954 1 0 Ptpn6
NM_023852 chr13 - 3.617692222 1 0 Rab3c
NM_028226 chr4 + 15.836735 1 0 Rbm12b
NM_009049 chr1 - 0.683699333 1 0 Resp18
NM_028713 chr1 - 2.495623222 1 0 Rftn2
138
refID chr strd ES_exp und 3RA name
NM_183163 chr4 + 9.43289 1 0 Rhbdl2
NM_020599 chr7 - 34.8106 1 0 Rlbp1
NM_026301 chr18 + 269.3866667 1 0 Rnf125
NM_199057 chr4 + 73.14975 1 0 Rusc2
NM_015772 chr14 - 25.45373333 1 0 Sall2
NM_009130 chr9 - 3.432306667 1 0 Scg3
NM_146013 chr11 + 32.31553333 1 0 Sec14l4
NM_148942 chr13 - 119.1670667 1 0 Serpinb6c
NM_019982 chr5 - 11.730275 1 0 Sez6l
NM_018780 chr19 - 10.30011 1 0 Sfrp5
NM_177816 chr14 - 5.34699 1 0 Sh2d4b
NM_001081028 chr7 - 71.8359 1 0 Sipa1l3
NM_020333 chr2 + 19.59880556 1 0 Slc12a5
NM_001083902 chr16 + 25.11923 1 0 Slc12a8
NM_022411 chr11 - 9.612196667 1 0 Slc13a2
NM_053079 chr14 - 41.56753333 1 0 Slc15a1
NM_080853 chr7 + 2.828433333 1 0 Slc17a6
NM_173774 chr4 - 41.82163333 1 0 Slc45a1
NM_053077 chr15 + 10.73790667 1 0 Slc45a2
NM_139142 chr9 - 2.142096667 1 0 Slc6a20a
NM_172861 chr3 - 3.139431667 1 0 Slc7a14
NM_199065 chr14 - 6.191556667 1 0 Slitrk1
NM_146064 chr15 + 23.5759 1 0 Soat2
NM_009235 chr11 + 180.655 1 0 Sox15
NM_001025559 chr7 - 5.789103833 1 0 Sox6
NM_009263 chr5 + 4039.823333 1 0 Spp1
NM_053188 chr17 - 16.15736667 1 0 Srd5a2
NM_016911 chrX - 8.859126667 1 0 Srpx
NM_175162 chr8 - 40.7198825 1 0 Stox2
NM_172294 chr1 + 52.34398583 1 0 Sulf1
NM_027890 chr10 - 135.4453333 1 0 Susd2
NM_153579 chr7 - 7.300501667 1 0 Sv2b
NM_026805 chr5 - 9.40786 1 0 Svop
NM_011523 chr17 + 16.26727517 1 0 Synj2
NM_009308 chr18 - 12.05706833 1 0 Syt4
NM_016908 chr7 - 14.34537667 1 0 Syt5
NM_011536 chr11 + 11.55927833 1 0 Tbx4
NM_013836 chr15 - 89.70518889 1 0 Tcf20
NM_009337 chr12 - 1014.861333 1 0 Tcl1
NM_013688 chr17 + 23.71636667 1 0 Tcte1
139
refID chr strd ES_exp und 3RA name
NM_175030 chr4 + 9.883396667 1 0 Tctex1d4
NM_011562 chr9 - 6064.253333 1 0 Tdgf1
NM_013690 chr4 + 25.03686667 1 0 Tek
NM_011569 chr11 - 25.448 1 0 Tekt1
NM_009384 chr16 - 65.58181667 1 0 Tiam1
NM_001037744 chr14 + 7.006266667 1 0 Timm8a2
NM_181856 chr11 + 45.72756667 1 0 Tmc8
NM_175408 chr6 + 15.03183333 1 0 Tmem139
NM_178381 chr7 - 147.8876667 1 0 Tmem16j
NM_178915 chr12 - 17.69183333 1 0 Tmem179
NM_144936 chr9 - 14.16273333 1 0 Tmem45b
NM_025452 chr4 + 20.3242 1 0 Tmem54
NM_001033334 chr12 - 8.828598167 1 0 Tmem90a
NM_011609 chr6 + 78.80666667 1 0 Tnfrsf1a
NM_033042 chr4 + 7.575616667 1 0 Tnfrsf25
NM_009401 chr4 - 15.6071 1 0 Tnfrsf8
NM_023517 chr11 - 151.102 1 0 Tnfsf13
NM_033622 chr8 + 8.671323444 1 0 Tnfsf13b
NM_031880 chr11 - 49.49483333 1 0 Tnk1
NM_001025261 chr3 - 963.531775 1 0 Tpd52
NM_009426 chr6 - 375.4086667 1 0 Trh
NM_181853 chr7 - 2.693260667 1 0 Trim66
NM_053166 chr11 + 7.347169 1 0 Trim7
NM_001035239 chr19 + 3.242314167 1 0 Trpm3
NM_022017 chr5 - 3.71322 1 0 Trpv4
NM_028417 chr7 + 9.24646 1 0 Ttc9b
NM_172818 chr15 - 32.04264 1 0 Ttll8
NM_134028 chr11 + 7.185812667 1 0 Tubg2
NM_001009573 chr11 - 25.4736 1 0 Unc13d
NM_152823 chr17 + 19.22723333 1 0 Unc5cl
NM_021397 chr7 - 56.149145 1 0 Zbtb32
NM_009540 chr10 - 34.00788889 1 0 Zfa
NM_022985 chr7 - 720.0477246 1 0 Zfand6
NM_028913 chr7 + 139.16 1 0 Zfp819
NM_009567 chr7 + 33.89545 1 0 Zfp93
NM_001039242 chr11 - 9.701914167 1 0
NM_017461 chr7 - 66.57913333 1 0
NM_029687 chr2 + 18.79973167 1 0
NM_026152 chr19 + 17.11593333 0 1 0610010D20Rik
NM_028747 chr2 + 5.25449 0 1 0610012H03Rik
140
refID chr strd ES_exp und 3RA name
NM_001081123 chrX + 4.789186667 0 1 1100001E04Rik
NM_025427 chr14 - 112.2610333 0 1 1190002H23Rik
NM_029639 chr9 + 54.8588 0 1 1600029D21Rik
NM_001024614 chr5 + 4.915230333 0 1 1700007G11Rik
NM_025851 chr17 + 4.274049444 0 1 1700010I14Rik
NM_001017407 chr10 + 4.903274833 0 1 1700021K02Rik
NM_029338 chr17 - 2.929013333 0 1 1700027N10Rik
NM_026931 chr8 - 21.886605 0 1 1810011O10Rik
NM_025459 chr15 + 95.92802189 0 1 1810015C04Rik
NM_027363 chr7 + 6.496243333 0 1 2010110P09Rik
NM_001081226 chr1 - 44.64756667 0 1 2310009B15Rik
NM_001077348 chr17 - 22.78533333 0 1 2310076L09Rik
NM_172884 chr5 - 41.98977583 0 1 2900026A02Rik
NM_028725 chr8 - 1.025398667 0 1 4632417N05Rik
NM_028732 chr10 + 10.61635 0 1 4632428N05Rik
NM_172540 chrX - 29.04042983 0 1 4732479N06Rik
NM_029425 chr3 + 3.226433333 0 1 4833424O15Rik
NM_001078646 chr3 + 2.723946667 0 1 4921515J06Rik
NM_001033170 chr7 + 1.642651 0 1 4930403C10Rik
NM_029053 chr16 - 5.779 0 1 4930451C15Rik
NM_207267 chrX - 119.235175 0 1 4930488E11Rik
NM_029070 chr16 - 2.51222 0 1 4930511J11Rik
NM_026262 chr11 + 9.746416667 0 1 4930524B15Rik
NM_027644 chr17 - 39.6732 0 1 4931440B09Rik
NM_177230 chr5 - 13.43488333 0 1 4932413O14Rik
NM_175017 chr6 + 13.315773 0 1 4933427D06Rik
NM_021493 chr11 + 38.18616417 0 1 4933428G20Rik
NM_001033304 chr3 - 6.272151667 0 1 5330417C22Rik
NM_001032727 chr15 - 3.617248333 0 1 5730410E15Rik
NM_001033465 chr7 - 11.3524605 0 1 6430531B16Rik
NM_175677 chr7 - 8.526778333 0 1 9230105E10Rik
NM_001081351 chr6 + 5.894446444 0 1 A430107O13Rik
NM_001004174 chr2 + 75.20116667 0 1 AA467197
NM_172961 chr16 + 15.82053333 0 1 Abat
NM_029600 chr11 - 9.345783333 0 1 Abcc3
NM_018795 chr7 - 3.0721 0 1 Abcc6
NM_009599 chr5 + 1.612181333 0 1 Ache
NM_028790 chr13 + 6.214099444 0 1 Acot12
NM_009606 chr8 - 190.4283333 0 1 Acta1
NM_033268 chr13 - 17.38644333 0 1 Actn2
141
refID chr strd ES_exp und 3RA name
NM_172126 chr5 - 9.396541333 0 1 Adam1a
NM_029967 chr4 + 7.953871111 0 1 Adamtsl1
NM_009623 chr15 - 3.796002 0 1 Adcy8
NM_009627 chr7 + 45.18346667 0 1 Adm
NM_013461 chr14 + 3.314106667 0 1 Adra1a
NM_134044 chr12 - 224.184 0 1 AI413782
NM_001039220 chr8 + 27.09473333 0 1 AI429214
NM_027406 chr6 + 24.48371 0 1 Aldh1l1
NM_009662 chr6 - 26.0207 0 1 Alox5
NM_009661 chr11 - 7.138656667 0 1 Alox8
NM_172553 chr10 - 4.674681667 0 1 Alx1
NM_007442 chr2 + 13.95086667 0 1 Alx4
NM_175667 chr2 + 1.466679667 0 1 Ankrd5
NM_019456 chr2 + 11.27054833 0 1 Apbb1ip
NM_013476 chrX + 4.930932083 0 1 Ar
NM_138630 chrX - 16.65101111 0 1 Arhgap4
NM_009707 chrX + 5.040312778 0 1 Arhgap6
NM_007486 chr6 - 38.29646667 0 1 Arhgdib
NM_001081083 chr2 + 3.093956667 0 1 Armc3
NM_001038499 chr18 + 26.35153333 0 1 Arsi
NM_009710 chr7 + 28.72191 0 1 Art1
NM_007495 chr1 + 0.928610667 0 1 Astn1
NM_133699 chr12 - 2.938616667 0 1 Atp6v1c2
NM_015803 chr14 - 10.70687556 0 1 Atp8a2
NM_177809 chr13 + 3.729253667 0 1 AU042651
NM_009732 chr2 - 12.68647333 0 1 Avp
NM_029007 chr12 - 4.273366667 0 1 AW125753
NM_033149 chr16 + 7.256472333 0 1 B3galt5
NM_001005477 chr5 - 8.420356667 0 1 Barhl2
NM_007526 chr13 + 9.090933333 0 1 Barx1
NM_001033128 chr19 - 24.2736 0 1 Bbs1
NM_183162 chr2 - 24.92806667 0 1 BC006779
NM_145389 chr16 - 1.991186667 0 1 BC016579
NM_145577 chr7 - 17.93193 0 1 BC023179
NM_001033284 chr1 + 41.07904667 0 1 BC026585
NM_153584 chr9 + 20.53253889 0 1 BC031353
NM_172295 chr3 - 62.51023333 0 1 BC037703
NM_153172 chr9 + 6.565373333 0 1 BC107230
NM_009738 chr3 - 7.504622444 0 1 Bche
NM_007528 chr11 - 25.4331 0 1 Bcl6b
142
refID chr strd ES_exp und 3RA name
NM_007542 chrX + 136.4230222 0 1 Bgn
NM_080641 chr2 - 5.18289 0 1 Bhlhb4
NM_022884 chr13 - 5.784758667 0 1 Bhmt2
NM_001079873 chr5 + 12.30290444 0 1 Brdt
NM_133195 chr18 - 28.16772925 0 1 Brunol4
NM_026161 chr2 + 14.95829667 0 1 C1qtnf4
NM_177883 chr6 + 15.46726667 0 1 C330043M08Rik
NM_009782 chr1 - 1.564223333 0 1 Cacna1e
NM_009788 chr4 + 2.224458 0 1 Calb1
NM_021371 chr5 + 3.916604333 0 1 Caln1
NM_028296 chr11 + 7.815518333 0 1 Car10
NM_178396 chr9 + 12.79397478 0 1 Car12
NM_001081493 chr13 - 5.093545333 0 1 Cartpt
NM_013803 chr16 - 9.848468333 0 1 Casr
NM_016900 chr6 + 13.93943333 0 1 Cav2
NM_172633 chr18 + 1.247748 0 1 Cbln2
NM_007626 chr15 - 325.2177753 0 1 Cbx5
NM_172274 chr5 + 53.03453333 0 1 Cc2d2a
NM_146178 chr7 + 41.70396667 0 1 Ccdc106
NM_172914 chr8 + 10.90281667 0 1 Ccdc113
NM_025455 chr4 - 26.6168715 0 1 Ccdc28b
NM_201362 chr18 + 62.61506667 0 1 Ccdc68
NM_001048179 chr4 - 70.69874444 0 1 Ccl27
NM_001039150 chr2 - 38.90918667 0 1 Cd44
NM_009856 chr13 + 3.592613333 0 1 Cd83
NM_028176 chr4 - 32.8504 0 1 Cda
NM_009866 chr8 - 15.796495 0 1 Cdh11
NM_011800 chr1 + 4.06222 0 1 Cdh20
NM_009868 chr8 + 7.93545 0 1 Cdh5
NM_009880 chr18 - 6.198353333 0 1 Cdx1
NM_007674 chrX + 3.356251 0 1 Cdx4
NM_199032 chr5 + 11.57768 0 1 Cep135
NM_021050 chr6 + 0.553694333 0 1 Cftr
NM_007697 chr6 + 3.436331083 0 1 Chl1
NM_031258 chrX - 3.15341925 0 1 Chrdl1
NM_033269 chr13 - 6.779846667 0 1 Chrm3
NM_007702 chr18 + 55.0458 0 1 Cidea
NM_173876 chr8 - 327.597275 0 1 Clcn3
NM_172621 chr17 + 13.90686667 0 1 Clic5
NM_153508 chr6 - 45.96013333 0 1 Clstn3
143
refID chr strd ES_exp und 3RA name
NM_001081047 chr4 - 24.799 0 1 Cnksr1
NM_173004 chr6 + 5.875346167 0 1 Cntn4
NM_007729 chr3 + 15.79626667 0 1 Col11a1
NM_007730 chr9 - 13.98062244 0 1 Col12a1
NM_009928 chr4 + 7.367626667 0 1 Col15a1
NM_007733 chr1 - 4.793060667 0 1 Col19a1
NM_007737 chr1 - 32.95301283 0 1 Col5a2
NM_016919 chr9 - 19.43762833 0 1 Col5a3
NM_146007 chr10 - 26.69700667 0 1 Col6a2
NM_199473 chr4 + 11.10308333 0 1 Col8a2
NM_009898 chr7 - 42.26711444 0 1 Coro1a
NM_030703 chr19 - 19.41252 0 1 Cpn1
NM_007758 chr1 - 2.665696667 0 1 Cr2
NM_007759 chr3 + 191.5546667 0 1 Crabp2
NM_030209 chr8 + 11.88480889 0 1 Crispld2
NM_021541 chr1 - 12.27302 0 1 Cryba2
NM_145473 chr15 + 15.80996444 0 1 Csdc2
NM_139001 chr9 + 4.572242 0 1 Cspg4
NM_026778 chr15 + 51.1359 0 1 Cthrc1
NM_001012477 chr6 + 30.96568333 0 1 Cxcl12
NM_009140 chr5 + 5.13467 0 1 Cxcl2
NM_009996 chr2 - 6.758166667 0 1 Cyp24a1
NM_010008 chr4 - 5.051503333 0 1 Cyp2j6
NM_177307 chr17 + 36.02816667 0 1 Cyp4f39
NM_001003947 chr4 - 6.350996667 0 1 Cyp4x1
NM_001024931 chr11 - 15.48262 0 1 D11Bwg0517e
NM_001081051 chr13 + 5.68623 0 1 D130043K22Rik
NM_153574 chr6 - 8.775338333 0 1 D430015B01Rik
NM_033079 chr6 + 51.733 0 1 D6Mm5e
NM_001008231 chr17 - 6.258941833 0 1 Daam2
NM_001037905 chr15 + 141.4350167 0 1 Dab2
NM_001001602 chr2 + 103.1778667 0 1 Dab2ip
NM_001005232 chr7 - 5.168793333 0 1 Dbx1
NM_207533 chr15 - 0.959807333 0 1 Dbx2
NM_007835 chr6 + 220.4691667 0 1 Dctn1
NM_177914 chrX + 7.97494 0 1 Dgkk
NM_020265 chr3 + 2.207786333 0 1 Dkk2
NM_015789 chr7 - 26.21506667 0 1 Dkkl1
NM_010052 chr12 + 25.89073333 0 1 Dlk1
NM_010055 chr11 + 14.53574 0 1 Dlx3
144
refID chr strd ES_exp und 3RA name
NM_028772 chr13 + 6.908885 0 1 Dmgdh
NM_145831 chr19 + 2.971846667 0 1 Dmrt2
NM_001034878 chr11 + 15.374675 0 1 Dnaic2
NM_025926 chr3 - 33.89873267 0 1 Dnajb4
NM_001038619 chr1 - 9.031808556 0 1 Dnm3
NM_021791 chr19 + 43.40593333 0 1 Doc2g
NM_010071 chr14 + 142.5763333 0 1 Dok2
NM_199021 chr1 - 3.335886722 0 1 Dpp10
NM_007878 chr7 + 9.339783333 0 1 Drd4
NM_007882 chr18 - 5.281264333 0 1 Dsc3
NM_025777 chr2 + 10.55824667 0 1 Duoxa2
NM_001077694 chr6 + 46.065285 0 1 Dysf
NM_010095 chr14 + 4.100060333 0 1 Ebf2
NM_021306 chr1 - 18.14236667 0 1 Ecel1
NM_007903 chr2 + 11.35396583 0 1 Edn3
NM_010332 chr8 - 4.8863125 0 1 Ednra
NM_146015 chr11 + 25.9915 0 1 Efemp1
NM_001034882 chr14 + 12.73593333 0 1 EG432879
NM_153068 chr7 - 18.00237833 0 1 Ehd2
NM_023737 chr16 - 8.27246 0 1 Ehhadh
NM_183141 chr15 - 9.98515 0 1 Elfn2
NM_024474 chr5 - 3.308851667 0 1 Emid2
NM_133918 chr5 + 7.10736 0 1 Emilin1
NM_010131 chr6 + 4.887960833 0 1 Emx1
NM_010132 chr19 + 5.7946 0 1 Emx2
NM_010133 chr1 + 4.57889 0 1 En1
NM_007933 chr11 + 78.660805 0 1 Eno3
NM_032003 chr17 + 75.98556667 0 1 Enpp5
NM_009848 chr19 + 3.140346667 0 1 Entpd1
NM_023580 chr6 - 15.94314889 0 1 Epha1
NM_027984 chr11 - 2.8445 0 1 Epn3
NM_029495 chr14 + 8.528187667 0 1 Epsti1
NM_010154 chr1 - 4.213521333 0 1 Erbb4
NM_007950 chr5 + 14.50606667 0 1 Ereg
NM_023154 chr7 + 134.0493333 0 1 Ethe1
NM_007959 chr7 - 46.64126667 0 1 Etv2
NM_007966 chr6 + 10.18014333 0 1 Evx1
NM_015795 chr14 + 37.87736667 0 1 Fbxo16
NM_153111 chr1 - 10.46433333 0 1 Fev
NM_030610 chr8 - 3.965891333 0 1 Fgf20
145
refID chr strd ES_exp und 3RA name
NM_008034 chr7 - 405.341 0 1 Folr1
NM_008259 chr12 - 6.605289667 0 1 Foxa1
NM_008023 chr19 - 1.889806667 0 1 Foxb2
NM_008592 chr13 + 10.06806 0 1 Foxc1
NM_010225 chr13 + 7.128838 0 1 Foxf2
NM_010237 chr10 + 6.323597133 0 1 Frk
NM_172869 chr4 + 5.065050833 0 1 Frmd3
NM_172475 chr2 + 62.563515 0 1 Frmd4a
NM_177136 chr5 - 99.041375 0 1 Fryl
NM_178673 chr3 + 6.596066667 0 1 Fstl5
NM_001081454 chr7 - 88.59076667 0 1 Furin
NM_019503 chr7 - 19.90463333 0 1 Fxyd1
NM_022007 chr7 - 2.891096 0 1 Fxyd7
NM_008067 chrX - 4.538809333 0 1 Gabra3
NM_008070 chr11 + 9.478448667 0 1 Gabrb2
NM_010252 chr5 - 3.089753667 0 1 Gabrg1
NM_173739 chr7 - 13.74223333 0 1 Galntl4
NM_008083 chr16 - 10.750891 0 1 Gap43
NM_010258 chr18 + 45.39638333 0 1 Gata6
NM_001077411 chr3 + 174.8891667 0 1 Gba
NM_018734 chr3 + 43.25273333 0 1 Gbp3
NM_010267 chr1 + 8.4745415 0 1 Gdap1
NM_145741 chr14 + 5.137793333 0 1 Gdf10
NM_010278 chr5 - 2.519437 0 1 Gfi1
NM_010280 chr18 - 34.28203333 0 1 Gfra3
NM_144786 chr2 - 2.382863333 0 1 Ggt7
NM_001010937 chr14 - 5.285336667 0 1 Gjb6
NM_010290 chr2 - 4.26456 0 1 Gjd2
NM_025374 chr17 - 753.5391 0 1 Glo1
NM_001085513 chr4 + 29.57993333 0 1 Gm693
NM_001007580 chrX - 81.5337 0 1 Gm784
NM_001005424 chr2 - 6.164707 0 1 Gm996
NM_025331 chr6 + 6.849093333 0 1 Gng11
NM_026680 chr1 + 6.171436667 0 1 Golt1a
NM_198192 chr3 - 4.149433333 0 1 Gpr103
NM_177346 chr3 - 1.293719222 0 1 Gpr149
NM_173365 chr15 - 33.82423333 0 1 Gpr20
NM_001079847 chrX + 2.820535 0 1 Gpr64
NM_030720 chr15 - 9.4807 0 1 Gpr84
NM_182805 chr15 + 55.45773333 0 1 Gpt
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refID chr strd ES_exp und 3RA name
NM_153528 chr16 - 4.410622667 0 1 Gramd1c
NM_001039195 chr3 - 8.472208833 0 1 Gria2
NM_016886 chrX + 2.503239833 0 1 Gria3
NM_133355 chr5 + 20.13223333 0 1 Grid2ip
NM_010348 chr16 - 1.687404833 0 1 Grik1
NM_010350 chr11 - 5.344683333 0 1 Grin2c
NM_181850 chr5 - 3.13942 0 1 Grm3
NM_177328 chr6 + 3.185946833 0 1 Grm7
NM_001080553 chr6 - 12.52174 0 1 Gsg1
NM_133256 chr5 + 8.280863333 0 1 Gsx2
NM_023630 chr17 + 6.832416667 0 1 Gtf2a1l
NM_021896 chr3 - 5.387448 0 1 Gucy1a3
NM_017469 chr3 - 18.75116667 0 1 Gucy1b3
NM_178747 chr14 - 24.01483333 0 1 Gulo
NM_010369 chr8 + 2.144092833 0 1 Gypa
NM_001048207 chr18 - 16.9261 0 1 Gypc
NM_013500 chr13 + 4.121338722 0 1 Hapln1
NM_009330 chr11 + 12.29476667 0 1 Hnf1b
NM_013920 chr3 + 2.258252111 0 1 Hnf4g
NM_008263 chr6 - 4.802387833 0 1 Hoxa10
NM_010450 chr6 - 14.3211 0 1 Hoxa11
NM_010451 chr6 - 6.729223333 0 1 Hoxa2
NM_010455 chr6 - 3.9294 0 1 Hoxa7
NM_010456 chr6 - 16.056205 0 1 Hoxa9
NM_008267 chr11 + 5.42563 0 1 Hoxb13
NM_134032 chr11 + 16.10728667 0 1 Hoxb2
NM_010458 chr11 + 10.03229667 0 1 Hoxb3
NM_010459 chr11 + 7.950618333 0 1 Hoxb4
NM_008268 chr11 + 1.575192333 0 1 Hoxb5
NM_008269 chr11 + 3.263401 0 1 Hoxb6
NM_010460 chr11 + 5.128853333 0 1 Hoxb7
NM_010461 chr11 + 7.116043333 0 1 Hoxb8
NM_013553 chr15 + 2.986306667 0 1 Hoxc4
NM_175730 chr15 + 2.922351556 0 1 Hoxc5
NM_010466 chr15 + 4.701613333 0 1 Hoxc8
NM_013554 chr2 + 3.160286667 0 1 Hoxd10
NM_010468 chr2 + 5.093916667 0 1 Hoxd3
NM_013555 chr2 + 8.84794 0 1 Hoxd9
NM_152803 chr5 - 16.16563333 0 1 Hpse
NM_001045527 chr11 + 22.51836667 0 1 Hsf5
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refID chr strd ES_exp und 3RA name
NM_028306 chr2 + 1.444075667 0 1 Hspa12b
NM_010483 chr1 - 5.209976667 0 1 Htr5b
NM_001042489 chr5 + 82.3278 0 1 Hvcn1
NM_023892 chr9 + 19.51003333 0 1 Icam4
NM_027835 chr2 - 6.151863333 0 1 Ifih1
NM_028968 chr16 - 15.35856667 0 1 Ifitm7
NM_010512 chr10 + 11.59969422 0 1 Igf1
NM_010514 chr7 - 83.30496667 0 1 Igf2
NM_010544 chr1 - 10.60878333 0 1 Ihh
NM_011771 chr11 - 6.374703 0 1 Ikzf3
NM_008357 chr8 - 8.35968 0 1 Il15
NM_008358 chr2 + 5.863516667 0 1 Il15ra
NM_013563 chrX - 26.68428333 0 1 Il2rg
NM_001008700 chr7 + 5.956526778 0 1 Il4ra
NM_008380 chr13 + 30.73955833 0 1 Inhba
NM_013754 chr19 - 53.3247 0 1 Insl6
NM_011832 chr3 + 6.265636667 0 1 Insrr
NM_016850 chr7 - 4.453696667 0 1 Irf7
NM_010572 chrX - 15.542355 0 1 Irs4
NM_010573 chr13 - 12.77979667 0 1 Irx1
NM_018885 chr13 + 1.703066667 0 1 Irx4
NM_172471 chr2 + 2.003182 0 1 Itih5
NM_001017426 chr11 - 189.7974833 0 1 Jmjd3
NM_021566 chr2 - 10.79746667 0 1 Jph2
NM_010590 chr14 - 963.1553333 0 1 Jub
NM_027721 chr18 - 17.28128333 0 1 Katnal2
NM_001024135 chr14 + 64.93765911 0 1 Kbtbd7
NM_013568 chr6 - 5.748365556 0 1 Kcna6
NM_021487 chrX - 2.997803333 0 1 Kcne1l
NM_201531 chr12 - 2.652526833 0 1 Kcnf1
NM_027398 chr11 - 9.952791667 0 1 Kcnip1
NM_001039484 chr1 + 15.69733333 0 1 Kcnj10
NM_010638 chr19 + 767.4868529 0 1 Klf9
NM_053105 chr14 - 2.916557 0 1 Klhl1
NM_177261 chr7 + 20.47016556 0 1 Kndc1
NM_145416 chr9 - 81.58837917 0 1 Kri1
NM_010664 chr15 + 603.3416667 0 1 Krt18
NM_023256 chr11 - 30.07633333 0 1 Krt20
NM_172946 chr11 - 3.892977 0 1 Krt222
NM_033073 chr15 + 87.78863333 0 1 Krt7
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refID chr strd ES_exp und 3RA name
NM_010681 chr10 + 2.539671 0 1 Lama4
NM_010692 chr6 + 13.874 0 1 Lbx2
NM_010701 chr14 - 2.172976667 0 1 Lect1
NM_008495 chr15 + 1444.747333 0 1 Lgals1
NM_010708 chr11 - 65.76143333 0 1 Lgals9
NM_145219 chr14 + 5.650827444 0 1 Lgi3
NM_023063 chr15 - 417.3001421 0 1 Lima1
NM_053106 chr1 + 8.558926667 0 1 Lmod1
NM_001024712 chr14 - 610.4124111 0 1 LOC544988
NM_001081983 chrX - 3.50135 0 1 LOC666244
NM_134152 chr19 + 3.216616667 0 1 Lpxn
NM_019457 chr15 - 3.063235167 0 1 Lrrc6
NM_025730 chr15 + 7.4304555 0 1 Lrrk2
NM_001013019 chr19 + 27.37016667 0 1 Lrrn4cl
NM_028880 chr6 + 2.143821 0 1 Lrrtm1
NM_172492 chr6 - 1.924463333 0 1 Lrtm2
NM_175548 chr16 + 4.576220889 0 1 Lsamp
NM_010736 chr6 - 37.55273333 0 1 Ltbr
NM_178705 chr7 + 0.645647333 0 1 Luzp2
NM_023463 chr17 + 16.99554 0 1 Ly6g6c
NM_145532 chr2 - 7.322345833 0 1 Mall
NM_174857 chr19 - 2.401620667 0 1 Mamdc2
NM_001081354 chrX + 16.51658 0 1 Mamld1
NM_008555 chr16 - 10.9115836 0 1 Masp1
NM_013592 chr2 - 7.85363 0 1 Matn4
NM_001025251 chr18 + 19.4648255 0 1 Mbp
NM_181407 chr7 + 6.315526667 0 1 Me3
NM_001001979 chr18 + 2.130553333 0 1 Megf10
NM_008595 chr15 - 63.85243333 0 1 Mfng
NM_029662 chr4 - 9.178802333 0 1 Mfsd2
NM_172499 chr1 - 19.36157167 0 1 Mfsd9
NM_153049 chr15 - 79.07283333 0 1 Mkl1
NM_198831 chr7 - 417.3805 0 1 Mrpl48
NM_019544 chr12 - 13.78201 0 1 Msgn1
NM_181409 chr3 + 17.53432778 0 1 Mtmr11
NM_008639 chr8 + 6.679793333 0 1 Mtnr1a
NM_001005865 chr8 - 33.09148667 0 1 Mtus1
NM_010850 chrX - 6.77478 0 1 Mycs
NM_145136 chr11 - 4.554471167 0 1 Myocd
NM_011848 chr8 - 137.122 0 1 Nek3
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refID chr strd ES_exp und 3RA name
NM_001037906 chr7 + 3.845489667 0 1 Nell1
NM_144946 chr18 + 3.6237675 0 1 Neto1
NM_010896 chr13 - 9.241877333 0 1 Neurog1
NM_009719 chr10 + 8.037597167 0 1 Neurog3
NM_001037178 chr2 - 13.50962111 0 1 Nfatc2
NM_008685 chr15 - 2.827183333 0 1 Nfe2
NM_022414 chr12 - 8.56494 0 1 Ngb
NM_178777 chr3 + 2.919561667 0 1 Nhlh2
NM_009385 chr12 - 1.642526667 0 1 Nkx2-1
NM_001077632 chr2 - 3.752078667 0 1 Nkx2-2
NM_008699 chr19 + 11.15045111 0 1 Nkx2-3
NM_008700 chr17 - 25.90706667 0 1 Nkx2-5
NM_007524 chr5 - 2.467476667 0 1 Nkx3-2
NM_138666 chr3 - 3.185986333 0 1 Nlgn1
NM_199024 chr18 - 2.965663778 0 1 Nol4
NM_027988 chr17 + 4.72214 0 1 Noxo1
NM_013780 chr12 + 6.081867417 0 1 Npas3
NM_130456 chr1 + 3.697845667 0 1 Nphs2
NM_008726 chr4 + 38.28886667 0 1 Nppb
NM_010934 chr8 + 7.469448333 0 1 Npy1r
NM_016708 chr8 - 2.9322395 0 1 Npy5r
NM_010151 chr13 - 5.292623333 0 1 Nr2f1
NM_008173 chr18 - 45.51891853 0 1 Nr3c1
NM_015743 chr4 + 3.752434444 0 1 Nr4a3
NM_008734 chr14 - 5.228855952 0 1 Nrg3
NM_013724 chrX + 8.337085556 0 1 Nrk
NM_009513 chr13 - 29.0076 0 1 Nrsn1
NM_018766 chr2 + 4.94512 0 1 Ntsr1
NM_021431 chrX + 42.75136667 0 1 Nudt11
NM_029385 chr9 - 38.93716667 0 1 Nudt16
NM_031259 chrX - 14.4451 0 1 Nxf2
NM_145211 chr5 - 78.6007 0 1 Oas1a
NM_177068 chr1 + 17.54806667 0 1 Olfml2b
NM_133859 chr3 - 9.527223333 0 1 Olfml3
NM_147049 chr7 - 2.254426667 0 1 Olfr658
NM_016967 chr16 + 177.9406667 0 1 Olig2
NM_139226 chr10 + 1.587215 0 1 Onecut3
NM_011012 chr2 + 6.620716556 0 1 Oprl1
NM_054076 chr1 - 7.088313333 0 1 Optc
NM_024289 chr7 - 14.06153333 0 1 Osbpl5
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refID chr strd ES_exp und 3RA name
NM_001081147 chr6 - 4.429875 0 1 Oxtr
NM_011028 chr16 + 10.71542 0 1 P2rx6
NM_130887 chr12 + 0.855134 0 1 Papln
NM_027995 chr4 + 14.803495 0 1 Paqr7
NM_008780 chr2 + 2.171236667 0 1 Pax1
NM_025273 chr10 + 153.947 0 1 Pcbd1
NM_001081385 chrX + 1.183087 0 1 Pcdh11x
NM_001013753 chr14 + 1.699420889 0 1 Pcdh17
NM_054072 chr18 + 4.014749889 0 1 Pcdha1
NM_138662 chr18 + 4.014749889 0 1 Pcdha3
NM_009959 chr18 + 4.014749889 0 1 Pcdha5
NM_009957 chr18 + 4.014749889 0 1 Pcdha7
NM_138661 chr18 + 4.014749889 0 1 Pcdha9
NM_053126 chr18 + 3.731304333 0 1 Pcdhb1
NM_053139 chr18 + 1.863453 0 1 Pcdhb14
NM_053146 chr18 + 2.617686333 0 1 Pcdhb21
NM_053131 chr18 + 1.102107667 0 1 Pcdhb6
NM_033579 chr18 + 170.787 0 1 Pcdhgb7
NM_153565 chr4 - 24.70686667 0 1 Pcsk9
NM_001081033 chr2 - 4.127126667 0 1 Pde11a
NM_001039376 chr3 - 37.4920075 0 1 Pde4dip
NM_027924 chr9 + 6.301365333 0 1 Pdgfd
NM_011058 chr5 + 41.70233444 0 1 Pdgfra
NM_016798 chr8 + 23.81056667 0 1 Pdlim3
NM_019417 chr11 - 66.39936667 0 1 Pdlim4
NM_001013369 chr2 + 1511.94 0 1 Pfdn4
NM_029303 chr13 - 15.24156667 0 1 Pfn3
NM_008827 chr12 - 16.23056667 0 1 Pgf
NM_175013 chr19 - 1.477770333 0 1 Pgm5
NM_008840 chr4 - 50.59018133 0 1 Pik3cd
NM_011097 chr13 - 6.540935 0 1 Pitx1
NM_001042504 chr3 + 268.802 0 1 Pitx2
NM_001039051 chr10 + 1.249808167 0 1 Pkib
NM_019645 chr1 - 7.2576 0 1 Pkp1
NM_008869 chr1 - 12.84538333 0 1 Pla2g4a
NM_207279 chr5 + 15.96748 0 1 Plcxd1
NM_013738 chr12 - 28.25993333 0 1 Plek2
NM_027196 chr19 + 130.3963333 0 1 Pold4
NM_008901 chrX + 5.299595833 0 1 Pou3f4
NM_001080963 chr7 + 14.08566667 0 1 Ppapdc1a
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refID chr strd ES_exp und 3RA name
NM_011169 chr15 + 6.281253333 0 1 Prlr
NM_178774 chr17 + 3.777096667 0 1 Prr18
NM_028707 chr18 + 1.457858667 0 1 Psd2
NM_001093750 chrX - 10.46040333 0 1 Ptchd1
NM_013641 chr8 + 23.69642833 0 1 Ptger1
NM_053256 chr7 + 26.4975 0 1 Pth2
NM_008970 chr6 - 3.1040055 0 1 Pthlh
NM_025760 chr4 - 23.75793 0 1 Ptplad2
NM_027900 chr10 + 213.7746667 0 1 R3hdm2
NM_026677 chr3 + 88.00843333 0 1 Rab13
NM_198409 chrX + 1.645422667 0 1 Rai2
NM_001033158 chr9 + 19.4411 0 1 Rasl12
NM_009028 chr7 - 9.147291667 0 1 Rasl2-9
NM_028478 chr5 - 39.41113333 0 1 Rassf6
NM_013833 chr18 - 9.926003333 0 1 Rax
NM_011254 chr9 + 107.6246333 0 1 Rbp1
NM_001080928 chr5 + 794.4473492 0 1 Rbpj
NM_009036 chr2 + 2.620941667 0 1 Rbpjl
NM_030017 chr12 + 5.16908 0 1 Rdh12
NM_020002 chr14 + 100.9974 0 1 Rec8
NM_001024918 chr10 + 4.11309 0 1 Rfx4
NM_023622 chr9 - 20.77326333 0 1 Rgl3
NM_019799 chr7 - 2.532366667 0 1 Rhcg
NM_023275 chr12 + 10.82528833 0 1 Rhoj
NM_023894 chrX - 79.9963 0 1 Rhox9
NM_001081388 chr5 - 17.40011333 0 1 Rimbp2
NM_028724 chr2 + 11.31981 0 1 Rin2
NM_001083938 chr17 - 1287.257667 0 1 Rnaset2a
NM_026611 chr17 - 862.8054678 0 1 Rnaset2b
NM_026205 chr17 - 17.66623333 0 1 Rnf151
NM_001033489 chr4 - 30.76783333 0 1 Rnf207
NM_001043354 chr19 - 6.738308333 0 1 Rorb
NM_026594 chr16 + 573.852 0 1 Rpl39l
NM_011302 chrX + 13.43143167 0 1 Rs1
NM_028351 chr10 - 2.891793333 0 1 Rspo3
NM_001025364 chr7 + 60.73233333 0 1 Rtn2
NM_009107 chr1 + 15.12421667 0 1 Rxrg
NM_010101 chr13 + 6.578155556 0 1 S1pr3
NM_172809 chr14 + 72.55737822 0 1 Sacs
NM_175303 chr2 - 1050.996833 0 1 Sall4
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refID chr strd ES_exp und 3RA name
NM_146025 chr11 + 22.5558 0 1 Samd14
NM_153790 chr16 + 11.86023922 0 1 Scarf2
NM_018852 chr2 - 3.954262444 0 1 Scn9a
NM_009150 chr3 + 33.753 0 1 Selenbp1
NM_011340 chr11 - 78.93481667 0 1 Serpinf1
NM_009776 chr2 - 146.3313333 0 1 Serping1
NM_011891 chr11 - 3.509288833 0 1 Sgcd
NM_015825 chr16 + 6.589544889 0 1 Sh3bgr
NM_001077595 chr5 + 80.991668 0 1 Shroom3
NM_001033186 chr11 + 3.391901714 0 1 Skap1
NM_173403 chr5 + 2.790973667 0 1 Slc10a4
NM_009197 chrX - 16.65259167 0 1 Slc16a2
NM_020516 chr15 - 19.35266667 0 1 Slc16a8
NM_009200 chr10 + 4.526708667 0 1 Slc1a6
NM_011395 chr17 - 4.803183333 0 1 Slc22a3
NM_019687 chr11 - 3.779623333 0 1 Slc22a4
NM_178934 chr10 + 9.328763333 0 1 Slc2a12
NM_022025 chr17 - 8.678536667 0 1 Slc5a7
NM_145423 chr10 + 5.597236667 0 1 Slc5a8
NM_201353 chr18 - 25.54696667 0 1 Slc6a7
NM_001033289 chr1 + 3.62139 0 1 Slc9a2
NM_198864 chr3 - 2.44498 0 1 Slitrk3
NM_178740 chrX - 7.028866667 0 1 Slitrk4
NM_026003 chr19 + 8.507941111 0 1 Smarca2
NM_011427 chr2 + 17.72363333 0 1 Snai1
NM_025696 chr19 + 8.51482 0 1 Sorcs3
NM_001025428 chr11 + 146.9288078 0 1 Spag9
NM_027641 chr2 - 9.264008333 0 1 Spef1
NM_007463 chr1 + 22.55948333 0 1 Speg
NM_172430 chr1 - 2.980400778 0 1 Sphkap
NM_145584 chr7 + 8.204268889 0 1 Spon1
NM_080448 chr6 - 32.6975 0 1 Srgap3
NM_011371 chr11 - 1.333303333 0 1 St6galnac1
NM_012028 chr3 - 5.741171333 0 1 St6galnac5
NM_001083315 chr6 + 9.88613 0 1 St7
NM_029682 chr19 + 39.92205 0 1 Stambpl1
NM_145934 chr17 - 149.3431667 0 1 Stap2
NM_022416 chr5 - 10.22711833 0 1 Stk32b
NM_009292 chr6 + 147.239 0 1 Stra8
NM_025491 chr13 - 4.905306667 0 1 Susd3
153
refID chr strd ES_exp und 3RA name
NM_022030 chr3 + 29.6678 0 1 Sv2a
NM_001079686 chr10 + 13.89172222 0 1 Syne1
NM_018804 chr3 - 23.81815167 0 1 Syt11
NM_030725 chr2 + 20.34911667 0 1 Syt13
NM_016663 chr7 + 20.63093333 0 1 Syt3
NM_018800 chr3 + 4.507696 0 1 Syt6
NM_009309 chr17 + 26.5558 0 1 T
NM_009311 chr6 + 7.638955667 0 1 Tac1
NM_009313 chr6 + 1.508643333 0 1 Tacr1
NM_020047 chr6 - 8.873333333 0 1 Tacstd2
NM_028958 chrX - 18.0802 0 1 Taf7l
NM_145391 chr6 - 12.92504833 0 1 Tapbpl
NM_009322 chr2 + 6.609723333 0 1 Tbr1
NM_011532 chr16 - 1.018372333 0 1 Tbx1
NM_146236 chrX + 34.31716667 0 1 Tceal1
NM_001029978 chrX + 2.31834 0 1 Tceal3
NM_011547 chr13 - 16.13752111 0 1 Tcfap2a
NM_001025305 chr1 + 11.33709189 0 1 Tcfap2b
NM_015749 chr11 - 167.29026 0 1 Tcn2
NM_153533 chr15 + 10.32118667 0 1 Tenc1
NM_031381 chrX - 6.4734265 0 1 Tex13
NM_009364 chr6 - 10.792 0 1 Tfpi2
NM_009369 chr13 + 99.73055 0 1 Tgfbi
NM_011580 chr2 + 558.5631667 0 1 Thbs1
NM_009381 chr7 - 19.89140333 0 1 Thrsp
NM_028927 chr8 + 3.98509 0 1 Tktl2
NM_011904 chr19 - 0.618975 0 1 Tll2
NM_126166 chr8 - 4.988200667 0 1 Tlr3
NM_001040130 chr2 - 67.82738333 0 1 Tmem141
NM_178642 chr7 - 3.657576333 0 1 Tmem16a
NM_177794 chr10 + 3.843107333 0 1 Tmem26
NM_009396 chr12 + 22.19111778 0 1 Tnfaip2
NM_025566 chr17 + 59.07876667 0 1 Tnfaip8l1
NM_028075 chr15 - 31.37126667 0 1 Tnfrsf13c
NM_011610 chr4 - 50.70891667 0 1 Tnfrsf1b
NM_024290 chr7 - 27.38840333 0 1 Tnfrsf23
NM_021327 chr11 - 718.3313333 0 1 Tnip1
NM_001081260 chr2 + 59.51983333 0 1 Tnks1bp1
NM_031176 chr17 + 6.205793333 0 1 Tnxb
NM_145711 chr4 - 4.990573667 0 1 Tox
154
refID chr strd ES_exp und 3RA name
NM_001024134 chr17 - 9.0054 0 1 Trim15
NM_177781 chr1 - 8.464893333 0 1 Trpa1
NM_080455 chr2 + 4.311494583 0 1 Tshz2
NM_001083618 chr2 + 5.252902111 0 1 Ttll9
NM_009451 chr17 - 23.6571 0 1 Tubb4
NM_011656 chr3 - 42.18440667 0 1 Tuft1
NM_175309 chr5 + 3.055062833 0 1 Upk3b
NM_011909 chr6 + 7.571813333 0 1 Usp18
NM_181399 chr2 + 98.48841667 0 1 Usp6nl
NM_011691 chr17 + 3.3373 0 1 Vav1
NM_009501 chr19 - 1.219994 0 1 Vax1
NM_177683 chr6 - 24.1832 0 1 Vgll4
NM_011700 chr9 + 107.5786333 0 1 Vill
NM_012038 chr12 - 3.597153 0 1 Vsnl1
NM_027725 chr1 + 1.119412667 0 1 Wdr69
NM_021279 chr15 + 3.76374 0 1 Wnt1
NM_053116 chr6 + 3.84006 0 1 Wnt16
NM_009521 chr11 + 3.233383333 0 1 Wnt3
NM_133208 chr11 - 12.7194575 0 1 Zfp287
NM_172385 chr7 - 5.634516667 0 1 Zfp536
NM_001024950 chr17 + 20.98453333 0 1 Zfp563
NM_001033205 chr7 - 13.39923667 0 1 Zfp575
NM_177622 chr13 - 31.55963333 0 1 Zfp595
NM_175751 chr18 - 19.52446333 0 1 Zfp608
NM_172486 chr17 + 43.14073333 0 1 Zfp677
NM_153194 chr15 + 310.272 0 1 Zfp740
NM_175513 chr2 + 1.281704167 0 1 Zfp804a
NM_009573 chr9 - 2.518656667 0 1 Zic1
NM_177086 chr8 + 8.355600778 0 1 Zmat4
NM_011483 chr17 - 1.296146667 0 1 Znrf4
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